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Abstract 
Metabolic engineering, defined as the rational engineering of organisms towards 
production goals, has greatly evolved since its conception over three decades ago. Once 
applied to overproduce cell endogenous metabolites, it is now a promising approach also 
for the biosynthesis of non-natural compounds through the expression of synthetic 
metabolic pathways. Improved over billions of years by evolution, enzymes are however 
less adapted to new catalytic functions as required by synthetic metabolism. The present 
work was aimed at the construction of artificial routes for the biosynthesis of commodity 
chemicals through the application of concepts of enzyme engineering. 
(L)-2,4-dihydroxybutyrate (DHB) is a non-natural compound of industrial interest for the 
synthesis of methionine analogues, and whose biological production was previously 
demonstrated by the expression of a two-step pathway via homoserine in Escherichia 
coli. The pathway sequentially employs homoserine (HMS) transaminase and 2-keto-4-
hydroxybutyrate (OHB) reductase activities. In this thesis, rational enzyme design was 
used as a strategy to improve the last catalytic step of the pathway. Simultaneous 
expression of the evolved OHB reductase Ec-Mdh-5Q and HMS transaminase Ec-AlaC 
A142P:Y275D variant in an engineered homoserine-overproducing E. coli strain resulted 
in the production of 89.0 mM DHB from glucose, the highest titer reported to date. 
Of industrial relevance is also the synthesis of 1,3-propanediol (PDO), a metabolite 
generated from glycerol catabolism in various Clostridia species. Expanding the susbtrate 
range to sugars would render PDO production more flexible. Therefore, a six-step 
synthetic pathway yielding PDO from glucose via malate was conceived. While the three 
first reaction steps were previously demonstrated, the remaining DHB dehydrogenase, 
OHB decarboxylase and PDO oxidoreductase activities were identified in candidate 
enzymes acting on sterically cognate substrates. Improved enzyme activities were 
obtained based on sequence- and structure-based protein design. The feasibility of the 
PDO pathway was validated though expression of all required enyme activities in a single 
E. coli strain, while further improvements were achieved through co-cultivation of two 
E. coli strains each one expressing a partial segment of the completepathway (up to 3.8 
mM PDO). 
During the design and construction of the PDO pathway, OHB decarboxylases which 
release 3-hydroxypropanal as product of OHB decarboxylation, were found to be 
catalytically low efficient. To this end, a transcription factor-based metabolite sensor 
towards high-throughput detection of aldehydes in E. coli was developed. Optimization 
tasks of the metabolite sensor through 5’-UTR engineering rendered the sensor more 
sensitive to target compounds. In a proof of concept, simultaneous expression of the 
metabolite sensor and a segment of the PDO pathway in E. coli afforded the 
discrimination of two OHB decarboxylases with distinct kinetic properties. Therefore, the 
metabolite sensor can be implemented in directed evolution campaigns aiming at OHB 
decarboxylase development. 
Keywords: metabolic engineering, synthetic pathways, enzyme engineering, 2,4-
dihydroxybutyrate, 1,3-propanediol 
 
Résumé 
 
L’ingénierie métabolique utilise des techniques de clonage pour moduler directement les 
voies métaboliques de microorganismes dans le but de produire des molécules d’intérêts. 
Précédemment envisagée pour surproduire des métabolites endogènes, l’ingénierie 
métabolique est aussi considérée maintenant comme une approche prometteuse pour la 
biosynthèse de composés non naturels par l'expression de voies métaboliques 
synthétiques. Cependant, les enzymes sont moins adaptées aux nouvelles fonctions 
catalytiques requises par le métabolisme synthétique. Le but de cette thèse est donc la 
construction de voies artificielles pour la biosynthèse de molécules d’intérêts en 
appliquant des concepts d'ingénierie enzymatique. 
Le (L)-2,4-dihydroxybutyrate (DHB) est un composé non naturel qui présente un intérêt 
industriel pour la synthèse d'analogues de la méthionine. Des travaux précédemment 
réalisés dans notre équipe ont démontré la biosynthèse de DHB par l'expression d'une 
voie à deux étapes via l'homosérine chez Escherichia coli. Cette voie emploie 
séquentiellement l’action d’enzymes ayant une activité homosérine (HMS) transaminase 
et 2-céto-4-hydroxybutyrate (OHB) réductase. Dans ce travail, l’optimisation de la 
dernière étape de la voie catalytique a été envisagé grâce à l’ingénierie rationnelle des 
enzymes. Ainsi une OHB réductase évoluée, Ec-Mdh-5Q, exprimée simultanémment 
avec la HMS transaminase Ec-AlaC A142P:Y275D dans E. coli a permis la production 
de 89.0 mM DHB à partir de glucose, le titre le plus élevé signalé à ce jour. 
La synthèse du 1,3-propanediol (PDO), un métabolite généré par le catabolisme du 
glycérol chez diverses espèces de Clostridia, apporte un intérêt industriel. 
L’élargissement de la gamme de matières premières aux sucres rendrait la production des 
PDO plus flexible. Par conséquent, une voie de synthèse en six étapes produisant du PDO 
à partir du glucose via le malate a été conçue. Si les trois premières étapes de cette réaction 
ont été ingénierées dans des travaux précédents, les trois activités enzymatiques suivantes 
(DHB déshydrogénase, OHB décarboxylase et PDO-oxydoréductase) ont due être 
identifiées dans des enzymes candidates agissant sur des substrats similiaires. Des 
activités enzymatiques améliorées ont été obtenues par mutagénèse dirigée en se basant 
sur l’analyse de la séquence et de la structure de ces protéines. La faisabilité de la voie 
PDO a ensuite été validée par l'expression de ces six activités enzymatiques dans E. coli 
et des améliorations supplémentaires ont été obtenues grâce à la co-culture de deux 
souches E. coli exprimant chacune un segment partiel de la voie complète (jusqu'à 3,8 
mM PDO). 
Au cours de la construction de la voie PDO, les OHB décarboxylases qui en 
décarboxylant l'OHB libérent l’aldéhyde 3-hydroxypropanal se sont révélées être 
faiblement efficaces sur le plan catalytique. Ainsi afin de cribler à haut débit des banques 
d'enzymes mutées enzymes, un biosenseur a été mis au point afin de détecter les 
aldéhydes libérés par cette bioconversion. Son optimisation via l’ingénierie de 5’-UTR a 
par la suite permis de le rendre plus sensible aux composés ciblés. Dans une preuve de 
concept, l'expression simultanée du biosenseur et d'une partie de la voie PDO dans E. coli 
a permis de distinguer les capacités catalytiques de deux OHB décarboxylases. Par 
conséquent, ce biosenseur pourra être mis en œuvre dans de futures campagnes 
d'évolution dirigée visant à optimiser l’OHB décarboxylase. 
Mots clés: ingénierie métabolique, voies synthétiques, ingénierie enzymatique, 2,4-
dihydroxybutyrate, 1,3-propanediol 
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Chapter 1. Introduction 
 
1.1 Microbial cell factories 
Developments in petrochemistry have greatly enhanced industrial and societal progress. 
The continuous increasing rate of oil reserve exploitation has served as an abundant and 
inexpensive raw material for the synthesis of transportation fuels and production of 
commodity chemicals. But triggered by a rising energy demand, geopolitical 
uncertainties, environmental effects and oil-depletion concerns, industries have in recent 
times been demonstrating interest in the utilization of alternative feedstocks, including 
plant biomass and inexpensive sugars1.  
Originally seen as a source of food and beverage products, the past few decades have 
disclosed the potential of microorganisms as cell factories for the production of 
industrially relevant molecules such as biofuels2,3 and commodity chemicals4,5. Since the 
advent of metabolic engineering, a few number of bio-synthesized molecules (e.g. 
ethanol, succinate, lactate) successfully achieved commercialization thereby contributing 
to a shift towards a more sustainable economy6,7. However, the development of microbial-
based processes at prices competitive to those derived from petroleum are in part 
responsible for the still limited success rates of process industrialization.  
Cellular metabolisms are diverse and complex, composed of metabolic pathways from 
which thousands of unique chemicals are produced6. While metabolic engineering 
traditionally aims at channeling carbon flux towards overproduction of a target 
metabolite, recent advances in computational biology, molecular genetics and protein 
engineering are moving this young and exciting field to a new era8. By enabling the 
creation of non-natural metabolic pathways, the production of non-natural compounds 
can now be foreseen while the biosynthesis of natural metabolites can be achieved by 
multiple and diversified routes. Improved by evolution to perform metabolic functions, 
enzymes are however less adapted towards novel functions as required by synthetic 
metabolism.  
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1.2 Objective and outline of this thesis  
The construction of synthetic metabolic pathways requires the discovery of new enzyme 
functions. The main objective of this doctoral thesis was to engineer enzymes with new 
catalytic activities to be implemented in non-natural pathways aiming at the production 
of commodity chemicals, in particular 1,3-propanediol (PDO) and 2,4-dihydroxybutyrate 
(DHB). 
In Chapter 2, the field of metabolic engineering is reviewed. Starting by pathway design, 
the creation and implementation of metabolic pathways is approached, and optimization 
tasks reviewed. Particular attention is given to the construction of non-natural pathways 
and the domain of enzyme engineering, which permits (re)creating enzymes with new 
functions.  
In Chapter 3, rational enzyme engineering was employed as a strategy to improve the 
efficiency of the last reaction step towards DHB production from glucose via homoserine. 
The kinetic properties of created enzyme variants were determined, and those displaying 
the highest catalytic efficiencies were further evaluated upon implementation in the 
synthetic pathway.  
In Chapter 4, a synthetic pathway was designed and established in E. coli for the direct 
production of 1,3-propanediol from glucose via 2,4-dihydroxybutyrate. While those 
enzyme activities linking glucose to DHB were previously reported, the downstream 
pathway converting DHB into PDO employs two unknown enzyme functions. In this 
study, the discovery and engineering of those enzymes was reported and PDO production 
demonstrated.  
In Chapter 5, an E. coli metabolite sensor was designed and optimized towards 
intracellular aldehyde detection. Coupled to a powerful screening/sorting system, it can 
be used in directed evolution campaigns for the detection and isolation of improved 
aldehyde-producing enzyme variants. 
In Chapter 6, the main conclusions of this thesis are presented and the significance of 
current and future work discussed. 
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Chapter 2. Metabolic engineering meets enzyme design 
 
The concept of engineering metabolic pathways has been widely used in the past. For 
instance, 500-fold improved productivities of the antibiotic penicillin were found after 
submitting the fungi Penicillium chrysogenum to repeated rounds of random mutation 
and selection1. With the introduction of recombinant DNA technology by Cohen and 
Boyer2 started the development of techniques focused on rationally engineering 
microorganisms towards production goals, a field known today as metabolic engineering. 
First proposed by Bailey3 over three decades ago, metabolic engineering aims ultimately 
at the development of cost-efficient processes for the microbial production of fuels, 
chemicals and pharmaceuticals. Three are the main parameters used to evaluate the 
success of metabolic engineering projects: titer, yield and productivity4.  
The field of metabolic engineering assumes an industrial dimension. As such, it comprises 
not only the design and implementation of a functional pathway in a suitable host, but 
also its optimization so that a commercial process can be envisaged. Metabolic 
engineering can therefore be considered as an iterative design-build-test cycle. These 
elements encompass genetic engineering and molecular biology, but also components 
from graph theory, chemical reaction engineering, biochemistry, and optimization4,5.  
In this thesis, E. coli has been chosen as the host for metabolic engineering, reason for 
which only this organism is covered in this chapter. Considered as a prokaryotic model 
organism for which gene-editing tools and genome sequence information are readily 
available, E. coli constitutes the primary choice as host for metabolic engineering studies. 
In addition, the well-understood physiology, metabolism and genetics further aided in its 
development as a production organism. However, several other organisms have been 
explored for the successful biosynthesis of high-value metabolites4. While not covered in 
this thesis, the choice of an appropriate host is determinant for the success of metabolic 
engineering projects and should be carefully executed in each case scenario. 
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2.1 Pathway design  
When aiming at the overproduction of a target compound, both metabolic engineers and 
synthetic organic chemists pose themselves a common question: what pathways can be 
used to produce the compound of interest? The concept of pathway design is well-
established in organic chemistry, and aims at identifying the most favorable set of 
reactions towards the synthesis of a given compound. Metabolic engineering introduces 
three additional constraints in pathway design:  
- Set of reactions must be in overall thermodynamically favorable under biological 
conditions; 
- Intermediate molecules should not be toxic; 
- Enzymes required for conversion must be expressible in the host organism. 
Nature has evolved cell metabolism as a large and complex metabolic reaction network, 
in which through an extensive number of intermediates and enzymatic control 
mechanisms, the functional adaptability and stability required by life is maintained. The 
interconnectedness of metabolic reactions thus results in a very high number of potential 
pathways linking substrate to product. This means that pathways must be annotated, 
enumerated and assessed against other criteria6–8. The first complete method for pathway 
enumeration from a database of biochemical reactions was published in 1990 by 
Mavrovouniotis and colleagues9 and was used to identify several routes yielding lysine. 
In particular, the method allowed the authors to conclude that oxaloacetate is a necessary 
precursor for the biosynthesis of lysine. Advances in genome sequencing further 
permitted the construction and refinement of genome-scale metabolic models by linking 
metabolic and genomic data. Two major extensive collections of metabolic networks for 
a large number of organisms which describe interactions between enzymes and substrates 
are provided by KEGG Pathway and MetaCyc, whose inspection represents today the 
first step of any metabolic engineering project10. Intuition and manual design have been 
the preferred strategy for postulating both natural and non-natural pathways enabling the 
synthesis of a desired metabolite. But during the last decade a range of computational 
tools to assist in the prediction and prioritization of new metabolic pathways yielding  a 
target compound have been developed.  
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Early pathway finding algorithms (e.g. FMM, PathComp, Pathway Hunter Tool, 
MetaRoute) were developed based on known enzymatic reactions. These tools, also 
known as network-based path finding methods, all extract information from biochemical 
databases (e.g. KEGG, MetaCyc, BRENDA, MetRxn, Rhea) to identify those pathways 
that in a minimum set of reaction steps can link an input molecule to a target compound. 
On the other side, pathway prediction tools (e.g. BNICE, RetroPath, Route Designer) 
allow the user to design pathways that encompass novel reactions not found in metabolic 
databases. Those are mostly based on the concept of retrosynthesis, that by starting from 
a target product iteratively applies reversed biotransformations to reach a precursor 
present in natural metabolism11–14. Such strategy may for instance be applied in metabolic 
engineering projects which aim at overproducing non-natural compounds. 
While pathway design tools often identify multiple routes, these are now associated with 
pathway prioritization which allows to rank predicted routes. The most common method 
to rank pathways is based on the number of reactions steps (e.g. FindPath), in which the 
shortest pathway is considered as more favorable since it implies minimal enzyme 
requirement and avoids metabolic burden. Thermodynamic feasibility, intermediate 
toxicity, number of known reactions and kinetic proficiency are lately combined with 
pathway length for a more reliable prioritization of predicted pathways (e.g. BNICE, 
Retropath, SimPheny)11.  
The selection of the most appropriate computational tool for pathway design very much 
depends on user specifications, but one should keep in mind that the combination of 
prediction with ranking may yield more satisfactory results. For example, aiming at 
demonstrating the production of the non-natural compound 1,4-butanediol in E. coli, Yim 
and co-workers15 used the SymPheny Biopathway Predictor software to elucidate and 
evaluate all potential pathways linking host central metabolites to the target compound. 
Based on the transformation of chemical groups by known chemistry, the algorithm 
identified more than 10,000 possible pathways. Combined with the utilization of an in-
house software for pathway sorting and ranking, the authors identified the 1,4-butanediol 
pathway through 4-hydroxybutyrate as the highest priority for construction and 
implementation in an E. coli host strain. Rounds of optimization further resulted in a 
process which today paves its way to commercialization. In another example, Fehér and 
colleagues16 experimentally validated the RetroPath software in a study aiming at the 
design and implementation of a pathway yielding the flavonoid pinocembrin in an E. coli 
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strain. Starting with the desired compound as an input, the software searches and lists all 
possible pathways that link an endogenous metabolite in the host organism to the target 
molecule. Each of the listed pathways corresponded to a unique list of known enzymatic 
reactions, for which a set of criteria was pre-established towards pathway ranking. Of the 
11 found pathways, the algorithm identified as expected the natural flavonoid synthesis 
route as the most favorable one, and proposed a series of genes encoding for desired 
enzyme activities. After assembling and expressing the metabolic pathway in E. coli, 
pinocembrin was produced up to 24.1 mg L-1, a value in line with other studies targeting 
flavanone biosynthesis. 
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2.2 Pathway construction 
Pathway engineering involves ultimately at finding the right combination of enzymes that 
permits linking in an efficient manner a given molecule (e.g. substrate, endogenous 
metabolites) to a target compound. For clarity, in this thesis enzyme development is 
considered as a stage in pathway construction rather than a pathway optimization task. 
According to the synthetic character and biochemical solution space, Erb and colleagues17 
have previously classified engineered metabolic pathways into five levels, which are 
described in the next subsections.  
 
2.2.1 Endogenous pathways 
Early stages of metabolic engineering focused on optimizing the endogenous metabolism, 
i.e. existing pathways within their natural hosts, towards production goals (Figure 2.1a). 
Based on genome sequencing and annotated pathways, individual gene deletion and/or 
over-expression can be predicted aiming at pathway optimization. For example, Zhang 
and co-workers18 successfully redirected carbon flux towards overproduction of the Krebs 
cycle intermediate (L)-malate in E. coli. Starting with a previously engineered succinate-
overproducing strain (E. coli ΔldhA ΔackA ΔadhE ΔpflB), step-wise gene deletion of 
carbon diverting and malate degradation encoded-enzymes afforded the creation of a 
strain with 11 gene deletions which was able to significantly accumulate the desired 
metabolite under anaerobic conditions. Optimization of cell cultivation conditions further 
enhanced malate titers and productivities (up to 34 g L-1 and 0.47 g L-1 h-1).  
 
2.2.2 Copy, paste and fine-tuning pathways 
In a more advanced strategy named “copy, paste and fine-tuning”, annotated pathways or 
sub-pathways are introduced to a heterologous host (Figure 2.1b). Expressing the 
Weimberg pathway from Caulobacter crescentus in E. coli allows for an alternative route 
for xylose assimilation19 and illustrates the concept of copy-paste. While the engineered 
pathways keep unaltered their basic structure, minor changes can be a result of improved 
kinetics and/or thermodynamics. The replacement of individual enzymes is included in 
the latter case. For instance, in a pathway dedicated to the production of n-butanol 
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expressed in E. coli, substituting the thermodynamically limiting acetoacetyl-Coa 
synthetase with an irreversible acetyl-CoA:malonyl-CoA acetyltransferase 
(decarboxylating) substantially improved product titers, resulting in a fine-tuning of the 
production system20.  
 
 
Figure 2.1. The process of engineering natural pathways can be divided in two strategies. (A) Engineering endogenous 
pathways (highlighted in blue) involves gene deletion and/or overexpression aiming at carbon flux channeling towards 
target metabolite (square). (B) The concept of copy-paste is based on the transfer of entire pathways or genes (green) 
to a heterologous host, while fine-tuning can be achieved by replacing rate-limiting enzymes (e.g. thermodynamically 
unfavorable, in which ΔG > 0) by more favorable ones (e.g. thermodynamically favorable, in which ΔG < 0) (orange). 
Adapted from Hossain et al21. 
 
While engineering existing pathways or “copy, paste and fine-tuning” pathways is 
confined to the manipulation of natural metabolism, the creation of non-natural or 
synthetic pathways came to revolutionize the field of metabolic engineering. In specific, 
non-natural routes as described next enlarge the metabolic solution space by enabling the 
creation of both natural and non-natural compounds. Scientists are therefore able to 
implement the so-called concept of “total synthesis” also in the domain of industrial 
biotechnology17.  
 
2.2.3 Mix and match synthetic pathways 
Whilst the utilization of natural enzymes may enable the creation of synthetic pathways, 
the creation of new enzymes and engineering of natural ones may further expand the 
metabolic solution space.  The simplest form of synthetic metabolism is built upon a “mix 
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and match” concept, in which non-natural pathways are created through combinatorial 
expression of natural enzymes from various sources (Figure 2.2). Provided that the host 
strain produces the necessary precursors from its own primary or secondary metabolism, 
subsequent conversion to the desired target metabolite can be accomplished through 
heterologous gene expression. Without the need to evolve novel enzymatic reactions, a 
wide range of previously unreported pathways can be identified.  
 
 
Figure 2.2. The process of engineering non-natural pathways based on a “mix and match” approach. Based on 
endogenous metabolism (blue) which results in the synthesis of a certain precursor (blue square), expression of natural 
enzymes from various sources (each color, each source) can link the referred precursor to a desired metabolite (star). 
From Hossain et al21. 
 
The biosynthesis of arbutin, a glycoside used as skin-lightering agent, from glucose 
illustrates well this concept. By expressing 4-hydroxybenzoate 1-hydroxylase from 
Candida parapsilopsis (MNX1) and arbutin synthase from Rauvolfia serpentina (AS) 
enzyme activities in an E. coli host strain, Shen and co-workers22 were able to connect 
the endogenous precursor p-hydroxybenzoic acid to the desired metabolite. Other 
examples include production of pinocembrin and polyketide analogs, as summarized by 
Hossain and colleagues21.  
 
2.2.4 Synthetic pathways with novel reactions 
Pathway design frequently results in the identification of routes involving reaction steps 
that natural enzymes are unable (or unknown) to catalyze. Those catalytic steps may 
involve new enzymatic functions based on new reactions (Figure 2.3a). Designing 
metabolic pathways involving new reactions relies on the fact that biocatalysts can 
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catalyze the conversion of new substrates whilst keeping unaltered the respective 
enzymatic mechanisms. Three different strategies have been attempted to accomplish this 
goal (Figure 2.3b-d).  
 
Figure 2.3. The process of engineering non-natural pathways based on novel reactions (A). Based on endogenous 
metabolism (blue) which results in the synthesis of a certain precursor (blue square), expression of natural enzymes 
from various sources (each color, each source) can link the referred precursor to a desired metabolite (star). Novel 
reactions can be accomplished based on reaction reversibility (B), enzyme promiscuity (C) and/or enzyme engineering 
(D). Legend: mutation (black inverted triangle).  
 
The first approach is built upon the concept of reversibility of (bio)chemical reactions 
(Figure 2.3b). While some enzymatic reactions have been experimentally shown to be 
reversible in a cellular context depending on reactant(s)/product(s) ratio (e.g. branched-
chain amino acid transaminase), others are clearly irreversible (e.g. glycolytic enzymes 
hexokinase, phosphofructokinase). In some other cases, in vivo reversibility is still matter 
of debate. The case of the anaerobic pyruvate formate-lyase clearly shows how 
reversibility can enlarge the metabolic and enzyme solution spaces. Despite possessing a 
strong preference (standard Gibbs free energy,  ΔrG
0 = -21 kJ mol-1) for the CoA-
dependent pyruvate cleavage yielding formate and acetyl-CoA, Zelcbuch and co-
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workers23 demonstrated this same enzyme to enable growth on acetate and formate in 
cells devoid of the glyoxylate shunt by catalyzing the reverse reaction in vivo.  
Another alternative to find new reactions consists in exploring the substrate repertoire of 
natural enzymes (Figure 2.3c). Notably, around 10% of bacterial and archaeal enzymes 
have been reported as promiscuous24. Identification of those enzymes accepting 
substrates structurally analogous to the prospective substrate may therefore constitute a 
feasible strategy for constructing a non-natural pathway. For instance, in this doctoral 
thesis the NADPH-dependent broad-range aldehyde reductase from E. coli (Ec-YqhD) 
was employed as part of an alternative synthetic PDO pathway starting from glucose due 
to its ability to reduce various aldehydes into corresponding alcohols (see Chapter 4). 
While in this specific case 3-hydroxypropanal (3-HPA) was the target substrate, others 
took advantage of the relaxed substrate specifity of Ec-Yqhd to engineer other non-natural 
pathways for synthesis of e.g. 1,2,4-butanetriol25 and ethylene glycol26 (in which YqhD 
substrates were D-3,4-dihydroxybutanal and glycolaldehyde, respectively). Another 
example of a non-natural route based on substrate promiscuity is the xylulose-1-
phosphate pathway (addressed in Chapter 5), seen as an alternative route for xylose 
assimilation, that generates stoichiometrically equivalent amounts of glycolaldehyde and 
dihydroxyacetone phosphate (DHAP)27.  
Despite providing a convenient alternative towards the creation of synthetic pathways, 
the utilization of natural enzymes catalyzing reverse reactions and/or multiple substrates 
frequently results in poor product titers and yields. For example, Ec-YqhD has a catalytic 
efficiency (kcat / Km) for HPA equal to 0.13 s
-1 M-1, a value lower by 6-orders of magnitude 
when compared with an average enzyme (~105 s-1 M-1)28,29. Engineering enzymes 
displaying promiscuity and / or activity on sterically cognate substrates may in those cases 
be a strategy to further improve the efficiency of both, biocatalysts and pathways (Figure 
2.3d). The exciting field of enzyme engineering and methods thereof will be reviewed 
later in this chapter. Two textbook examples of pathway construction based on engineered 
enzyme activities have been recently reported. In the first one, Walther and colleagues30 
successfully created a complete synthetic route that produces the non-natural compound 
DHB from the TCA cycle intermediate (L)-malate based on structure-guided rational 
protein design. In the second one, Schwander and co-workers31 followed a similar 
approach to engineer a synthetic pathway composed of 17 enzyme activities for the in 
vitro fixation of CO2 (CETCH cycle) at rates up to 5 mU mg protein
-1.  
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2.2.5 Synthetic pathways with novel chemistries 
Empowered by the rapid growth of computational tools for engineering proteins, de novo 
enzyme design towards new biochemistries can now also be envisaged, i.e. new reactions 
with new mechanisms (e.g. using artificial co-factors). Out of the scope of this thesis, new 
enzyme biochemistries may enable the creation of fully artificial pathways that represent 
the maximum exponent of synthetic metabolism. The most remarkable example is 
perhaps the development of a formolase enzyme that allows the previously unreported 
carboligation of three formate molecules into a single molecule of DHAP, involved in 
central metabolism32.  
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2.3 Pathway optimization  
Once the possible pathways have been established in the host organism, the next step in 
engineering a production strain is to analyze the respective phenotype. Conventional 
chromatography techniques (e.g. HPLC, GC-MS) enable the user to quantify product 
formation, substrate consumption and accumulation of commonly released by-products 
(e.g. acetate, formate) at different stages of cell cultivation. This strategy enables a rapid 
phenotypic evaluation and allows the user to predict the most obvious genetic 
modifications that need to be introduced in the product strain aiming at improving product 
formation. A more comprehensive and systemic overview of cell metabolism as provided 
by omics data analysis is however necessary at later stages of metabolic engineering 
projects when all obvious genetic modifications have been attempted. This strategy may 
provide for a wide knowledge on network topography, kinetics and regulation of a 
metabolic pathway, identification of kinetic bottlenecks and competing pathways, and an 
assessment of dysfunction in pathway operation. Alternatively or in combination with 
rational-based approaches, adaptive laboratory evolution is not uncommon in the field on 
metabolic engineering, while pathway co-localization has recently emerged as an 
alternative but effective strategy for metabolism optimization5.  
 
2.3.1 Metabolic flux analysis (MFA) 
MFA aims at determining intracellular reaction rates (i.e. in vivo fluxes) which can be 
compared between different conditions (e.g. two engineered strains). More important than 
the flux values per se are the deviations from control conditions which can provide 
insights into metabolic and regulatory responses, e.g. identification of key branch point 
flux distributions, detect carbon loss through competing pathways, evaluate engineered 
strains. While MFA has mostly been used to quantify fluxes in central metabolism, efforts 
have been made towards its application on a genome-scale. Typically, a 13C-labeled 
substrate is fed with cells and used to label downstream metabolites whose isotopic 
distributions are measured by GC-MS or 13C-NMR techniques. Intracellular fluxes are 
then determined by using a stoichiometric model for the major intracellular reactions and 
applying mass balances around intracellular metabolites. A set of measured extracellular 
fluxes, normally substrate uptake rates and product secretion rates, is used as input to 
computational analysis platforms (e.g. 13CFLUX2, OpenFlux, FiatFlux). The output of 
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MFA is a metabolic flux map showing a diagram of biochemical reactions included in 
calculations along with estimated reaction flux4,5,33. For example, MFA analysis of an 
engineered E. coli strain for the biosynthesis of 1,4-butanediol aided in the identification 
of the two last enzyme-reaction steps as rate-limiting, as their intracellular flux values 
were considerably lower than those of the upstream reaction steps34.   
 
2.3.2 Metabolomics 
Metabolomics analysis can point for metabolic bottlenecks, redox co-factor ratios and 
energy charge by looking at the instantaneous accumulation or depletion of metabolites, 
or by monitoring dynamic labeling of metabolites by using a labeled tracer. The 
combination of chromatography separation techniques with mass spectrometry detection 
affords the identification and quantification (relative or absolute) of a wide range of 
compounds. Comparison between different conditions associated with statistical analysis 
methods (e.g. PCA) may afford discrimination between samples34.   
 
2.3.3 Transcriptomics and proteomics 
Transcriptomics (e.g. RNAseq, microarray, qPCR) and proteomics (e.g. iTRAQ, MRM) 
elucidate the user on the expression levels of endogenous, heterologous and manipulated 
genes or proteins. They may enable the user to assess the physiology and overall cell 
health, based on the expression of regulons associated with global stress responses5,34.  
 
2.3.4 Genomics 
As costs associated with next-generation sequencing technologies keep decreasing, 
genomics emerges as a rapid method which permits to analyze engineered strains at a 
DNA scale during the different stages of a metabolic engineering project. In specific, 
genome and/or plasmid sequences allow to verify that the desired genetic modifications 
were correctly introduced. In addition, DNA sequence analysis enables the detection of 
unwanted introduction of mutations during cloning processes34. 
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2.3.5 Computational modelling 
A range of computational tools have been developed in an attempt to reduce the 
experimental workload required in pathway optimization tasks. 
 
Flux balance analysis 
A common problem associated with MFA is the cost and expertise that experimental 
procedures require. In this line, purely computational stoichiometric-methods to estimate 
fluxes have been developed, such as flux balance analysis (FBA). Both FBA and MFA 
make use of genome-scale metabolic models and mass balances. However, FBA is an 
undetermined system in which equations are formulated as a constrained optimization 
problem with a specific objective function to be maximized or minimized. By taking 
advantage of genome-scale models in simulating cell metabolism behavior, cell designs 
for maximizing chemical production can in principle be predicted. A common objective 
function are the maximization of cell growth and the minimization of metabolic 
adjustment. There are three key advantages of this methodology over the experimental 
approach:  
- Minimal experimental data are needed; 
- Perturbations (e.g. gene knockouts) can be made by changing a 1 to a 0 in silico; 
- Models can be continuously refined as new omics data become available. 
However, the major disadvantage of FBA-derived fluxes is that they are not the real fluxes 
of the system but fluxes yielding maximum biomass. A number of FBA-based algorithms 
have been developed to identify groups of gene knockouts that are predicted to change 
the fermentation profile of a cell when growing at a maximum growth rate, allowing 
simultaneously for the maximization of metabolite synthesis and growth rate (e.g. 
COBRA 2.0, OptKnock). OptKnock derivatives may also enable the simultaneous 
application of multiple up- or down-regulations and gene deletion (e.g. 
OptForce)4,5,10,33,35. 
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Protein expression levels 
Cells do not always express proteins at levels sufficient to provide enzyme activities at 
velocities compatible with the well-functioning of expressed metabolic pathways. While 
transcriptomics, proteomics and/or enzymatic assays may provide with valuable 
information on protein expression in its various levels (mRNA transcript, translation, 
activity), computational methods may allow to fine-tune their expression in cells. In 
particular, the ribosomal binding site (RBS) of an mRNA transcript has been shown to 
affect translation initiation rates and presents therefore an alternative approach for 
controlling enzyme production at the RNA level. The RBS Calculator tool is a web-based 
application that correlates translation initiation rates with RBS sequences. A protein 
coding sequence, together with desired translation initiation rate, and host organism are 
required as inputs so that RBS calculator can suggest a DNA sequence10,36. For example, 
RBS modification was previously used as a strategy to improve the phenotype of 
production strains37. 
 
2.3.6 Adaptive laboratory evolution 
Adaptive laboratory evolution, also known as evolutionary engineering, aims at the 
random introduction of mutations in the host genome at rapid rates through serial 
passaging that successively improves phenotype fitness by imposing a growth dependent-
selective pressure. Alternatively, the process can be executed in well-controlled reactors 
under steady state (i.e. chemostat) which can last from several weeks to several months. 
The strategy is particularly useful in cases where sugar assimilation is rate limiting or the 
cells are sensitive to toxic metabolites.  In the scope of metabolic engineering, this 
strategy is normally applied when all possible rational genetic modifications have been 
exhausted38.  
 
2.3.7 Pathway co-localization  
The spatial proximity of enzymes has previously been reported to allow for metabolic 
flux fine-tuning8. For example, inspired by those enzymes exhibiting substrate channeling 
(e.g. tryptophan synthase), Dueber and colleagues39 constructed synthetic protein 
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scaffolds towards the recruitment of target enzymes involved in the synthesis of 
melavonate in E. coli. By providing a modular control over metabolic flux, product titers 
were improved up to 77-fold when compared to spatially unorganized enzymes. In 
another study, Lewicka and co-workers40 fused pyruvate decarboxylase and alcohol 
dehydrogenase enzymes from Zymomonas mobilis. Expression of the resulting chimeric 
protein in E. coli JM109 wild-type cells resulted in the production of more than 400 mM 
ethanol after 72 h of cultivation, which corresponded to an improvement of ~2-fold if 
compared to cells expressing the two non-fused proteins. 
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2.4 Enzymes as key biocatalysts 
Most biochemical reactions cannot occur at rates compatible with life without the 
presence of catalysts41. While the first evidence of biological catalysis was found by the 
end of the 18th century, only in 1877 was the term enzyme employed by Kühne in 
reference to the ferments isolated from living organisms42. Enzymes are the product of 
billions of years of evolution, having evolved substrate and function specificity to 
improve the overall fitness of organisms in response to environmental needs43. All 
enzymes are by definition proteins, but other types of molecule such as RNA (i.e. 
ribozymes) may act to accelerate reactions, and are thus also catalysts.  
 
2.4.1 Structure and catalytic function 
Enzymes are mostly globular entities of variable size, with subunits ranging from 
approximately 60 to several hundreds of amino acids. They catalyze reactions where 
substrates are converted into products, which occur in a small region of the enzyme 
usually referred to as the active site. Often consisting of a partially or completely buried 
cavity or cleft constituting at most 10-20% of the total volume of an enzyme, the side 
chains of active site residues orient the substrate (binding site) for its subsequent 
conversion into a product (catalytic site)44. In Figure 2.6, the three-dimensional structure 
of the malate dehydrogenase enzyme from E. coli (Ec-Mdh) and corresponding active 
site are shown.  
 
 
Figure 2.4. Three-dimensional X-ray crystal structure of Ec-Mdh (left) and its active site region (right) bound with 
NAD+ (red sticks) and citrate (blue sticks) (PDB code 1emd). Side-chains of active site residues are shown in a dark 
stick representation. 
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Enzymes engage in both intra- and inter-molecular interactions (electrostatic, van der 
Waals interactions) which are important in catalytic functions and thermal stability. 
Substrate and/or product interactions should not be too tight to avoid enzyme inhibition, 
but exceptions do exist in which enzyme feedback inhibition has been reported as a 
mechanism of pathway regulation (e.g. phosphoenol pyruvate carboxylase)45,46.  
Enzymes are extraordinary catalysts able to accelerate the rates of biological reactions 
under mild conditions of temperature and pressure up to 1017-fold47. Like any other 
catalyst, enzymes enhance chemical reaction rates by following two main principles. 
First, they are not consumed or permanently altered by the reaction and second, the 
chemical equilibrium between reactants and products remains unchanged in accordance 
with the laws of thermodynamics. By decreasing the activation energy required to form 
an unstable transition-state complex, enzymes are able to convert substrates into products 
at higher rates when compared with uncatalyzed reactions. Among the factors responsible 
for the enhanced catalytic activities of enzymes are: 
- Approximation of reactants; 
- Covalent catalysis;  
- Acid-base catalysis; 
- Conformational distortion; 
- Pre-organization of the active site for transition state complementarity.  
Most enzymes utilize several of the referred effects to ensure efficient catalysis48.  
 
2.4.2 Enzyme specificity 
The substrate specificity of an enzyme depends on the arrangement of atoms in the 
enzyme active site pocket such that they complement the transition-state structure of the 
enzyme-bound substrate molecule, as opposed to its ground-state structure48. Enzyme 
specificity can be measured experimentally as (kcat/Km), corresponding to the difference 
in free energy of the enzyme-bound substrate transition-state relative to that of the 
substrate and enzyme free in solution. The (kcat/Km) parameter therefore provides a direct 
measure of the catalytic efficiency of the enzyme (relative to the uncatalyzed reaction in 
solution with a much higher transition-state activation energy barrier). This kinetic 
parameter is also used to evaluate the degree of enzyme stringency towards substrate 
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acceptance. For instance, enzymes involved in central metabolism (e.g. malate 
dehydrogenases) tend to be highly specific, while detoxification enzymes like Ec-YqhD 
are less specific since they act on a broad range of substrates. In the latter case, enzymes 
are called as promiscuous (or generalist). It is noteworthy to mention that promiscuity is 
a generic term, that can be based on: the ability of enzymes to utilize alternative co-factors 
(e.g. farnesyl diphosphate synthase), active site plasticity (e.g. β-lactamases) and 
ambiguous substrate (e.g. cytochrome P450)49. In the scope of this thesis, promiscuity is 
used for those enzymes with activity on a large spectrum of substrates.  
According to the neutral drift theory of evolution, highly specific-modern-day enzymes 
are thought to have evolved from promiscuous but more thermally stable primitive 
ancestral enzymes through an iterative trajectory of random gene duplication and 
mutation events49. In a similar fashion, enzyme promiscuity can be exploited in protein 
engineering to create new functions by mimicking natural evolution in a laboratory 
environment.  
 
2.4.3 Enzyme selectivity  
Selectivity refers to the ability of enzymes to discriminate between closely related 
substrates. It can be quantified as the ratio of the (kcat / Km) values for the individual 
substrates concerned. The concept of selectivity can be categorized into three distinct 
classes: chemoselectivity, regioselectivity and stereoselectivity. Chemoselectivity refers 
to the ability of an enzyme to catalyze the transformation of a single functional group in 
the presence of others in a substrate molecule. On the other hand, a regioselective enzyme 
can distinguish between one or more identical functional groups located in different sites 
of the substrate molecules. As a result, only one group participates in the reaction yielding 
a selective product. Finally, stereoselectivity refers to the capability of an enzyme to 
distinguish between a pair of stereoisomers, resulting in an 100% optically pure product 
in the case of fully selective catalysis50. For example, (L)-malate dehydrogenases are 
highly selective as they are able to only catalyze the NAD-dependent oxidation of (L)-
enantiomer of malate.  
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2.4.4 Enzyme kinetics  
When aiming at creating metabolic pathways towards production goals, the evaluation of 
enzyme performance plays a vital role by allowing possible bottlenecks to be predicted. 
The field of enzyme kinetics aims at studying the reaction rates of enzyme-catalyzed 
reactions, which in many cases can be conveniently described by a simplified Michaelis-
Menten model. According to the Michaelis-Menten model, enzyme activity increases 
hyperbolically with the increase of substrate concentration up to a maximum level at 
which enzyme saturation is reached. The Michaelis-Menten equation is given by 
𝑣 =  
𝑉𝑚𝑎𝑥×[𝑆]
𝐾𝑚+[𝑆]
  
where v is the initial enzyme velocity, Vmax is the maximum velocity, [S] the substrate 
concentration and Km the Michaelis constant.  
The performance of a given enzyme is evaluated based on three fundamental kinetic 
parameters, of which only any two are independent: (1) the catalytic constant or turnover 
number (kcat) which is defined as the maximum number of substrate molecules that a 
single enzyme copy converts to product per unit of time, and is a function of Vmax  
𝑘𝑐𝑎𝑡 =  
𝑉𝑚𝑎𝑥
𝐸0
 
where E0 is the total enzyme concentration; (2) the Michaelis constant (Km) is the 
substrate concentration at half-maximal velocity, which under conditions of quasi-
equilibrium substrate binding approximates to the affinity of the enzyme for its substrate, 
but which in general is defined by a more or less complicated function of kinetic rate 
constants describing the enzyme mechanism, and (3) ratio of  kcat and Km (kcat/Km) which 
measures the catalytic efficiency at which an enzyme converts a substrate into the 
corresponding product, and allows information concerning substrate specificity to be 
inferred51. Among the external factors influencing the performance of an enzyme are pH, 
temperature and ionic strenght. Enzymes are usually experimentally characterized in vitro 
following protein purification based on affinity chromatography techniques.  
Although many enzymes follow the Michaelis-Menten kinetics, others show deviations. 
Many factors can cause such behavioral deviations, including product/substrate 
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inhibition, kinetic and binding cooperativity, or the action of an allosteric effector at 
physically remote binding site. In these cases, other more complex models of the enzyme 
kinetics have been proposed48. 
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2.5 Creating new enzymes 
Although a considerable number of enzymes has been characterized (104,000 enzyme 
names available in BRENDA database by 2016), it corresponds only to a small fraction 
of the earth’s biodiversity52–54. The creation of new enzymes performing new reactions 
and/or chemistries remains therefore as a major goal in the successful implementation of 
non-natural metabolic pathways.  
In the last decades, protein engineering emerged as a popular approach for enzyme 
discovery largely contributing to the creation of the concept of “made-to-order” enzymes. 
Protein engineering towards a novel function can be accomplished by two main strategies, 
(i) site-directed mutagenesis based on rational protein design and (ii) random mutagenesis 
coupled with directed evolution55. Both approaches have their advantages and challenges. 
Lately, the combination of the two strategies in an iterative approach has been attempted. 
In this section, enzyme engineering is presented with special emphasis on engineering 
template specialist enzymes acting on sterically cognate substrates or promiscuous 
generalist enzymes. The shift towards gain in new function most typically follows a weak 
negative trade-off in which engineered enzymes display activity on multiple substrates 
(Figure 2.5). The creation of enzymes truly specialized in a new function still remains a 
holy grail in the field of synthetic biology, and is limited to very few examples.  
  
 
Figure 2.5. Possible routes for acquisition of new enzymatic function. The gain–loss of the new versus old function, 
and the conversion of one ‘specialist’ protein into another, may trade-off linearly (dashed line), or follow either concave 
or convex routes. From Khersonsky et al56. 
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2.5.1 Rational design  
In the process of rationally engineering enzymes, available information on protein 
sequence, structure and function may be exploited, and computational tools used to 
identify target mutation sites likely to improve a desired trait (e.g. new function, activity, 
affinity, inhibition tolerance, thermostability). By focusing on specific amino acid 
positions, a small number of variants is generated resulting in reduced screening efforts 
when compared to enzyme directed evolution-based approaches. Rationally engineered 
enzymes are usually assayed in low-throughput assays, e.g. by traditional 
chromatographic and NMR techniques, or microplate-based assays. However, although a 
rational design strategy is particularly powerful in the prediction of the molecular factors 
influencing catalytic activity, only a small number of examples of the successful 
engineering of stereospecificity or enantioselectivity have been reported in the 
literature57,58.  
 
Sequence-based design 
The primary structure (i.e. amino acid sequence) of enzymes provides the most abundant 
source of information concerning natural diversity which may be exploited in rational 
design. In particular, the analysis of multiple sequence alignments (MSA) of homologous 
proteins is used in the identification of functional- and specificity-related residues, spatial 
constraints in 3D protein modeling and protein function prediction. While those residues 
determining catalytic activity show high degree of conservation, more variability can be 
found in other regions among homologous proteins. Several multiple sequence aligners 
are publicly available (e.g. ClustalW, MAFFT, Muscle)59. Position-dependent residue 
profiling and mutation correlation analysis can be performed using software such as 
EVfold, CCMpred or pySCA. The applicability of this strategy has been demonstrated 
e.g. in a design study aiming at converting Ec-Mdh into an enzyme with (L)-lactate 
dehydrogenase activity, in which target mutations were predicted on the basis of multiple 
sequence alignments between proteins belonging to the Ldh/Mdh superfamily of 
enzymes60. 
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Structure-based design 
The function of a given enzyme is intrinsically linked to its 3D structure, as well as its 
sequence. With the increasing number of solved protein crystal structures with bound 
substrate(s) and/or inhibitor(s) available in the PDB (Protein Data Bank), protein design 
is expected to be more accurate compared to sequence-based methods. However, 
experimentally solved structures are not available for all enzymes. Enzyme structure can 
often be predicted in these cases by homology or comparative modeling methods given 
the existence of a known structure of at least one homologous protein (sequence identity, 
> 30%). A number of structural bioinformatics tools and web-severs can be used for this 
purpose (e.g. I-Tasser, Modeller, SwissProt). Several studies report enzyme engineering 
strategies based on the multiple overlay of protein and protein-ligand crystal structures. 
Root mean square deviation (RMSD) measures allow the identification of locally variable 
protein chain conformations resulting from residue substitution, and the clustering of 
bound substrate configurations within the active sites of homologous enzyme families. 
Structure-based design approaches can be used in conjunction with complementary MSA 
analysis methods59.  
 
Computational structure-based enzyme design  
Besides structure comparison, enzyme structures can be used as starting templates in 
computationally more intensive automated combinatorial exploration of sequence and 
protein conformational space. Computational protein design (CPD) software such as 
ROSETTA61 can be used to perform side-chain rotamer conformational searching with 
either fixed, or more computationally demanding, flexible representations of the protein 
main-chain backbone. The introduction of protein backbone flexibility permitted a > 18-
fold increase in Diels-Alderase activity62 in an artificial enzyme previously designed 
using a fixed backbone63. CPD atom-based energy functions64, used to score relative 
folding free energies and ligand-protein binding interaction energies, have been primarily 
constructed on the basis of their computational efficiency and amenability to pair-wise 
residue interaction energy decomposition. The computational overheads of automated 
enzyme design typically limit the search of substrate/ligand configurational space to six 
external translational and rotational degrees of freedom of pre-calculated conformers of 
low internal energy. Automated computational methods do not require any prior 
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knowledge of natural sequence variation, although appropriate constraints on the types of 
permitted residue substitutions can be applied.  
Classical ligand docking methods alone can be used to predicting the preferred binding 
mode of (non-) natural ligands within the binding pocket of individual mutant or wild-
type protein structures. Scoring functions predict ligand-protein binding energies, in 
which top ranked scores correspond to the most likely ligand configuration. Key residue 
positions involved in substrate binding and catalysis may be located through reasoned 
analysis of experimental or model structural data. Docking applications range from 
enzyme drug design to engineer enzyme promiscuity to enable conversion of synthetic 
substrates. For example, by manually docking the synthetic OHB substrate in to the 
crystal structure of (L)-lactate dehydrogenase from Geobacillus stearothermophilus, 
Walther and colleagues65 observed a steric clash between the glutamine residue at 
position 85 and the synthetic substrate (Figure 2.6). Saturation mutagenesis at this 
position revealed the variant Q85C from E. coli to confer enhanced enzyme activity on 
OHB when compared to the wild-type counterpart.    
 
 
Figure 2.6. Active site region in X-ray crystal structure of the (L)-lactate dehydrogenase from Geobacillus 
stearothermophilus. The synthetic OHB substrate (green sticks) was manually docked into the enzyme complex bound 
with NAD+ and the substrate analogue oxamate (PDB code 1ldn). Side-chains of active site residues are shown in a 
grey stick representation. From Walther et al65. 
 
While early ligand docking tools focused primarily on the assumption of a static nature 
of the receptor protein, changes observed in protein conformation upon binding of a small 
molecule suggested that both protein backbone and side-chain and ligand flexibility were 
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important to correctly model protein/ligand interactions. Numerous tools have been 
developed to better address the ligand docking over the past decades (e.g. Gold, FlexX, 
Dock, AutoDock, Glide, RosettaLigand). These tools utilize a wide range of protein 
representations, sampling algorithms and scoring functions to predict protein/ligand 
binding geometry66,67. While many predicted residue mutations are typically confined to 
the active site, rational engineering should ideally aim for a complete description of the 
enzymatic process, in which substrate migration and recognition (studied by biophysical 
techniques), and the biochemical reaction (modeled by combined quantum 
mechanics/molecular mechanics (QMMM) methods) are addressed68. 
 
2.5.2 Directed evolution  
As opposed to enzyme rational design, the strategy of directed evolution mimics the 
theory of Darwinian evolution (mutation, recombination and selection) to evolve template 
enzymes towards an impaired user-specified phenotype. The workflow for a standard 
directed evolution assay can be divided into two consecutive stages: (a) in vitro diversity 
generation and transformation, and (b) screening and selection. Each step can impose 
significant technical limitations on the efficient exploration of sequence space69. 
 
Diversity generation and transformation 
Next to the selection of an appropriate template enzyme, genotypic variability is 
introduced in vitro into the protein-coding sequence. Although knowledge of protein 
structure or respective catalytic mechanism is not necessary for diversity generation, a 
thoughtful analysis is required so that a mutant library can significantly cover the protein 
sequence space. For example, in a protein composed of 100 amino acids random 
mutagenesis could generate up to 1.3×10130 variants. While ensuring a full coverage of 
the sequence space, the overwhelming majority of residue substitutions will result in 
unfolded or misfolded proteins, and neutral or deleterious effects on the thermal stability 
and biological function of correctly folded proteins. In addition, screening and selection 
methods are limited in throughput (as later discussed). To this end, diversity generation 
techniques are commonly limited to a few possible substitutions in the sequence space 
(e.g. two substitutions per 100 amino acids yield up to 2.0×106 possible variants) thereby 
increasing the average quality of mutant libraries. Random mutagenesis of a given 
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protein-coding sequence is normally performed by error-prone PCR with the aid of low-
fidelity DNA polymerases, followed by ligation of resulting DNA fragments to a plasmid 
backbone. The obtained plasmid libraries are typically composed of 1012 molecules per 
mg plasmid.  
Subsequently, plasmid libraries are introduced in a host strain so that protein-encoding 
genes can gain in vivo functionality. E. coli and S. cerevisiae are the most common host 
strains, but other hosts can be used to meet the specifications of the protein of interest. 
Transformation of an in vitro library into an in vivo screening context can entail 
significant losses in library size. Enabling screening and selection in an in vitro 
environment through compartmentalization, the utilization of cell-free transcription-
translation systems has lately gained particular attention as it bypasses the process of 
library transformation. Out of the scope of this thesis, an excellent review70 on enzyme 
directed evolution through cell-free systems is available. Another alternative would be 
the utilization of bacterial mutator strains (e.g. E. coli XL1-Red) to generate in vivo 
mutant libraries thereby avoiding the low efficiencies imposed by plasmid 
transformation71.   
 
Screening and selection 
Last but not least in a directed evolution campaign stand the screening and selection of 
strains expressing best-performing enzyme variants. Screening and selection processes 
represent the most significant bottleneck in directed evolution as they need to be 
optimized in each case scenario considering three main factors: throughput, sensitivity 
and selectivity. A variety of screening assays ranging in their throughput are presented in 
Figure 2.7. 
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Figure 2.7. Flowchart of a directed evolution campaign, typically based on two main stages: diversity generation and 
transformation, followed by screening and selection of improved variants. From Dietrich et al69.  
 
In the bottom of the throughput scale are the traditional chromatographic and NMR 
techniques. Despite enabling a precise identification and quantification of metabolites 
from in vivo or in vitro enzyme bioconversion studies, their throughput is not compatible 
with a strategy of directed evolution. Microplate-based assays may therefore represent a 
more adequate strategy for screening enzyme mutant libraries (~104 variants per day)69. 
By miniaturizing test tubes to multiple wells, high density formats are available (up to 
9600-well) albeit a 96-well format is the most widely used. After cell culture and enzyme 
production, traditional enzymatic reactions can be performed in a microtiter plate by 
adding reaction components together with manually added crude extracts of purified 
proteins. Using a plate reader, production formation or substrate consumption can be 
followed by UV-vis absorbance or fluorescence72. This strategy is particularly convenient 
for engineering NAD(P)(H)-dependent enzymes or NAD(P)(H)-coupled enzyme 
activities. For example, Irague and colleagues73 developed a general coupled assay for 
screening poorly active kinase enzymes, in which a NAD+ alkali derivate is used as a 
measurable output signal at 360 nm. The method was successfully validated by screening 
an aspartate kinase mutant library towards improved unnatural malate kinase activities.  
Higher in the throughput scale are the agar plate-based methods (~105 mutants per day). 
By shifting from an in vitro to an in vivo environment, colonies are incubated with the 
enzyme substrate whose conversion yields a (in)direct output signal (e.g. fluorescence, 
color). While agar plate screenings are easy to operate and outstanding in identifying 
active variants, they do not allow the inspection of different enzyme catalytic rates. For 
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this reason, they are commonly coupled with a second screening system aiming at 
estimating enzyme activities74,75. In an ingenuous example, an agar plate assay based on 
pH indicators was established in which color change upon substrate hydrolysis allowed 
the detection of improved esterase variants acting on 3-hydroxyester58.   
Growth complementation assays further extend the throughput scale. In this strategy, the 
utilization of a strain auxotrophic for an essential molecule is required (e.g. amino acids, 
key precursors). Growth complementation is a robust and accurate assay that enables 
selection on the basis of growth rates, which means that an auxotrophy will only be 
relieved when the lost enzymatic function is regained upon transformation with an 
improved enzyme variant. This technique is however limited in the enzyme sequence 
space, and it is frequently associated with detection in microtiter plates (growth rates) or 
agar plates (colony size). Another drawback is the limited growth dynamic range, as 
active enzymes cannot be distinguished from very active enzymes in which wild-type 
growth is restored. Fine-tuning of protein expression levels may solve this problem69. 
Close to the threshold of plasmid transformation efficiency and on the top of the 
throughput scale (~109 variants per day) is fluorescence activated cell sorting (FACS). 
Based on the concept of flow cytometry, FACS technology allows a rapid evaluation of 
size and fluorescence levels of each single cell with additional sorting. Specifically, 
libraries are first passed through a preliminary screen, in which top-fluorescent cells 
(~0.5-1 % of cell population) are sorted and enriched. Post-sorting viable cells are then 
submitted to a second screen in which the desired phenotype is confirmed. Further 
enrichments can be performed to reduce cell population and decrease false positive rates. 
The best performing enzyme variants (around 10-103) are further characterized with 
suitable low-throughput techniques. The direct detection of fluorescent metabolites (e.g. 
carotenoids, lipids) or proteins is well explored in FACS. In the last few years, particular 
attention has been paid to the development of genetic biosensors, which can detect a 
molecule of interest and output a fluorescent reporter protein. Living cells dispose of an 
extensive repertoire of natural sensor devices that by detecting a metabolite (e.g. 
riboswitches, transcription factors) are able to regulate downstream gene expression. 
Taking advantage of this mechanism, replacement of downstream gene by a fluorescent 
reporter protein ensures product detection. The co-expression of desired enzyme activities 
and an appropriate genetic sensor in an in vivo context, in which product formation rate 
regulates the reporter output signal, enables the creation of metabolite and/or whole-cell 
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biosensors. While FACS technology empowers throughput to unprecedent levels, genetic 
biosensors must be highly sensitive and selective towards the presence of a molecule of 
interest in a crowded intracellular environment. The creation of genetic sensors for 
detection of small molecules is further discussed in Chapter 5. 
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"Knowing is not enough; we must apply. Wishing is not enough; 
we must do."  
―Johann Wolfgang Von Goethe 
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Chapter 3. Rational enzyme design towards improved microbial 
production of 2,4-dihydroxybutyric acid 
 
3.1 Introduction 
A central challenge in the creation of a resource-efficient and sustainable bioeconomy lies 
in the reduction of our dependence on fossil resources and a shift in focus towards the 
development of efficient biochemical pathways for the production of fuels and bio-based 
chemicals1. (L)-2,4-dihydroxybutyrate (DHB), an α-hydroxy acid whose industrial interest 
has been rapidly growing, can serve as a precursor of methionine analogues for animal 
nutrition2. Petrochemical synthesis of DHB is however not cost-competitive and no natural 
biosynthetic pathways leading to its production are currently known, despite its occurrence 
at trace levels in patients with succinic semialdehyde dehydrogenase deficiency3. Most 
recent developments in synthetic biology domain have enabled the development of non-
natural biochemical pathways, leading to the production of economically relevant 
compounds4–6 and in particular DHB. Previous work from our group has demonstrated the 
feasibility of DHB biosynthesis from glucose through the engineering of glyoxylate7, 
homoserine8 or artificial malyl-phosphate9 pathways in E. coli (Figure 3.1a-c). More 
recently, Dischert and colleagues have disclosed a new artificial DHB route through the 
extension of a synthetic 1,2,4-butanetriol pathway (Figure 3.1d), thus enabling product 
formation from xylose, a pentose sugar and a major constituent of the hemicellulose fraction 
in lignocellulosic biomass10.  
In particular, DHB production from glucose via extension of the homoserine pathway is 
enabled by the introduction of a two-step pathway composed of two hitherto unknown 
enzymatic activities (Figure 3.1a). Homoserine is first converted into 2-keto-4-
hydroxybutyrate (OHB) by the action of an engineered homoserine transaminase. This 
compound is then reduced to DHB by an improved OHB reductase variant. In an ongoing 
effort to improve DHB production, strategies to further increase the efficiency of the 
pathway are highly desired. Pathway optimization strategies11 (e.g. gene 
disruption/overexpression, 5’-UTR engineering, plasmid copy number variation, codon 
optimization) to redirect carbon flux towards a molecule of interest are today well 
established in the scientific community, with numerous successful examples reported in the 
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literature12,13. However, those do not address situations in which poor performance of a 
given pathway is hindered by enzyme-associated limitations. Protein design has been 
described in these cases as an indispensable tool to engineer an optimal pathway14. 
 
Figure 3.1. Disclosed synthetic (L)-2,4-dihydroxybutyrate (DHB) pathways starting from pentose and hexose 
sugars. Adapted from Dischert and colleagues10.  Legend: OHB – 2-keto-4-hydroxybutyric acid. 
 
Our group has previously identified enzymes displaying homoserine transaminase and OHB 
reductase activities, but which however possessed low affinities towards the corresponding 
substrates. In particular, studies carried out by our group have revealed the (L)-lactate 
dehydrogenases from Lactococcus lactis (Ll-LdhA)2 and rabbit muscle (Rm-Ldh) as 
candidate OHB reductases8,15. (L)-lactate dehydrogenases (Ldh) are NAD-dependent 
dehydrogenases and one the most well-studied enzyme families, comprising over 100 fully 
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biochemically characterized members that also include (L)-malate dehydrogenases (Mdh). 
Ldh and Mdh notably both act on 2-keto acids: pyruvate and oxaloacetate, respectively. 
Additionally, they share a similar tertiary fold in which the nucleotide co-enzyme binding 
pocket and catalytic residues are conserved16. On the basis of these findings, a strategy to 
rationally engineer OHB reductase activity into the (L)-malate dehydrogenase from E. coli 
(Ec-Mdh) was employed based on a comparative structural analysis with Ldh enzymes 
complexed with sterically similar cognate substrates. The best-performing mutants as 
assessed in vitro were introduced into the homoserine DHB pathway and product titers 
evaluated.  
 
3.2 Strategy for OHB reductase design 
The dimeric Ec-Mdh enzyme was previously shown to possess only residual activity 
towards OHB (reductive reaction) and DHB (oxidative reaction). Malate dehydrogenases 
are highly selective and specific for dicarboxylic acids, while the OHB/DHB target 
molecules are monocarboxylic acids. Increased activity towards the OHB/DHB 
substrate/product couple was therefore envisaged using a rational design approach to guide 
site-directed mutagenesis of Ec-Mdh.  
As a first step, the possibility of using a homologous protein template for OHB reductase 
design was investigated. Both Ldh and Mdh, catalyze the interconversion between 2-
hydroxyacids and their corresponding 2-keto acids using the NAD/NADH co-enzyme 
system17. Ldh and Mdh share a similar tertiary structural fold in which the nucleotide 
binding pocket and catalytic residues are conserved, but yet maintain strong selectivity for 
mono- (pyruvate/lactate) and dicarboxylic acids (oxaloacetate/malate), respectively16,18. 
Key differences between the enzymes are found in the sequences of a mobile loop region 
(positions 79 through 91 in Ec-Mdh) covering the active-site.  The loop is known to exist in 
two distinct conformations in Mdh: an open form, in which the enzyme is inactive, and a 
closed form, in which the enzyme is active (Figure 3.2).  
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Figure 3.2. Superposition of X-ray structures of an Ec-Mdh complex with bound NAD+ (stick representation), 
showing the “closed” form of the mobile active-site loop in green (PDB code 1ib6), and the “open” (gold 
colored) loop form of the apo enzyme (PDB code 1ie3). An overlay of the malate substrate from the modelled 
ternary complex with coenzyme (PDB code 1cme) is shown as van der Waals spheres. Side-chain positions 
Arg81 and Arg87 involved in binding of the malate substrate are indicated in the two loop conformers. 
 
Conformational change is triggered by the binding of the β-carboxylate group of the 
substrate to Arg81 and/or Arg87, and involves a change in the local secondary structure of 
the loop at positions 86 through 89 in Ec-Mdh19,20. In the homologous Ldh system, ordered 
binding of NADH and pyruvate triggers incremental conformational changes in the active 
site and the expulsion of solvent necessary for catalysis to occur. The existence of a common 
kinetic mechanism in Ldh and Mdh enzymes implies that a similar conformational transition 
of the active-site loop operates in both enzymes. Crucially however, Ldh active-site loop 
closure occurs in the absence of the favorable energy contributions of a stabilizing salt 
bridge formed between a second substrate carboxylate group, absent in pyruvate, and a 
second arginine guanidinium group (replaced by Glu81 in Ldh, Table 3.1). Since pyruvate 
and OHB are both monocarboxylic acids, the identification of compensatory stabilizing loop 
interactions in Ldh afforded a design strategy for the engineering of OHB reductase activity 
into Ec-Mdh. 
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Table 3.1. Comparison of Mdh/Ldh active-site loop sequences in selected species. Entirely conserved residue 
positions are highlighted in red. Main-chain residue conformation key: H, helix; P, +ve ϕ main-chain dihedral 
angle; C, random coil. 
 
 
3.3 Identification of target mutation sites in Ec-Mdh 
Comparison of active-site loop sequences in representative Mdh and Ldh enzymes shows 
complete conservation of three structurally important residues at positions Gly78, Gly84 
and Leu90, as well as the conservation of Arg87 directly involved in substrate binding 
(Table 3.1). Analysis of larger multiple sequence alignments of Mdh and Ldh enzymes 
further confirmed the heavily conserved nature of residue types at these positions. These 
common "key" or "canonical" residues21 thus appear to be necessary for the stabilization of 
the active-site loop in the same overall conformation in Mdh and Ldh enzymes. On the other 
hand, comparison of overlaid closed loop conformers in experimental structures of Ldh and 
the binary complex of Ec-Mdh/NAD+ (Figure 3.3a) revealed the presence of two internal 
loop stabilizing interactions specific to Ldh. The first is the replacement of Ala80 in Ec-
Mdh by an arginine, which would be expected to assist in the orientation of the side-chain 
towards the solvent and stabilize the co-enzyme binding through favorable electrostatic 
interactions with phosphate groups bridging adenine and nicotinamide nucleotides. The 
second loop stabilizing interaction involves the substitution of Met85 by either glutamate or 
glutamine. Stabilization occurs via hydrogen bond formation between the main-chain -NH 
group at position 82 with either the carboxylate oxygen of a glutamate, or the side-chain 
carbamoyl oxygen of a glutamine. The mobile active-site loop in Ldh appears to be further 
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stabilized by a third specific set of non-covalent interactions at position 86 on the solvent-
exposed surface (Figure 3.3b). In principle, these interactions can be reproduced in Ec-Mdh 
via the following residue exchanges: D86S (in the mobile loop), G179D (in the Gly176-
Thr181 loop) and T211Y (in the Gly210-Ala216 helix). The mutually stabilizing side-chain 
interactions at the juncture of the three structural elements in Ldh fill the space otherwise 
occupied by the (A317) sulphate ion in the X-ray structure of Ec-Mdh. 
 
 
Figure 3.3. Structural alignment of Ldh X-ray structures from multiple organisms (PDB codes 1lth, 1ldn, 
2v7p, 3ldh, 1i0z, 9ldt) depicted with green carbon atoms, with the binary complex of Ec-Mdh and NAD+ (PDB 
code 1ib6). (A) Overlay of closed loop conformations (positions 79-91, Ec-Mdh). (B) Overlay of three 
structural elements in the solvent-exposed region surrounding protein active-site. The malate substrate, 
extracted from an Ec-Mdh model ternary complex with co-enzyme (PDB code 1cme), replaces the (A316) 
sulphate ion bound in the active site. The second sulphate (A317) ion which stabilizes the mobile loop 
(residues 79 to 81) is shown as a stick representation. Overlays were obtained by pairwise structural 
superposition at all aligned protein chain residue positions with respect to Ec-Mdh subject to a 2Å cut-off (Cα 
- Cα) separation distance. 
 
 
 
 
Visual inspection of an Ec-Mdh ternary complex model construct with malate (reaction 
product) and NAD+ (PDB code 1cme), and multiple sequence alignment analysis were used 
to identify putative target positions for mutation in the substrate and co-enzyme binding 
sites. Residue positions closest to the C4 atom in bound malate, and by implication to the 4-
OH group in the DHB/OHB couple, are Arg81, Val214 and Ser222. Estimation of the 
relative Shannon entropy (HX, see Methods) of amino acid frequency distributions revealed 
that all three positions are fully conserved (HX = 0) amongst Mdh enzymes, with more 
variation being observed in the wider Ldh/Mdh superfamily: HX values for the Pfam 
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(Ldh_1_N and Ldh_1_C) protein family alignments at positions 81, 214 and 222 were 0.34, 
0.43 and 0.54, respectively. Putative residue side-chain replacements at these positions in 
the active-site of Ec-Mdh were further explored by flexible docking of OHB (Figure 3.4), 
suggesting that mutation of residue Arg81 is likely to be essential for OHB reductase 
activity.  
 
Figure 3.4. Active-site regions in molecular models of (A) A80R:R81A:M85Q:D86S:G179D:T211Y:V214T 
and (B) A80R:R81Q:M85Q:D86S:G179D:T211Y:V214T mutant Ec-Mdh with NAD+ and flexibly docked 
OHB. The OHB carbons in five members of the two top-ranked clusters with equal interaction energies are 
shown in green and cyan in (A). Members of an additional high-ranking energy interaction OHB cluster are 
depicted in (B) with grey carbons. The OHB cluster with the most favorable interaction energy in (B) is that 
shown with green colored carbon atoms. A potentially displaceable crystallographic water molecule is 
represented as a magenta colored sphere. Each of the models is overlaid on the X-ray structure of an Ec-Mdh 
model ternary complex with co-enzyme (PDB code 1cme) from which it was derived as described in Methods. 
 
In Figure 3.4a, OHB docking into an R81A-containing mutant resulted in two ligand 
conformational clusters (green and blue sticks) with equal Boltzmann averaged interaction 
energies. On the other hand, replacement of Arg81 by glutamine (as in Ldh, Figure 3.4b) 
revealed a clear preference (of 2.3 kcal mol-1) for the green conformer. Whilst the latter can 
interact favorably with Gln81, it is at the same time forced into making close contact with 
the α-carbon of Gly210. The R81Q mutation did not therefore appear to confer any real 
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improvement in substrate/product binding interactions, and may indeed hinder access to the 
binding site. In this regard, the replacement of Arg81 by alanine seemed more preferable 
since it should allow for unimpeded access to the active-site by the substrate. As shown in 
Figure 3.4b, favorable hydrogen bonding interactions of the substrate/product 4-OH group 
can be made in two of the three bound ligand conformations (shown with green or grey 
carbons) with the side-chain of Ser222. Thus, there did not seem to be any obvious 
advantage to be gained from the modification of this residue. In contrast, isosteric mutation 
of Val214 to threonine might be expected to aid in the orientation of the Ser222 side-chain 
through intra-protein hydrogen bonding. However, the closest approach distance of the 
substrate/product 4-OH group to the Thr214 oxygen was observed to be too long (at 
approximately 4.0 to 4.6 Å) for the formation a good hydrogen bond. The effects of amino 
acid changes introduced at this position were investigated experimentally and the results are 
described in the next section. 
Further analysis of the Ldh multiple sequence alignment notably revealed the presence of 
smaller residues close to the co-enzyme nicotinamide ring at equivalent positions Ile12, 
Ile117 and Met227 in Ec-Mdh (Figure 3.5). Substitution of smaller residue types at these 
positions could potentially influence the positioning of the nicotinamide ring, and thereby 
exert a direct effect on catalysis (e.g. on the rate of hydride transfer). Candidate residue type 
replacements at these positions were identified from frequency analysis of the Ldh multiple 
sequence alignment: position 12: Val; position 117: Ala or Val; position 227: Ile or Val. 
The introduction of mutations at these three residue positions was by inference expected to 
shift the substrate specifity of Ec-Mdh towards the OHB/DHB couple.  
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Figure 3.5. Positions of variable residue positions (highlighted with green carbon side-chain atoms) in 
Ldh/Mdh superfamily in the vicinity of the co-enzyme nicotinamide ring in a modelled ternary complex of 
Ec-Mdh mutant (A80R:R81A:M85Q:D86S:G179D:T211Y:V214T) NAD+ and flexibly docked OHB 
conformer representatives of the top-ranked ligand pose (shown in stick representation with cyan carbon 
atoms). The model is overlaid on the X-ray structure of an Ec-Mdh model ternary complex with co-enzyme 
(PDB code 1cme) from which it was derived as described in Methods. 
 
 
3.4 In vitro analysis of site-directed variants 
In order to experimentally assess the rational engineering approach, both wild-type and site-
directed enzyme variants were characterized in the reductive (biosynthetic) reaction using 
OHB as the substrate (Figure 3.6). As expected, the wild-type enzyme Ec-Mdh displayed 
very little OHB reductase activity (kcat = 0.03 s
-1). Point mutations were then introduced in 
a step-wise manner into the substrate-binding region of Ec-Mdh, either individually or as 
groups. Substitution of Arg81 by alanine resulted in a dramatic 287-fold increase in 
maximum enzyme activity on OHB (kcat = 8.6 s
-1). In contrast, insertion of an additional 
mutation at position 214 in the R81A:V214T variant resulted in lower activity (kcat = 3.1 s
-
1).  
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Figure 3.6. Activity of wild-type and Ec-Mdh enzymes on OHB, expressed in s-1, and shown on a logarithmic-
scale.  The abscissa positioning allows the relative effects of each enzyme mutant to be readily discerned. 
Enzymes highlighted with an asterisk could not be saturated under the test conditions, and the reported 
activities were obtained at a substrate concentration of 50 mM. Activities of the other mutant enzymes 
correspond to calculated turnover numbers. The results are the mean of at least two biological replicate 
experiments. Error bars correspond to the standard deviation of the mean.  
 
The R81A mutation was then combined with amino acid changes either at residue position 
Ile12 proximal to the coenzyme nicotinamide ring, residue positions in the mobile loop 
covering the active site (Ala80, Met85 and Asp86) or at positions Gly179 and Thr211 
contacting the mobile loop. Increased OHB reductase activity (kcat = 13.4 s
-1) was observed 
in the I12V:R81A double mutant, as compared to the R81A variant, when residue changes 
were simultaneously introduced in the substrate binding site and the coenzyme nicotinamide 
ring binding pocket. Grouping amino acid changes in the substrate binding site with those 
elsewhere in the active-site resulted in distinct underlying patterns of response. Thus, while 
changes in loop residue positions Met85, Asp86 and Gly179 enhanced OHB reductase 
activities yielding kcat values of up to 85.4 s
-1 (variant R81A:M85Q), substitutions at the 
Ala80 and Thr211 target sites showed the opposite tendency. It is however noteworthy that 
the R81A:M85Q mutant could not be saturated within the tested OHB concentration range, 
and that the reported activity value was obtained at a substrate concentration of 50 mM. The 
results suggest that residue alterations at different locations within the active-site region 
elicit synergistic effects on both binding and catalysis. 
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To investigate whether OHB reductase activity could be further improved, the 
simultaneously introduction of amino acid changes in the substrate binding site, coenzyme 
binding pocket and at a structural contact region on the external surface of the mobile loop 
covering the active-site during catalysis was attempted. Variants from this group were found 
to be highly active on OHB, but more importantly could be saturated at lower substrate 
concentrations (< 35 mM). The catalytic efficiencies (kcat/Km) of the wild-type and best 
mutant enzymes were then evaluated for comparison on both OHB and the natural substrate 
oxaloacetate (Figure 3.7). The results indicate that Ec-Mdh engineering not only 
significantly improved enzyme efficiency for OHB, but also considerably decreased that 
towards oxaloacetate by at least 50-fold. Despite observing increased catalytic efficiencies 
towards OHB, the cumulation of amino acid changes in the best mutants resulted in variants 
with lower specificities (i.e. (kcat/Km)OHB / (kcat/Km)Oxaloacetate). However, intracellular 
concentrations of oxaloacetate are known to be very low, and for this reason we decided to 
fully kinetically characterize the four variants with the highest catalytic efficiency towards 
OHB notwithstanding their lowered specificity22,23.  
 
 
Figure 3.7. Catalytic efficiency (kcat/Km) in units of s-1 mM-1 of the wild-type and best Ec-Mdh mutant 
enzymes on OHB and oxaloacetate. The results are presented on a logarithmic scale as the mean of at least 
two biological replicate experiments. Error bars correspond to the standard deviation of the mean. 
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Table 3.2 shows the kinetic parameters for the reductive (biosynthetic) reaction of the wild-
type enzyme and the best mutants, for brevity henceforth denoted as Ec-Mdh-4E 
(I12V:R81A:M85E:G179D), Ec-Mdh-4Q (I12V:R81A:M85Q:G179D), Ec-Mdh-5E 
(I12V:R81A:M85E:D86S:G179D) and Ec-Mdh-5Q (I12V:R81A:M85Q:D86S:G179D). In 
view of its structural similarity to OHB, enzyme kinetic analysis was also carried out using 
pyruvate as substrate. All four mutants exhibited affinity for oxaloacetate, OHB and 
pyruvate, in contrast to the wild-type enzyme that possesses high stringency for its natural 
substrate. Although the Ec-Mdh-5Q variant showed the highest affinity and efficiency 
towards OHB (Km = 1.6 mM, kcat/Km = 37 s
-1 mM-1), Ec-Mdh-4E was the most specific 
enzyme towards OHB ((kcat/Km)OHB / (kcat/Km)Oxaloacetate = 0.87). Of particularly important 
note, with the exception of Ec-Mdh-4E variant all four mutants displayed substrate-
inhibition kinetics towards OHB (Ki ~30 mM) and oxaloacetate. Lower catalytic 
efficiencies were recorded when using pyruvate as substrate (kcat/Km < 0.5 s
-1 mM-1), and 
consequently Ec-Mdh mutants were more specific towards OHB (by up to two-orders of 
magnitude). The Ec-Mdh wild-type and variants were also characterized in the oxidative 
reaction using (L)-malate, (D/L)-DHB and (L)-lactate as substrates (Table 3.3). As 
expected, the catalytic efficiency of wild-type enzyme was much higher (by two orders of 
magnitude) in the reductive reaction (kcat/Km = 6,387 s
-1 mM-1) than on (L)-malate (kcat/Km 
= 40 s-1 mM-1). The same trend was observed for Ec-Mdh mutants with respect to both 
natural and synthetic substrate/product couples. Additionally, the four best mutants 
displayed much higher DHB dehydrogenase activities when compared to the wild-type 
enzyme (by up to four orders of magnitude), but protein engineering resulted in considerably 
low affinities for the racemic mixture of DHB (Ec-Mdh-5Q, Km = 64.1 mM L-DHB). 
Finally, none of the mutants demonstrated saturation kinetics when using (L)-lactate as the 
substrate.
5
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3.5 Optimization of DHB production using site-directed variants 
In a previous study, Walther and colleagues2 have demonstrated the E. coli parent strain 
ECO4 (MG1655 ΔadhE ΔldhA ΔthrB ΔmetA) to functionally express the homoserine DHB 
pathway when transformed with the medium-copy number plasmid pZA23-thrAS345F-aspC-
ldhAQ85C, that encodes for the threonine-insensitive bifunctional aspartate 
kinase/homoserine dehydrogenase mutant ThrA S345F, the homoserine (HMS) 
transaminase Ec-AspC and the OHB reductase Ll-LdhA Q85C. The resulting strain ECO18 
was able to produce 3.7 mM DHB after 24 h of culture in M9 mineral medium supplemented 
with 20 g L-1 glucose9. To improve DHB production, the increase in the availability of 
homoserine pathway precursors was first attempted. Since overexpression of the 
aspartate/malate insensitive phosphoenol pyruvate (PEP) carboxylase mutant Ec-Ppc 
K620S has previously been shown to increase the intracellular concentration of 
oxaloacetate9,24, the corresponding gene was cloned downstream of the DHB operon and 
the obtained pECO2-ppc* plasmid was transformed into the ECO4 parent strain. After 24 h 
of culture, the resulting strain CF216 led to slightly improved DHB production (3.9 mM), 
demonstrating a moderate positive effect of the increase in PEP carboxylase activity (Table 
3.4). Further investigations were therefore carried out using the pECO2-ppc* plasmid as a 
backbone for further modification.  
The identified four highly active Ec-Mdh variants on OHB (Ec-Mdh-4E, Ec-Mdh-4Q, Ec-
Mdh-5E and Ec-Mdh-5Q) were employed as OHB reductases in the DHB operon, leading 
to the generation of strains CF132-135 (Table 3.4). In all cases, DHB titers and 
productivities were improved (by up to two- and three-fold, respectively) in comparison to 
the use of Ll-Ldh Q85C (strain CF216), demonstrating the superior performance of the 
characterized Ec-Mdh variants. The DHB production levels were similar for all the tested 
Ec-Mdh variants, despite their previously described distinctive kinetic properties. The 
highest DHB titers were obtained from the expression of either Ec-Mdh-5E (CF134, 7.9 
mM) or Ec-Mdh-5Q (CF135, 7.6 mM) with similar product yields (0.10 mol mol-1 glucose). 
The OHB reductase Ec-Mdh-5Q expressed from the pECO2-ppc*(Ec-Mdh-5Q) plasmid 
was therefore selected for further studies.  
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In an ongoing effort to achieve higher DHB titers and productivities, also the replacement 
of the currently used HMS transaminase Ec-AspC was envisaged, since it has been shown 
to be a particularly inefficient enzyme when (L)-homoserine is used as the substrate2. In 
this regard, Bouzon and co-workers25 have discovered a new HMS transaminase in a 
recent study of E. coli one-carbon metabolism following long-term cell cultivation. The 
newly identified HMS transaminase is a mutant variant of the alanine aminotransferase 
from E. coli (Ec-AlaC) with substitutions at positions Ala142 and Tyr275. The resulting 
variant Ec-AlaC A142P:Y275D displayed a high affinity for homoserine (Km, 1.7 mM), 
in contrast to Ec-AspC that was not saturated at homoserine concentrations of up to 50 
mM2,25. As such, Ec-AspC was replaced by the HMS transaminase Ec-AlaC 
A142P:Y275D variant in the pECO2-ppc*(Ec-Mdh-5Q) plasmid. When the vector 
obtained was expressed in the parent strain, resulting in the strain CF217, increased levels 
of DHB accumulation (19.8 mM) in higher yields (0.19 mol mol-1) were observed, 
suggesting that the homoserine transamination step is rate-limiting (Table 3.4). To further 
confirm this, the improved Ec-AlaC variant was expressed together with the Ll-Ldh 
Q85C OHB reductase variant (strain CF268). After 24 h of cell cultivation, DHB 
production more than doubled (to 9.7 mM) compared to the CF216 strain expressing Ec-
AspC and Ll-Ldh Q85C. Overall, our results show that redirection of the metabolic flux 
towards homoserine when combined with the improved (Ec-AlaC A142P:Y275D) HMS 
transaminase and (Ec-Mdh-5Q) OHB reductase variants led to an up to five-fold 
improvement in the DHB titer and productivity as compared to the original ECO18 strain. 
 
3.6 Fed-batch cultivation of DHB-producing strains 
The best DHB-producing strain CF217 (which expresses Ec-Mdh-5Q and Ec-AlaC 
A142P:Y275D enzymes) was further studied in a 1.5 L medium-containing fed-batch 
reactor (Figure 3.8a). Under fully aerobic conditions and non-limiting glucose 
concentrations, 89.0 mM DHB were produced from glucose after 48h of culture. 
Considering this period, DHB was produced at a rate of 1.85 mmol L-1 h-1 with a yield 
equal to 0.18 mol mol-1. Accumulation of DHB was accompanied by the production of 
lactate and acetate (up to 21.3 mM and 20.8 mM, respectively). To further confirm the 
role of HMS transaminase as main rate-limiting step towards DHB biosynthesis, the strain 
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CF135 which expresses both Ec-AspC and Ec-Mdh-5Q enzymes was also cultivated 
under similar conditions (Figure 3.8b). Lower DHB production was observed (up to 41.5 
mM) with a yield of 0.09 mol mol-1 when compared to the strain CF217. Also the 
extracellular accumulation of the by-products acetate and lactate was kept at low levels.  
 
Figure 3.8. Fed-batch cultivation of the DHB-producing strains CF217 (A) and CF135 (B). Cells were 
cultivated on 1.5 L defined mineral medium (pH 7.0) which was supplemented with 1 g L-1 threonine and 
methionine to complement strain auxotrophies. Glucose was manually added to assure non-limiting carbon 
source concentrations (below 10 g L-1) during cell cultivation. Dissolved oxygen concentration was 
maintained above 40 % of saturating concentration to assure aerobic conditions. The results are derived 
from a single experiment. 
 
A comprehensive analysis of the extracellular accumulation of natural amino acids and 
homoserine DHB precursor was performed at the end of cultivation of each strain to 
understand in more detail cell metabolism during DHB production. While in both cases 
homoserine was released at relevant concentrations (> 28 mM), the utilization of Ec-AlaC 
A142P:Y275D yielded 1.4-fold higher accumulation of the referred DHB precursor 
(Figures 3.9a-b). However, the observed titers of alanine (107.6 mM) suggest a 
pronounced substrate promiscuity of the enzyme (Figure 3.9a). The accumulation of 
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glutamate (> 17.8 mM) was found to occur upon cultivation of both strains (Figures 3.9a-
b). 
 
 
Figure 3.9. Amino acid analysis after 48h of fed-batch cultivation of the DHB-producing strains CF217 
(A) and CF135 (B). Only those amino acids with concentrations exceeding 1 mM are shown. Cells were 
cultivated on 1.5 L defined mineral medium (pH 7.0) which was supplemented with 1 g L-1 threonine and 
methionine to complement strain auxotrophies. Glucose was manually added to assure non-limiting carbon 
source concentrations (below 10 g L-1) during cell cultivation. Dissolved oxygen concentration was 
maintained above 40 % of saturating concentration to assure aerobic conditions. The results are derived 
from a single experiment. Legend: OHPro – hydroxyproline, HSer – homoserine, * - not measured.  
 
3.7 Discussion 
A new metabolic engineering approach, based on the construction of de novo synthetic 
pathways constituted of novel reactions, has recently emerged enabling the production of 
non-natural compounds. This new concept however requires the discovery of novel 
enzyme functions by extensive data mining and/or protein engineering to generate new 
activities in the absence of naturally available biocatalysts1,26. In the development of an 
artificial route for the production of the non-natural compound DHB from glucose via 
homoserine, the development of highly-efficient HMS transaminase and OHB reductase 
enzymes has previously been identified as a major lever to boost the performance of the 
designed DHB pathway. In this work, the generation of a more efficient OHB reductase 
is described which was obtained by the step-wise rational engineering of a template 
enzyme homologue acting on a sterically similar cognate substrate. 
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Rational protein engineering is a well-established technique for the generation of novel 
enzyme variants with enhanced activity, stability or altered substrate specificity1,27,28. 
Based on the sequence, structural and functional information about target enzymes, amino 
acid changes likely to confer the desired enzymatic properties can be predicted in silico. 
The selection of an appropriate template enzyme to be redesigned is crucial to the 
experimental success of targeted mutagenesis29. In this study, Ec-Mdh served as the 
enzyme to be engineered for OHB reductase activity. Template selection was made on 
the basis that Ldh enzymes have been previously shown to convert the monocarboxylate 
OHB to DHB, and that Mdh and Ldh enzymes possess highly similar structures and a 
shared catalytic mechanism8,30. A key exploitable difference between Mdh and Ldh 
enzymes resides in their strict respective selectivity for di- and monocarboxylic acid 
substrates16,18. However, previous attempts to alter the substrate specificity of Ec-Mdh 
from the dicarboxylate oxaloacetate to the monocarboxylate pyruvate were met with only 
partial success31. While the engineered Ec-Mdh mutant enzymes reported in the literature 
exhibited reversed substrate specificity, they were significantly less active than the wild-
type Ldh enzyme towards the natural substrate pyruvate, illustrating the stringent 
substrate specificity of Ec-Mdh32,33. 
Based on comparative structural and sequence analysis combined with molecular 
modelling, target mutation sites in Ec-Mdh for the introduction of catalytic activity 
towards the monocarboxylic acid OHB were identified. The predicted amino acid residue 
exchange sites were located in distinct functional regions: the substrate binding site, the 
coenzyme nicotinamide ring binding pocket and at a structural contact region on the 
external surface of the mobile loop covering the active-site during catalysis. Mutations 
were introduced into wild-type Ec-Mdh in a step-wise manner. Experimental delineation 
of the observed increases in OHB reductase activity permitted to recombine mutations in 
different zones of the template protein active-site, leading to the identification of mutant 
combinations with better optimized kinetic properties. Favourable synergistic effects 
arising from the combination of correlated mutations have been documented in other 
studies34. In total, 17 Ec-Mdh variants were generated and the most promising amino acid 
changes bestowing OHB reductase activity were identified as (I12V, R81A, M85E/Q, 
G179D and/or D86S). Kinetic evaluation of the four best Ec-Mdh mutants revealed an 
improvement of up to three orders of magnitude in both the OHB reductase activity and 
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the Michaelis constant for OHB with respect to the wild-type enzyme. However, all four 
mutants displayed higher catalytic efficiencies for the natural substrate oxaloacetate than 
for OHB.  
The feasibility of the most promising Ec-Mdh mutants for in vivo applications was further 
evaluated by individual expression in the homoserine DHB pathway. All tested enzyme 
variants provided for approximately two-fold higher DHB production, as compared to the 
Ll-LdhA Q85C OHB reductase variant. Further improvements were obtained by 
channeling the carbon flux towards homoserine (Ec-Ppc K620S) and expression of the 
HMS transaminase variant Ec-AlaC A142P:Y275D in the DHB operon resulting in DHB 
titers up to 19.8 mM. Fed-batch cultivation under well-controlled conditions of the best 
DHB-producing strain (CF217) as assessed in cell culture at shake flask level further 
resulted in extracellular accumulation of DHB to levels up to 89.0 mM (or 10.7 g L-1), 
corresponding to the highest titer observed to date. The extracellular accumulation of high 
amounts of the homoserine DHB precursor suggests however that the currently used HMS 
transaminase is a major rate-limiting step of the pathway. Since the intracellular 
accumulation of homoserine has previously been shown to inhibit its own biosynthesis35, 
only a HMS transaminase with high catalytic efficiency could convert homoserine to 
OHB without substrate accumulation. The release of such amino acid to the medium may 
therefore be seen as a strategy of cell metabolism towards the continuous production of 
DHB. Additionally, the presence of alanine in the culture broth further confirms the 
substrate promiscuity of the Ec-AlaC A142P:Y275D enzyme, reason for which HMS 
transaminase may need to be further engineered if industrially relevant DHB titers are 
desired. The accumulation of glutamate may similarly be a consequence of the 2-
ketoglutarate dependent HMS transaminase activity which yields homoserine and 
glutamate at stoichiometrically equal amounts, or alternatively from the oxidation of the 
2-ketoglurate metabolite derived from the Krebs cycle and catalyzed by a glutamate 
dehydrogenase enzyme. On the other side, other reasons may be behind the presence of 
lactate and acetate, mainly observed at a late-stage of fermentation in which cells were in 
a stationary phase. Being both metabolites generated from pyruvate inside cells, the 
accumulation of lactate was somehow unexpected due to the deletion of (L)-lactate 
dehydrogenase encoding-gene ldhA and since the other two lactate dehydrogenases from 
E. coli (LlDd and Dld) have a marked preference for lactate oxidation. The observed 
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lactate accumulation may therefore be linked to the observed residual activity of Ec-Mdh-
5Q on pyruvate. On the other side, the production of acetate may occur as a metabolic 
strategy towards the regeneration of intracellular ATP, if it proceeds via acetyl-CoA.  
In summary, the work outlined here shows production of DHB via homoserine up to 89.0 
mM at a yield of 0.18 mol mol-1 glucose. Further enzyme engineering to increase the 
efficiency of the synthetic pathway is necessary to solve the observed pathway 
imbalances and remove metabolic inefficiencies. Pathway optimization through 
combination of modeling technologies with omics data measurements can identify and 
address additional bottlenecks impeding higher product formation. 
 
3.8 Materials and methods 
3.8.1 Chemicals and reagents 
All chemicals and solvents were purchased from Sigma-Aldrich unless otherwise stated. 
Restriction endonucleases and DNA-modifying enzymes were purchased from New 
England Biolabs and used according to manufacturer’s instructions. DNA plasmid 
isolation was performed using GeneJET Plasmid Miniprep Kit (Thermo Scientific). DNA 
extraction from agarose gel was carried out using the GeneJET Gel Extraction Kit 
(Thermo Scientific). DNA sequencing was carried out by Beckman Coulter Genomics 
(Takeley, United Kingdom) or Eurofins SAS (Ebersberg, Germany). 
 
3.8.2 Protein cloning, mutagenesis, expression and purification 
E. coli DH5α (New England Biolabs) was routinely used for construction of plasmids. 
The mdh gene encoding the wild-type Ec-Mdh was amplified by PCR (primers listed in 
Table 3.5) and cloned into the corresponding sites of pET28a (Novagen) using T4 DNA 
ligase (Biolabs), thereby adding an N-terminal hexa-His tag. Point mutations were 
introduced on pET28-derived plasmid by inverse PCR using the primer pairs listed in 
Table 3.6. Resulting products were digested by DpnI to remove template DNA and 
transformed into competent cells. Mutated plasmids were verified by sequencing. 
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Table 3.5. Primers and restriction enzymes used to clone genes into pET28a expression vector 
 
Table 3.6. Primers used for site-directed mutagenesis in pET28a-Ec-mdh 
Mutation Primer sequences (5' – 3') Restr. 
site 
R81nnk TTATCTCTGCAGGCGTAGCGNNKAAACCCGGGATGGATCGTTC 
GAACGATCCATCCCGGGTTTMNNCGCTACGCCTGCAGAGATAA 
SmaI 
R81A M85E TTATCTCTGCAGGCGTAGCGGCTAAACCGGGTGAGGATCGTTCCGACCTG 
CAGGTCGGAACGATCCTCACCCGGTTTAGCCGCTACGCCTGCAGAGATAA 
none 
R81A M85Q TTATCTCTGCAGGCGTAGCGGCTAAACCGGGTCAGGATCGTTCCGACCTG  
CAGGTCGGAACGATCCTGACCCGGTTTAGCCGCTACGCCTGCAGAGATAA  
none 
I12V GTCGCAGTCCTCGGCGCCGCTGGCGGTGTCGGCCAGGCGCTTGCAC 
GTGCAAGCGCCTGGCCGACACCGCCAGCGGCGCCGAGGACTGCGAC  
NarI 
G179D CCGGTTATTGGCGGCCACTCTGATGTTACCATTCTGCCGCTGCTG  
CAGCAGCGGCAGAATGGTAACATCAGAGTGGCCGCCAATAACCGG  
EaeI 
R81A D86S GGCGTAGCGGCTAAACCGGGTATGTCTCGTTCCGACCTG  
CAGGTCGGAACGAGACATACCCGGTTTAGCCGCTACGCC  
none 
V214T ATCCAGAACGCGGGTACCGAAGTGACTGAAGCGAAGGCCGGT   
ACCGGCCTTCGCTTCAGTCACTTCGGTACCCGCGTTCTGGAT     
KpnI 
T211Y ACGGATCCAGAACGCCGGCTATGAAGTGGTTGAAGCG     
CGCTTCAACCACTTCATAGCCGGCGTTCTGGATCCGT 
NaeI 
R81A M85E D86S GCGGCCAAACCGGGTGAGTCTCGTTCCGACCTGTTTAACG 
CGTTAAACAGGTCGGAACGAGACTCACCCGGTTTGGCCGC 
HaeIII 
R81A M85Q D86S GCGGCTAAACCGGGCCAGTCTCGTTCCGACCTGTTTAACG 
CGTTAAACAGGTCGGAACGAGACTGGCCCGGTTTAGCCGC 
HaeIII 
 
Enzymes were expressed in E. coli BL21(DE3) cells (New England Biolabs) in 200 mL 
Luria-Bertani (LB) medium supplemented with 50 µg mL-1 kanamycin (37 ºC, 200 rpm) 
that were inoculated from an overnight culture at OD600 of 0.05 and grown to OD600 of 
0.6 before protein expression was induced for 3 h by addition of 1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) to the culture medium. Cells were harvested by 
centrifugation (15 min at 4,000 rpm, 4 ºC) and pellets stored at -20 ºC until further 
analysis. Protein purification starting from frozen cell pellets was performed as described 
elsewhere9. 
Gene Primer sequences (5' – 3') Restriction enzymes Resulting vector 
Ec-mdh TATAATCATATGAAAGTCGCAGTCCTC 
TATAATGGATCCTTACTTATTAACGAACTC 
NdeI 
BamHI 
pET28-Ec-mdh 
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3.8.3 Enzymatic assays 
Protein concentrations were determined prior to enzymatic assays by the method of 
Bradford (Bio-Rad). All enzyme assays were carried out at 37 ºC in 96-well flat-bottomed 
microtiter plates in a final volume of 250 µl. The reactions were followed by the 
characteristic absorption of NADH at 340 nm in a microplate reader (Epoch 2, BioTek). 
Enzyme activities of wild-type Ec-Mdh and variants were assayed in both senses of the 
reaction. Assays in the reductive (biosynthetic) direction were carried out by monitoring 
NADH oxidation during the reduction of 2-keto acids. The assay mixture contained 60 
mM Hepes (pH 7), 0.25 mM NADH, 5 mM MgCl2, 50 mM KCl and appropriate amounts 
of purified enzyme or crude extract. Reactions were started by adding variable 
concentrations of oxaloacetate, OHB or pyruvate. Since OHB is not commercially 
available, it was produced in house by the action of L-amino acid oxidase in a single-step 
reaction starting from (L)-homoserine, and quantified by a ketone calibration curve36. 
Assays in the oxidative direction were carried out by following the reduction of NAD+ 
during the oxidation of 2-hydroxy acids. The assay mixture contained 179 mM glycine 
buffer (pH 9), 10 mM NAD+, 5 mM MgCl2, 50 mM KCl and appropriate amounts of 
purified enzyme or crude extract. Reactions were started by adding variable 
concentrations of (L)-malate, DHB or (L)-lactate. (D/L)-DHB consisted of a racemic 
mixture of stereoisomers kindly provided by Adisseo SAS (France). Values of kcat and 
Km were estimated by fitting kinetic data from at least five different substrate 
concentrations with SigmaPlot v12.0 following non-linear regression of Michaelis-
Menten equation, unless uncompetitive substrate inhibition was observed. 
 
3.8.4 Construction of pECO2ppc* (Ec-mdh-X) 
The genes coding for the best OHB decarboxylase variants (Ec-mdh-X, in which X 
determines the mutant) were PCR amplified from pET28A-derived vectors using primer 
pairs 1707/cf115 (see Table 3.7). The primers introduced unique restriction sites flanking 
the gene of interest, and additionally forward primers inserted a ribosome binding 
sequence (RBS) immediately upstream coding sequence. PCR products and vector 
eco2ppc-Ll-ldh were digested with NotI and BamHI restriction enzymes and ligated using 
T4 DNA ligase (New England Biolabs). The resulting constructions were transformed 
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into NEB 5-α chemically competent E. coli cells (NEB) and verified by DNA sequencing 
to contain the correct insert. Plasmids were then transformed in strain of interest. 
 
Table 3.7. Primers used to construct plasmids expressing the biosynthetic DHB pathway 
Primer Sequence (5' – 3') 
1469 
 
1470 
 
CTCTCATGGAAGTTAGGAGTCTGACCCGGGGTTTAACTTTAAGAAGGAG
ATATACCATGTTTGAGAACATTACCGCCGCTC        
CCTACAAGGATAACTTTTTTACGTTGTTTATCAGCCATGGTATATCTCCTT
CTTAAAGTTAAACGCGGCCGCTTACAGCACTGCCACAATCGCTTCGC 
1471 
 
1472 
 
GCGGCCGCGTTTAACTTTAAGAAGGAGATATACCATGGCTGATAAACAA
CGTAAAAAAGTTATCCTTGTAGG 
CGCAATGCGGAATATTGTTCGTTCATGGTACCGAGCTCGAATTCTGTTTC
CTGTTCTAGATTAGTTTTTAACTGCAGAAGCAAATTCTTC 
1473 
 
1474 
TCTAGAACAGGAAACAGAATTCGAGCTCGGTACCATGAACGAACAATAT
TCCGCATTGCG 
GATGCCTCTAGCACGCGTACCATCCCGGGTTAGCCGGTATTACGCATACC
TGCCG 
1707(mdh_xbaI_rv) 
cf115 (rbspet_mdh*_NotIF) 
 
ATAATTCTAGATTACTTATTAACGAACTCTTCGCCCAGGGC 
ATTAAGCGGCCGCGTTTAACTTTAAGAAGGAGATATACCATGAAAGTCG
CAGTCCTCGGCGCCGCTGGCGGTGTCGGCCAGGCGCTTGCACTACT  
 
 
3.8.5 Shake flask cultures for DHB production 
All cell cultivation was carried out at 37 ºC on a rotary shaker (Infors HT, France) running 
at 200 rpm. Pre-cultures were grown overnight in 10 mL of M9 mineral medium 
supplemented with methionine and threonine (0.2 g L-1) in 50 mL falcon tubes. The 
biomass needed to start main cultures with a starting OD600 of 0.2 was transferred to 250 
mL baffled-shake flasks containing 25 mL of M9 mineral medium supplemented with 
methionine and threonine, and IPTG was added at a concentration of 0.5 mM when OD600 
reached ~0.6. The antibiotic kanamycin sulphate was added when required at 50 mg L-1. 
One liter of M9 mineral medium contained: 20 g glucose, 18 g Na2HPO4*12H2O, 3 g 
KH2PO4, 0.5 g NaCl, 2 g NH4Cl, 0.5 g MgSO4*7H2O, 0.015 CaCl2*2H2O, 1 ml of 0.06 
M FeCl3 stock solution prepared in 100 times diluted concentrated HCl, 2 ml of 10 mM 
thiamine HCl stock solution, 20 g MOPS, and 1 ml of trace element solution (containing 
per liter: 0.04 g Na2EDTA*2H2O, 0.18 g CoCl2*6H2O, ZnSO4*7H2O, 0.04 g 
Na2MoO4*2H2O, 0.01 g H3BO3, 0.12 g MnSO4*H2O, 0.12 g CuCl2*H2O). The pH was 
adjusted to 7, and the medium filter-sterilized. 
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3.8.6 Fed-batch bioreactor cultures for DHB production 
The pre-cultures for the inoculation of the bioreactors were cultivated in 1 L shake flasks 
containing 150 mL mineral medium (composition as previously indicated) until 
exponential phase. Cells were then harvested and used to inoculate a 2 L bioreactor 
(Biostat B Sartorius) that initially contained 1.5 L medium with an OD600 of ~0.3. The 
composition of the fermentation medium was similar to the mineral medium used in the 
shake flask experiments (see subsection 3.8.5), with the exception that it additionally 
contained 6 g L-1 (NH4)2HPO4, 0.4 g L
-1 (NH4)2SO4, 1 g L-1 threonine and methionine, 
6 g L-1 citrate and no MOPS. Initial glucose concentration was 45 g L-1. Glucose 
concentration was monitored during the fermentation and a concentrated glucose stock 
solution (500 g L-1) was manually added to assure non-limiting glucose concentrations 
during the first 45 h of cultivation. The pH of the cultures was kept at 7.0 by the addition 
of 5 M KOH, and reactors were aerated with air at 0.3–1.5 vvm. Dissolved oxygen tension 
was maintained above 30 % of the saturating oxygen concentration by adjusting the 
appropriate agitation speed (300–1500 rpm, Rushton rotor, 28 mm diameter) and aeration 
rate. Polypropylene glycol (P2000) was used as antifoaming agent during the culture. 
 
3.8.7 Analytical methods 
All samples were centrifuged (2 min at 13,000 rpm) and syringe-filtered (0.2 µm), and 
the resulting supernatant stored at -20 ºC before analysis. A standard calibration curve 
was obtained by injecting standards and used for all compound analysis.  
Extracellular concentrations of glucose, organic acids and DHB were determined on a 
Dionex Ultimate 3,000 HPLC system (Thermo Scientific, France) equipped with a RI 
detector (RID-10A, Shimadzu, Japan) and UV/Vis detector (SPD-20A, Shimadzu). The 
sample injection volume was 20 μL, and the compounds were separated on a Rezex RoA-
organic acid H+ (8%) resin-based column preceded by a SecurityGuard guard cartridge 
(Phenomenex, USA). The separation was performed at 80 ºC with 0.5 mM H2SO4 at 0.5 
mL min-1 as mobile phase.  
The analysis of homoserine and amino acids in culture broth was performed on an Agilent 
Infinity 1290 LC system coupled to an Agilent 6490 Triple Quadrupole LC/MS equipped 
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with Agilent Jet Stream and ion funnel technology. The chromatographic separation for 
amino acids was carried out on an InfinityLab Poroshell 120 HILIC-Z column (Agilent, 
France), which was maintained at a temperature of 30 °C, and the sample volume injected 
was 5 μL. Chromatographic separation was performed at a flow rate of 0.6 mL min-1 using 
a gradient with solvent A (10% 200 mM ammonium formate at pH 3 (formic acid) + 90% 
water) and solvent B (10% 200 mM ammonium formate at pH 3 (formic acid) + 90% 
acetonitrile). The mass spectrometer was operated in AJS ESI-Positive mode, capillary 
voltage 4.00 kV, nozzle voltage 1.00 kV, desolvation temperature 400°C, source 
temperature 250°C, cone gas flow 17 L min-1, desolvation gas flow was 12 L min-1, 
nebulizer 40 psi, iFunnel parameters (high-pressure and low‑pressure RF) were set to 140 
and 60, respectively. Collision energy, iFunnel parameters, and MRM transitions for the 
20 amino acids and nozzle voltage were optimized for each amino acid using MassHunter 
optimizer software. Dwell time was set to 45 ms, and delta EMV(+) to 200 V. Agilent 
MassHunter quantitative analysis software was used for data analysis.  
 
3.8.8 Computational methods 
Sequence alignments: Two sets of 1000 amino acid sequences were obtained by pair-wise 
BLAST searching of non-redundant data banks against Ec-Mdh (UniProtKB P61889) and 
Bacillus stearothermophilus lactate dehydrogenase (UniProtKB code P00344) sequences. 
The two sequence sets were multiply aligned using MUSCLE37. Pfam PF00056 
(Ldh_1_N) and PF02866 (Ldh_1_C) domain database alignments38, respectively 
corresponding to Ec-Mdh residue ranges Met1 through Gly145 and Thr147 through 
Val310, were used to explore position-dependent amino acid residue variation in the 
combined Ldh/Mdh superfamily. Residue frequencies and Shannon information entropy 
measures of residue variability, corrected for normalised frequencies of residue type 
occurrence in natural proteins, at selected corresponding positions in Ec-Mdh were 
calculated from the multiple sequence alignment data. The relative Shannon entropy (HX) 
is calculated at each residue alignment position (X) as 
 
𝐻𝑋 =
∑ 𝑝(𝑖|𝑋) ln 𝑝(𝑖|𝑋)
20
𝑖=1
∑ 𝑝(𝑖) ln 𝑝(𝑖)
20
𝑖=1
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where p(i/X) is the conditional probability of residue type (i) occurrence at the alignment 
position (X), and p(i) is the probability of residue type (i) occurrence at any position. To 
minimize sampling bias, p(i) was taken as the globally normalized residue type 
probability values for all natural proteins tabulated by Ranganathan and colleagues39. 
Values of HX vary continuously from zero, corresponding to a fully conserved residue 
position, to unity for a residue position exhibiting no intrinsic residue type preference.  
Structure alignments: Crystal structures of L-lactate dehydrogenases from 
Bidifobacterium longum (PDB code 1lth), Bacillus stearothermophilus (PDB code 1ldn), 
Thermus thermophilus (PDB code 2v7p), dogfish (PDB code 3ldh), human heart (PDB 
code 1i0z), and porcine muscle (PDB code 9ldt) were aligned with the binary complex of 
Ec-Mdh/NAD+ (PDB code 1ib6). Overlays were obtained by pair-wise structural 
superposition at all aligned protein chain residue positions with Ec-Mdh subject to a 2Å 
cut-off separation distance between aligned Cα atom centres. 
Molecular modelling: Chains A/B of the X-ray structure of binary complex Ec-Mdh 
R153C mutant with NAD+ (PDB code 1ib6) were used as a template dimeric structure for 
mutant enzyme modelling and OHB ligand docking studies. The mobile active-site loop 
in this structure is stabilized in the active form by the presence of two SO4
2- ions. The 
Arg153 side-chain was manually rebuilt in the same fully extended conformation 
observed in experimental Mdh and Ldh structures. Arg81 was truncated to alanine, and 
the resulting R81A mutant enzyme complex with NAD+ was energy minimized with 
harmonic constraints placed on all heavy atom positions. Minimization was carried out 
using the ff99SB Amber molecular mechanics force field variant for protein atoms40, and 
the GAFF force field41 for the co-enzyme. The electrostatic model comprised a distance-
dependent dielectric constant with ε = 4. Partial atomic charges for NAD+ were abstracted 
from the CHARMM27 residue topology file entry42. The (A317) sulphate ion stabilizing 
the mobile loop on the solvent-exposed surface was excised prior to the introduction of 
mutations in the loop and substrate binding-site. Residue modification was carried out 
using the interactive Richardson penultimate backbone-dependent side-chain rotamer 
library43 search facility and residue mutation functionality in the COOT molecular 
graphics and modelling package44. Mutant structures were re-minimized without 
constraints on atoms in modified and surrounding residue positions, with harmonic 
constraints placed on all other heavy atom positions. 
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Substrate docking: The (A316) sulphate ion and two water molecules (A344, A353) were 
removed from the active site of energy minimized binary complexes of the mutant 
enzymes before docking of OHB into the A subunit in the presence of bound NAD+. 
Docking was carried out using in-house HOMER software and the PANENERGY pair-
wise (non-local) protein-ligand atomic statistical potential45 without the application of 1-
3 covalent atom connectivity energy scaling. Docked solutions from 200 simulated 
annealing runs were clustered, and a Boltzmann weighted average interaction energy 
calculated for each cluster. 
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Chapter 4. Construction of a synthetic pathway for production 
of 1,3-propanediol from glucose 
 
4.1 Introduction 
A central goal of the bioeconomy consists in reducing our dependence on petroleum by 
focusing on the development of efficient, sustainable and eco-friendly processes for 
production of chemicals and fuels1. 1,3-Propanediol (PDO) is an important commodity 
chemical that can serve as a monomer for the synthesis of industrially relevant polymers, 
including polyesters, polyethers and polyurethanes. Among those, the polyester 
polytrymethylene terephthalate (PTT) is seen as a major competitor of Nylon in carpet 
industries, therefore making PDO a molecule of significant industrial interest. While both 
acrolein hydration, and ethylene oxide hydroformylation followed by reduction of resulting 
aldehyde enable PDO synthesis, low product yields and harsh reaction conditions impede 
the successful development of a cost-competitive chemical production process2,3.  
Alternatively, PDO can be microbially produced from glycerol by Klebsiella and 
Clostridium species under anaerobic conditions in a two-step pathway that employs vitamin 
B12-dependent glycerol dehydratase and PDO oxidoreductase enzymatic activities. Albeit 
expanding the range of substrates would render PDO production more flexible, no natural 
microorganisms have been found to directly convert sugars to this compound. Previous 
studies demonstrated the adoption of two-stage and co-fermentation processes to enable a 
better control of cultivation conditions and a wider flexibility in terms of substrate 
utilization4–6. Another approach is the engineering of microorganisms for the direct 
production of PDO from sugars via glycerol. Successful examples include engineering K. 
pneumoniae and Saccharomyces cerevisiae for enabling PDO biosynthesis from glucose7. 
In addition, Genencor and DuPont have commercialized a process which employs a 
genetically modified E. coli strain able to produce PDO at high titers and yields8. In both 
cases, the engineered PDO synthesis pathways are composed of necessary reaction steps 
linking the glycolysis-derived metabolite dihydroxyacetone phosphate (DHAP) to PDO via 
glycerol.   
While traditional metabolic engineering resulted in great improvements in PDO 
biosynthesis, the rapid development of powerful genome mining and protein engineering 
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tools enables now the creation of de novo designed non-natural pathways for the production 
of economically relevant compounds9. In this regard, an artificial pathway enabling PDO to 
be synthesized from glucose or sucrose was established by extending the naturally-occurring 
aspartate-homoserine pathway in E. coli. In this approach, homoserine is first deaminated 
by an enzyme with homoserine transaminase activity10. The resulting 2-keto-4-
hydroxybutyrate (OHB) is then decarboxylated by an enzyme displaying OHB 
decarboxylase activity, while 3-hydroxypropanal (3-HPA) is finally reduced to PDO by an 
enzyme with 1,3-propanediol oxidoreductase activity. While the last reaction of this 
artificial pathway is catalyzed by the broad substrate range NADPH-dependent aldehyde 
reductase encoded by yqhD gene from E. coli (Ec-yqhD), the two preceding enzymatic 
reactions are not known to naturally occur in cell metabolism. In demonstration of this 
pathway, the authors have engineered an E. coli strain overexpressing both the native serC-
encoded transaminase (Ec-SerC) and branched-chain 2-ketoisovalerate decarboxylase from 
Lactococcus lactis (Ll-KivD). Low PDO titers were however obtained (0.3 mM). In another 
study, Chen and colleagues11 recently attempted to optimize this pathway by replacing the 
first catalytic step with an enzyme displaying homoserine dehydrogenase activity obtained 
by rational engineering of the E. coli NADP-dependent glutamate dehydrogenase, but PDO 
titers were not further improved. 
In the present work, the design and construction of an alternative synthetic pathway enabling 
PDO synthesis from glucose via the TCA cycle intermediate malate through six non-natural 
enzymatic reaction steps is described. Malate is first converted to the non-natural metabolite 
(L)-2,4-dihydroxybutyrate (DHB) by employing malate kinase, malate semialdehyde 
dehydrogenase and malate semialdehyde reductase activities as recently demonstrated by 
our group12. Extending this pathway with DHB dehydrogenase, OHB decarboxylase and 
PDO oxidoreductase eventually yields PDO. Based on enzyme screening and engineering 
approaches, the required enzyme activities were demonstrated, improved and found to 
enable in vivo PDO production from DHB. Simultaneous expression of all six enzymatic 
activities in one E. coli strain enabled direct PDO production from glucose, while 
distributing the malate-to-DHB and DHB-to-PDO pathway individual modules into two E. 
coli strains co-cultivated in mineral medium further improved PDO titers. 
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4.2 Design of the PDO synthetic pathway 
In a previous study, a de novo metabolic pathway leading to the production of DHB from 
glucose via malate was designed and experimentally validated by expressing malate kinase, 
malate semialdehyde dehydrogenase and malate semialdehyde reductase enzyme activities 
in E. coli12. This work demonstrates that the non-natural DHB metabolite may serve as a 
precursor for the microbial production of PDO. The conversion of DHB to PDO proceeds 
via three reaction steps (Figure 4.1): DHB is first oxidized to OHB; the resulting α-ketoacid 
is then decarboxylated to yield 3-HPA which is finally reduced into PDO. These reactions 
are catalyzed by enzymes bearing DHB dehydrogenase, OHB decarboxylase and PDO 
oxidoreductase reductase activities, respectively. The negative standard Gibbs free energy 
for the proposed pathway attests its thermodynamic feasibility (Supplementary 
information p. 104-105: Note S4.1, Table S4.1). Stoichiometric analysis of the metabolic 
network in E. coli shows that PDO can be produced from glucose with a theoretical 
maximum yield of 1.5 mol mol-1 (Supplementary information p. 106: Note S4.2). The 
maximum yield is similar to those previously reported on PDO production from glucose via 
homoserine11 and glycerol8. Implementation of the pathway requires enzymes bearing the 
three constitutive enzymatic activities. The promiscuous broad range aldehyde reductase 
YqhD from E. coli (Ec-YqhD) was previously shown to catalyze the reduction of 3-HPA to 
PDO14, and was therefore also used in this work. In contrast, OHB decarboxylase activity 
was found for the pyruvate decarboxylase from Z. mobilis (Zm-Pdc) but with limited 
success11, while DHB dehydrogenase activity has not been reported in literature to date.  
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Figure 4.1. The proposed synthetic 1,3-propanediol (PDO) pathway. Based on the group contribution theory, 
the pathway is thermodynamically favorable and has an overall standard Gibbs free energy of -60.9 kJ mol-1 
(see Supplementary information p. 105: Note S4.1). 
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4.3 Engineering of DHB dehydrogenase activity 
The soluble NAD-dependent (L)-malate dehydrogenase enzyme variant from E. coli Ec-
Mdh-5Q (I12V:R81Q:M85Q:D86S:G179D) was previously shown to accept DHB as 
substrate (as discussed in Chapter 3). But since the NAD-dependent oxidation of DHB is 
thermodynamically unfavorable (ΔrG
0 = 15.7 kJ mol-1) and this enzyme possesses a reduced 
affinity for (L)-DHB (Km = 64.1 mM) and a strong preference for OHB reduction (> 100-
fold), other candidate enzymes were screened. Crucially, E. coli MG1655 was found to 
possess the capability to assimilate the (L)-form of DHB, but not its D-stereoisomer (data 
not shown). The identification of those enzymes from E. coli endogenous metabolism with 
DHB dehydrogenase activity was therefore attempted. In particular, the utilization of 2-
hydroxyacid dehydrogenase enzymes acting on substrates structurally similar to the target 
(L)-form of DHB molecule was envisaged. In this regard, E. coli displays of a set of three 
lactate dehydrogenase enzymes able to catalyze the interconversion between lactate and 
pyruvate (encoded by llDd, ldhA and dld genes), but of which only the membrane-associated 
(L)-lactate dehydrogenase (Ec-LldD) possesses activity on (L)-stereoisomers15–17. 
Additionaly, Ec-LldD relies on a FMN-dependent co-factor system16 which would render 
(L)-DHB oxidation thermodynamically favorable (ΔrG
0 = -23.1 kJ mol-1; Supplementary 
information p. 105: Note S4.1) as opposed to NAD-dependent enzymes. For these reasons, 
the Ec-LldD enzyme was further characterized towards DHB dehydrogenase activity. To 
this end, the wild-type Ec-LldD enzyme was produced from a pET28-derived vector 
expressed in E. coli BL21(DE3) cells and the corresponding activity determined in crude 
extract. As indicated in Table 4.1, the Ec-LldD enzyme showed measurable activity on (L)-
DHB (Vmax = 0.6 U mg
-1) which was however 4-fold lower than that on (L)-lactate (Vmax = 
2.1 U mg-1). In addition, a specificity (expressed as Vmax/Km) of 3-orders of magnitude 
higher for (L)-lactate than for (L)-DHB was observed, reason for which Ec-LldD was 
rationally engineered for increased DHB dehydrogenase activities as described next.  
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Amino acid residues responsible for substrate specificity in Ec-LldD were identified by 
visual inspection of the crystal structure of the homologous protein from Saccharomyces 
cerevisiae (Sc-Cyb2) bound to the reaction product pyruvate and the co-factor FMN18. Key 
residues in the active site of Sc-Cyb2 are shown in Figure 4.2. The negative charge of the 
α-carboxylate group of pyruvate is neutralized by electrostatic interaction with Arg376, 
while residues Leu199, Leu230, Leu286, Tyr254 and Phe325 delimit the active site pocket. 
The catalytic residue His373 deprotonates the α-hydroxyl group of (L)-lactate, but the 
mechanism of substrate oxidation is still not clear. The pivotal role of those residues in 
substrate binding was previously discussed by Mowat and colleagues19. In the same study, 
amino acid substitutions at residue Leu230 (corresponding to Val108 in Ec-LldD), which is 
in contact with the methyl group of pyruvate, were demonstrated to confer activity on larger 
substrates (e.g. mandelate). The amino acid valine in position 108 was therefore replaced 
by smaller amino acid residues such as alanine, serine, cysteine and glycine, and the 
activities of resulting mutants were analyzed (data not shown). Only the substitution V108C 
resulted however in an improved catalytic efficiency for DHB (Vmax/Km = 82 U mg
-1 M-1) 
when compared to the wild-type enzyme (Vmax/Km = 58 U mg
-1 M-1) (Table 4.1). Therefore, 
the Ec-LldD V108C mutant enzyme was chosen as the DHB dehydrogenase enzyme to be 
employed in the synthetic PDO pathway.  
 
 
Figure 4.2. Active site region in the X-ray crystal structure of S. cerevisiae flavocytochrome B2 (Sc-Cyb2) 
(PDB code 1fcb). The residues in contact with reaction product pyruvate (pyr) are highlighted. 
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4.4 Engineering of OHB decarboxylase activity 
The enzymes Zm-Pdc and the branched-chain ketoacid decarboxylase from L. lactis (Ll-
KdcA) were previously demonstrated to possess activity on a wide range of 2-ketoacids, 
yielding corresponding aldehydes and carbon dioxide as reaction products11. Due to the 
structural similarity between OHB and 2-ketoacids, activities of both enzymes on their 
natural substrates and OHB were examined. While both enzymes displayed OHB 
decarboxylase activities, a strong preference for the natural substrate of up to 3-orders of 
magnitude was observed (Table 4.2). For this reason, a rational engineering strategy was 
employed aiming at increasing enzyme activities towards the OHB substrate through site-
directed mutagenesis of both biocatalysts. 
Manual docking of OHB into the active site pocket of Zm-Pdc revealed the substrate binding 
site to be too small for its accommodation (Figure 4.3A). In particular, the steric clash of 
Trp392 with the OHB substrate can be avoided by replacement with glutamine (Figure 
4.3B), which may then be able to hydrogen bond with the 4-OH hydroxyl group, or leucine. 
Replacement of tryptophan by glutamine at residue 392 in Zm-Pdc resulted in 1.4-fold 
increased catalytic efficiency on OHB and a more than 100-fold improved specificity 
towards the non-natural substrate (Table 4.2). However, the measured enzyme activities for 
the variant W392Q still remained at low levels (Vmax = 0.02 U mg
-1). 
 
Figure 4.3. Active site region in the crystal structure of Z. mobilis pyruvate decarboxylase (Zm-Pdc) wild-
type (A) and W392Q (B). The synthetic 2-keto-4 hydroxybutyrate (OHB) substrate was manually docked into 
the X-ray structure of the enzyme with bound pyruvate (Pyr) and a TPP analogue complexed with a Mg2+ ion 
(PDB code 2wva). The individual mutation at residue 392 was introduced to Zm-Pdc manually in Pymol and 
resulting change in pocket size is shown.
8
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Contrarily to Zm-Pdc, the substrate binding site in Ll-KdcA can accept a wide range and 
more voluminous molecules including branched chain substrates. Visual inspection of the 
X-ray crystal structure of an enzyme-bound inhibitory TPP analogue reaction intermediate20 
manually docked with pyruvate and OHB substrates, enabled the identification of target 
residue positions for mutation (Figure 4.4A). In particular, Val461 lies at the entrance of the 
S-pocket to which it can control access. Replacement by a bulkier isoleucine residue, as 
observed in Zm-Pdc (Ile472), is expected to further hinder binding in the S-pocket, and to 
improve interactions with the OHB in the main substrate channel (Figure 4.4B). The active 
site of Ll-KdcA is lined by several other key residues previously identified to play a critical 
role in controlling S-pocket sized and acceptance of bulkier substrates, including Phe381, 
Gly402, Met538, and Phe54221. Substitution of Val461 by isoleucine in Ll-KdcA provided 
a 2-fold increase in maximum enzyme activity on OHB while decreasing affinity towards 
this non-natural substrate by approximately two-fold (Table 4.2). Also the replacement of 
Gly402 with a serine residue in Ll-KdcA was attempted but with no noticeable 
improvements (data not shown).  
 
 
Figure 4.4. Active site region in the crystal structure of L. lactis branched chain keto-acid decarboxylase (Ll-
KdcA) wild-type (A) and V461I (B). The X-ray structure bound with a TPP analogue complexed with a Mg2+ 
ion (PDB code 2vbg) was aligned with Zm-Pdc structure (PDB code 2wva) crystalized with pyruvate bound. 
Upon protein structure overlay, the Zm-Pdc structure was hidden, leaving only the pyruvate, TPP analogue and 
Mg2+ and the Ll-KdcA active site shown. The pyruvate molecule served as an indicator of the putative binding 
position and orientation of the 2-ketoacid substrates within Ll-KdcA, after which the synthetic 2-keto-4 
hydroxybutyrate (OHB) substrate was manually docked. The individual mutation at residue 461 was introduced 
to Ll-KdcA manually in Pymol and resulting change in pocket size is shown. 
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4.5 PDO production from DHB 
To evaluate the possibility of converting DHB to PDO, an operon composed of genes 
encoding for the DHB dehydrogenase Ec-LldD V108C variant, OHB decarboxylase variant 
from either Zm-Pdc or Ll-KdcA and the aldehyde reductase Ec-YqhD was assembled. The 
operons were cloned into the medium-copy pACT3 vector22 and resulting plasmids were 
transformed into the wild-type E. coli MG1655 strain. PDO production from a racemic 
mixture of 40 mM (D/L)-DHB after 47h of incubation was obtained for all constructs except 
for the strain Pen946 which harbored an empty plasmid (Table 4.3). These results indicate 
that the proposed reaction sequence to transform DHB into PDO is feasible. The strains 
which expressed the OHB decarboxylase variants Ll-KdcA V461I (strain Pen913) and Zm-
Pdc W392Q (strain Pen966) showed the highest PDO titers (3.75 and 2.82 mM, 
respectively). Thus, increased OHB decarboxylase activity of the mutants translated into 
increased PDO production. But since DHB consumption by cells was not further improved, 
DHB oxidation and/or DHB uptake were hypothesized as limiting factor(s) towards PDO 
biosynthesis. To evaluate this possibility, the PDO-producing strain Pen913 was incubated 
with various DHB concentrations (10-100 mM) and PDO titers evaluated (Figure 4.5).  
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Figure 4.5. Production of PDO from various concentrations of (D/L)-DHB by Pen913 strain (E. coli MG1655 
pACT3-llDdV108C-kdcAV461I-yqhD). Cells were cultivated in 250 mL non-baffled shake flasks on mineral 
medium containing 20 g L-1 glucose. At OD600 ~0.6, IPTG (1 mM) and a racemic mixture of (D/L)-DHB were 
added to the medium. After 47h incubation time, product and substrate titers were measured. Data are presented 
as the mean (±S.D.) of at least two replicates.  
 
 
Indeed, cells were able to assimilate more substrate at increasingly higher DHB 
concentrations. Crucially, supplementation with 50 mM and 100 mM (D/L)-DHB yielded 
however a marginal 12% increase in DHB consumption by cells (11.4 and 12.8 mM 
consumed, respectively). This occurrence suggests that DHB uptake systems may be DHB 
unspecific and/or saturated. Dischert and colleagues23 recently proposed various permeases 
from E. coli as putative DHB transporters, including glycolate permease (GlcA) and α-
ketoglutarate permease (KgtP). In line with this information, DHB consumption from strains 
expressing the synthetic pathway in parallel with the aforementioned DHB uptake systems 
was therefore investigated. Interestingly, DHB consumption was substantially increased 
within 48h only in strains that overexpressed GlcA (Figure 4.6), supporting the fact that 
DHB uptake was rate-limiting for PDO production. The lower PDO yields observed 
(glcAproD: 0.44 mol mol-1) in comparison to the wild-type host strain (0.62 mol mol-1) may 
however indicate downstream catalytic inefficiencies and/or DHB conversion into other 
products.  
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Figure 4.6. Production of PDO from (D/L)-DHB by various E. coli MG1655 host strains (as indicated in X-
axis) harboring the pACT3-llDdV108C-kdcAV461I-yqhD plasmid. For each condition PDO yields were as follows, 
wt: 0.62 ±0.23 mol mol-1, glcAproD: 0.44 ±0.14 mol mol-1, and kgtPproD: 0.54 ±0.17 mol mol-1. Cells were 
cultivated in 250 mL non-baffled shake flasks on mineral medium containing 20 g L-1 glucose. At OD600 ~0.6, 
IPTG (1 mM) and a racemic mixture of 50 mM (D/L)-DHB were added to the medium. After 47h incubation 
time, product and substrate titers were measured. Data are presented as the mean (±S.D.) of at least two 
replicates.    
 
 
4.6 Synthesis of PDO from glucose 
To demonstrate PDO production directly from glucose, the genes coding for the complete 
six-reaction step pathway were cloned into two different plasmids. The previously 
constructed medium-copy pDHBop(ppc*) vector12 provided all enzymatic activities 
required to transform malate into DHB by driving the expression of malate kinase Ec-LysC 
V115A:E119S:E250K:E434V, malate semialdehyde dehydrogenase Bs-Asd E218Q, and 
malate semialdehyde reductase Ms-Ssr H39R:N43H enzymes. Overexpression of the 
malate-insensitive phosphoenolpyruvate carboxylase variant Ec-Ppc K620S from the 
pDHBop(ppc*) plasmid was previously shown to greatly increase DHB production12. The 
three genes responsible for the conversion of DHB to PDO were cloned into a high-copy 
vector yielding pEXT20-lldDV108C-pdcW392Q-yqhD or pEXT20-lldDV108C-kdcAV461I-yqhD. 
The pDHBop(ppc*) and pEXT20-derived vectors were transformed into E. coli strains 
which were cultivated for 24h on mineral medium containing 20 g L-1 glucose as the carbon 
source. Resulting strains CF317 and CF318 which expressed all pathway genes produced 
small amounts of PDO (up to 0.1 mM), whereas the control strain CF316 which only 
harbored pDHBop(ppc*) and an empty control pEXT20 plasmid was unable to produce PDO 
(Figure 4.7). While it is still unclear why DHB excretion was 5-fold higher in CF318 than 
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CF317, these results suggested that the very low PDO production from glucose can be 
associated to a weaker catalytic capacity of the downstream DHB-to-PDO pathway as 
compared to the DHB-yielding pathway.  
 
Figure 4.7. PDO production from glucose after 24h of cultivation of an E. coli mono-culture system. Cells were cultivated 
in 250 mL baffled shake flasks on mineral medium containing 20 g L-1 glucose. At OD600 ~0.6, IPTG (1 mM) was added 
to the medium. Data are presented as the mean (±S.D.) of at least two replicates.  
 
 
 
 
 
 
4.7 Employing a two-strain co-cultivation mode to increase PDO production 
To get some insights about which of the two synthetic pathways is limiting in the PDO 
production from glucose, a co-cultivation strategy was considered in which an E. coli strain 
expresses the synthetic DHB-yielding pathway while another one bears the PDO-producing 
pathway. Adopting such strategy would additionaly reduce the metabolic burden imposed 
by the expression of the whole synthetic pathway in a single production strain. This idea is 
further supported by the previous demonstration of bacterial co-cultures as a mean towards 
increased production of small molecules, including muconic acid24, 3-amino-benzoic acid25 
and n-butanol26. The design of the co-culture strategy is shown in Figure 4.8.  
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Figure 4.8. Scheme of the co-culture design, in which a first cell expresses the upstream pathway enabling DHB synthesis 
from glucose, while a second cell incorporates extracellularly accumulated DHB and converts it to PDO due to expression 
of the downstream pathway. 
 
The upstream DHB-yielding pathway was expressed from the CF285 strain whilst the 
downstream part of the pathway which converted DHB into PDO was expressed in the 
strains Pen913 or Pen966 (which differed in the expression of the OHB decarboxylase 
mutants, Ll-KdcA V461I and Zm-Pdc W392Q, respectively). To evaluate the performance 
of the two-strain co-cultivation strategy, the DHB- and PDO-producing strains were 
cultivated alone or simultaneously (in the latter case, at 1:1 inoculation ratio) for 24h on 
glucose-containing mineral medium (Figure 4.9).  
 
 
Figure 4.9. PDO production from glucose after 24h of cultivation of E. coli-E. coli co-culture systems at an inoculation 
ratio equal to 1:1 (in which 1 corresponds to an OD600 of 0.2). Improved PDO titers were achieved by varying PDO 
producing strains (Pen913, Pen966, CF283, CF286) while keeping unchanged the DHB producing strain CF285. Cells were 
cultivated in 250 mL baffled shake flasks on mineral medium containing 20 g L-1 glucose. After 3h of cell cultivation, 
IPTG (1 mM) was added to the medium. Data are presented as the mean (±S.D.) of at least two replicates.    
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In a control experiment, strain CF285 alone produced 14.7 mM DHB but no PDO. The co-
cultivation of CF285:Pen913 resulted in two-fold higher PDO production than of 
CF285:Pen966 (0.8 mM vs 0.4 mM), indicating that the catalytic efficiency of chosen OHB 
decarboxylase is critical in the DHB-PDO pathway. In both cases, DHB was extracellularly 
accumulated, which accordingly was the highest in the co-culture producing PDO at lower 
titers. This observation is supported by the idea that the PDO-producing pathway bearing 
the DHB dehydrogenase variant Ec-LlDd V108C and either one of the OHB decarboxylase 
mutants (Ll-KdcA V461I and Zm-Pdc W392Q) is catalytically less efficient that the DHB-
yielding pathway. As GlcA overexpression was found to enhance DHB uptake, this co-
cultivation strategy was repeated using a PDO-producing strain that overexpressed glcA 
(CF283: MG1655 glcAproD pACT3-llDdV108C-kdcAV461I-yqhD or CF286: MG1655 glcA
proD 
pACT3-llDdV108C-pdcW392Q-yqhD). This resulted in increased PDO production up to 2.8 mM 
with CF285 and CF283 strain co-cultivation, whereas only 1.5 mM was obtained with co-
culture of CF285 with CF286, confirming the previous results suggesting that the OHB 
decarboxylase mutant Ll-KdcA V461I is more efficient than the Zm-Pdc W382Q (see Table 
4.3).  
In an attempt to fine-tune the best-performing CF285:CF2833 co-cultivation system, the 
inoculation ratios were varied (Figure 4.10). Specifically, the starting cell concentration 
(expressed as OD600) of PDO-producing strain CF283 was step-wise decreased while 
keeping constant the initial cell concentration of CF285 to assure DHB production at levels 
not inferior to those observed above. At least 2-fold higher accumulation of DHB was 
observed when less CF283 was added to the co-culture system, but improvements in PDO 
production were only marginal. In the overall, co-cultivation of CF285 and CF283 strains at 
an inoculation ratio of 1:0.5 resulted in the highest production of PDO (3.4 mM) from 
glucose.   
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Figure 4.10. PDO production from glucose after 24h of cultivation of DHB-producing strain CF285 and PDO-producing 
strain CF283 at various inoculation ratios (in which 1 corresponds to an OD600 of 0.2). Cells were cultivated in 250 mL 
baffled shake flasks on mineral medium containing 20 g L-1 glucose. After 3h of cell cultivation, IPTG (1 mM) was added 
to the medium. Data are presented as the mean (±S.D.) of at least two replicates.    
 
 
4.8 Discussion 
In this work, a synthetic pathway enabling PDO biosynthesis from glucose under aerobic 
conditions via the Krebs cycle intermediate (L)-malate is presented. The proposed route does 
neither involve supplementation of the expensive vitamin-B12 nor the use of glycerol as a 
precursor unlike naturally occurring PDO pathways. Instead, it is based on the extension of 
a previously published (L)-DHB metabolic pathway with three additional reaction steps. But 
as an energy and NADPH-intensive pathway which requires one mol of ATP and three mol 
of NAD(P)H per each mol of PDO generated from malate, co-factor supply is likely essential 
for achieving relevant PDO titers. In this scope, our group27 has previously engineered E. 
coli malate metabolism via Krebs cycle and glyoxylate shunt, which provides increased ATP 
and NADH amounts at the expense of a decreased maximum malate yield (1.33 mol mol-1 
glucose). Implementation of the complete PDO pathway in a malate-overproducing strain 
may therefore translate into increased PDO titers.   
One of the major challenges found during the construction of non-natural pathways consists 
in finding desired enzyme activities at rates compatible with in vivo applications. The 
proposed route uses a combination of natural and engineered enzymes acting on non-natural 
substrates. While the three first catalytic steps linking (L)-malate to DHB were demonstrated 
elsewhere12, the discovery of the three remaining steps that would render PDO production 
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possible was targeted in this work. Substrate promiscuity is a feature displayed by around 
one-tenth of naturally occurring enzymes and particularly useful towards the discovery of 
new enzyme functions28. Based on the selection of template enzymes performing similar 
reactions and acting on sterically cognate substrates, candidate (L)-DHB dehydrogenase and 
OHB decarboxylase enzymes were first screened. The chosen enzymes exhibited however 
weak activities on non-natural substrates, reason for which a protein rational engineering 
was considered towards optimization of desired catalytic efficiencies. But the relatively 
limited success in increased specificities towards these non-natural substrates obtained with 
engineered Ec-LlDd V108C and OHB decarboxylase variants (Ll-KdcA V461I and Zm-Pdc 
W392Q) demand for alternative strategies. In this regard, the recently developed 
transcriptional-based metabolite sensor for aldehyde detection (see Chapter 5), including 
the resulting 3-HPA product of OHB decarboxylation, may be used as a tool for in vivo 
screening of OHB decarboxylase and/or other rate-limiting upstream enzyme(s) mutant 
libraries generated by (semi-)random mutagenesis. 
For a more comprehensive understanding of the pathway, the feasibility of the proposed 
DHB-PDO pathway was first evaluated, but the uncomplete substrate consumption together 
with low PDO yields revealed an important limitation. This bioconversion experiments also 
indicated that the DHB uptake is a bottleneck, which was in part relieved by overexpression 
of the glycolate encoded transporter GlcA. However, even in a strain in which uptake of 
DHB has been improved, PDO yields were not increased which further suggests OHB 
decarboxylases to limit the rate at which DHB is converted to PDO. 
When the direct production of PDO from glucose was evaluated by expressing the six-step 
synthetic pathway in an E coli strain, a very weak production titer of 0.1 mM PDO was 
obtained from 110 mM glucose. In the same time, metabolic burden imposed by the 
expression of this whole synthetic pathway is likely to occur due to the presence of a 
medium- and high-copy plasmids in cells. Nevertheless, this experiment revealed that the 3-
step synthetic pathway that converts DHB to PDO was likely less efficient than the three-
step synthetic pathway yielding DHB from malate since a significant amount of DHB 
accumulated in the growth medium. As a mean to overcome the hypothetical metabolic 
burden arising from expression of this six-step synthetic pathway, a co-cultivation strategy 
was attempted in which the whole pathway was split into an E. coli strain expressing the 
DHB-yielding and another E. coli strain that expressed the PDO-producing pathway. This 
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strategy resulted in increased product formation (up to 3.4 mM PDO), thereby showing that 
the performance of a synthetic pathway can, in principle, be improved by splitting into 
functional modules that are expressed in different strains. In addition, a lower accumulation 
of DHB in the medium was observed when employing this co-cultivation approach as 
compared to the expression of the whole synthetic pathway in a single E. coli cell, which 
can be ascribed in part to a better functioning of the PDO-producing pathway when it is 
expressed alone. For industrial applications this is however not a preferable solution, in 
particular, for production of bulk chemical which requires extremely high carbon efficiency 
that cannot be achieved by co-culturing two strains. Overcoming the identified limiting steps 
of the DHB-PDO synthetic pathway, additional strain engineering towards increased 
availability of DHB to the PDO-producing pathway, as well as resolving the metabolic 
burden caused by expression of the six-step synthetic pathway are essential to achieve higher 
production of PDO from glucose in a single strain. 
 
4.9 Materials and methods 
4.9.1 Chemicals and reagents 
All chemicals and solvents were purchased from Sigma-Aldrich unless otherwise stated. 
Restriction endonucleases and DNA-modifying enzymes were purchased from New 
England Biolabs and used according to manufacturer’s instructions. DNA plasmid isolation 
was performed using GeneJET Plasmid Miniprep Kit (Thermo Scientific). DNA extraction 
from agarose gel was carried out using the GeneJET Gel Extraction Kit (Thermo Scientific). 
DNA sequencing was carried out by Beckman Coulter Genomics (Takeley, United 
Kingdom) or Eurofins SAS (Ebersberg, Germany). The racemic mixture of sodium (D/L)-
DHB (purity, 70%) was chemically synthetized by Adisseo SA (France).  
 
4.9.2 Protein cloning and mutagenesis 
E. coli DH5α (New England Biolabs) was routinely used for construction of plasmids. Wild-
type Ec-lldD and Zm-pdc genes were amplified from genomic DNA (extracted from E. coli 
MG1655 and Zymomonas mobilis ATCC® 31821, respectively) by PCR. The used primers 
are listed in Table 4.4. The gene Ll-kdcA from Lactococcus lactis B1157-NIZO was codon-
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optimized for expression in E. coli and synthesized by Eurofins. The resulting DNA 
fragments were digested with suitable restriction enzymes (see Table 4.4) and cloned into 
the corresponding sites of pET28a vector system (Novagen) using T4 DNA ligase (Biolabs), 
thereby adding an N-terminal hexa-His tag. Point mutations were introduced on pET28-
derived plasmid by inverse PCR using the primers listed in Table 4.5. Resulting products 
were digested by DpnI to remove template DNA and transformed into competent cells. The 
introduction of desired mutation was verified by sequencing. 
 
Table 4.4. Primers and restriction enzymes used to clone genes into pET28a expression vector 
* Ec (from Escherichia coli), Zm (from Zymomonas mobilis), Ll (from Lactococcus lactis) 
 
Table 4.5. Primers used for site-directed mutagenesis 
Matrix Mutated 
position 
Primer sequences (5' – 3') Restr. site 
pET28-Ec-lldD V108C TTCCGTTTACTCTGTCGACGTGTTCCGTTTGCCCGA 
TCGGGCAAACGGAACCCGTCGACAGAGTAAACGGAA 
HincII 
pET28-Zm-Pdc W392Q GTTATTGCTGAAACCGGTGACTCTCAGTTCAATGCGCA
GCGCATGAAGC 
GCTTCATGCGCTGCGCATTGAACTGAGAGTCACCGGT
TTCAGCAATAAC 
FspI 
pET28-Ll-kdcA V461I TTTGCTTTATCATTAATAATGACGGCTACACAATCGAG
CGCGAAATTCA 
TGAATTTCGCGCTCGATTGTGTAGCCGTCATTATTAAT
GATAAAGCAAA 
AseI 
 
 
4.9.3 Protein expression and purification 
Enzymes were expressed in E. coli BL21 (DE3) cells (New England Biolabs) in 200 mL 
Luria-Bertani (LB) medium supplemented with 50 µg/mL kanamycin (37 ºC, 200 rpm). 
Gene* Primer sequences (5' – 3') Restriction enzymes Resulting vector 
Ec-lldD CATATGATTATTTCCGCAGCCAGC 
AGATCTCTATGCCGCATTCCCTTTC 
NdeI 
BgI2 
pET28-Ec-lldD 
Zm-pdc CATATGAGTTATACTGTCGGTACC 
GGATCCCTAGAGGAGCTTGTTAAC 
NdeI 
BamHI 
pET28-Zm-pdc 
Ll-kdcA provided in vector by Eurofins NheI 
EcoRI 
pET28-Ll-kdcA 
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Expression cultures were inoculated from an overnight culture at OD600 of 0.05 and grown 
to OD600 of 0.6 before protein expression was induced by addition of 1 mM isopropyl β-D-
1-thiogalactopyranoside (IPTG) to the culture medium. Cells were harvested after 3 h of 
incubation by centrifugation (15 min at 4,000 rpm, 4 ºC) and pellets stored at -20 ºC until 
further analysis.  
Frozen cell pellets were resuspended in 1 mL of lysis buffer (50 mM Hepes, 300 mM NaCl, 
pH 7.5) and disrupted by four successive rounds of sonication (sonication interval: 30 s, 
power output: 30%, sonicator: Bioblock Scientific, VibraCell™ 72437). The resulting cell 
crude extract was directly used for measurement of FMN-dependent 2-hydroxyacid 
dehydrogenase activities, while 2-ketoacid decarboxylase enzymes were purified as 
described elsewhere12.  
 
4.9.4 Enzymatic assays 
Protein concentrations were determined prior to enzymatic assays by the method of 
Bradford29. All enzyme assays were performed in a microplate reader (Epoch 2, BioTek) at 
37ºC in 96-well flat-bottomed microtiter plates in a final volume of 250 µL.  
FMN-dependent 2-hydroxyacid dehydrogenase activity: Activity of wild-type membrane-
associated (L)-lactate dehydrogenase and mutant variant V108C assayed in the oxidative 
direction by monitoring reduction of 2,6-dichloroindophenol (DCIP) at 655 nm (ε = 5.9 mM-
1 cm-1) during oxidation of 2-hydroxy acids. The assay mixture contained 60 mM Hepes (pH 
7), 50 mM KCl, 0.06 mM DCIP and appropriate amounts of crude protein extract. Reactions 
were started by adding appropriate concentrations of (L)-lactate or a racemic mixture of 
(D/L)-DHB (Adisseo SAS, France). 
2-Ketoacid decarboxylase activity: Activity of keto-acid decarboxylase wild-type and 
mutant variants was assayed by coupling the decarboxylation reactions to the NAD(P)H-
dependent reduction of the produced aldehydes. The decarboxylation of natural substrates 
(pyruvate, 3-methyl-2-oxobutyric acid) was coupled to the NADH-dependent reduction of 
acetaldehyde catalyzed by yeast alcohol dehydrogenase (Sigma, A7011). OHB 
decarboxylase activity was assayed by coupling decarboxylase activity to the NADPH-
dependent reduction of the released 3-hydroxypropanal by purified aldehyde reductase Ec-
99 
 
YqhD. The assay mixture contained 60 mM Hepes (pH 7), 50 mM KCl, 5 mM MgCl2, 0.25 
mM NAD(P)H, 0.5 mM thiamine pyrophosphate, 100 µg mL-1 auxiliary enzyme and 
appropriate amounts of purified enzyme. Reactions were started by adding appropriate 
concentrations of pyruvate, 3-methyl-2-oxobutyric acid or OHB. The latter was synthesized 
in-house as previously described30.  
 
4.9.5 Construction of plasmids and strains for biosynthesis of PDO  
All plasmids and strains constructed and used in this study for PDO production are listed in 
Table 4.6.  
Plasmid construction: The gene Ec-yqhD was amplified by PCR from genomic DNA with 
primer pairs pen290/pen291, whilst the remaining genes were amplified from pET28-28 
derived vectors using primer pairs listed in Table 4.7. DNA fragments were purified and 
assembled by homologous recombination with BamHI/SalI digested pEXT20 or pACT3 
vector using the NEBuilder® HiFi DNA Assembly kit (New England Biolabs). The resulting 
plasmids were transformed into DH5α competent E. coli cells and assembled operons 
verified by DNA sequencing. 
Strain construction: E. coli K-12 substr. MG1655 (ATCC 47076) was used as the parental 
strain for all constructions in this study. Expression of glcA and ktgP genes was rendered 
constitutive by replacing the native chromosomal 5’-UTR of each gene by the synthetic 
constitutive and insulated promoter proD31. The proD sequence was preceded by a kan 
resistance cassette which was amplified by PCR adding 50 bp flanking sequences that were 
homologous to the target locus. The resulting DNA fragment was used to replace the natural 
gene promoter by homologous recombination32. Primers used are listed in Table 4.7. 
Positive clones were selected on LB agar plates containing kanamycin (50 µg mL-1) and 
verified by PCR analysis. The kan cassette was removed from the genome by expressing 
FLP recombinase from the pCP20 plasmid33 and correct excision of the cassette was verified 
by PCR using locus specific primers (Table 4.7). Plasmids were transformed into the target 
E. coli strains using standard protocols34. 
1
0
0
 
 
 
1
0
1
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4.9.6 Synthesis of PDO from DHB 
All cell cultivation was carried out at 37 ºC on a rotary shaker (Infors HT, France) running 
at 200 rpm. Pre-cultures were grown in 5 mL of LB in 50 mL falcon tubes. After ~10h, 500 
µL were used to inoculate a second pre-culture (10 mL of 90 % v/v M9 mineral medium 
supplemented with 20 g L-1 glucose and 10 % v/v LB in 50 mL falcon tubes) that was 
cultivated overnight. The biomass needed to start main cultures with a starting OD600 of 0.2 
was transferred to 250 mL baffled shake flasks containing 25 mL of 90 % v/v M9 mineral 
medium supplemented with 20 g L-1 glucose and 10 % v/v LB, and IPTG and (D/L)-DHB 
were added (at amounts indicated in each associated figure or table) when OD600 reached 
~0.6. The antibiotic chloramphenicol was added when required at 25 mg L-1. 
 
4.9.7 Synthesis of PDO from glucose 
Pre-cultures were grown in 5 mL of LB in 50 mL falcon tubes. After ~10h, 500 µL were 
used to inoculate a second pre-culture (10 mL of M9 mineral medium supplemented with 20 
g L-1 glucose in 50 mL falcon tubes) that was cultivated overnight. The biomass needed to 
start main cultures with a starting OD600 of 0.2 was transferred to 250 mL baffled shake 
flasks containing 25 mL of M9 mineral medium supplemented with 20 g L-1 glucose. The 
antibiotics ampicillin, kanamycin sulphate and chloramphenicol were added when required, 
respectively, at 100, 50 and 25 mg L-1. IPTG (1 mM) was added after 3 h of cell cultivation. 
In co-cultivation experiments, the different strains were inoculated at a ratio described in the 
text. 
 
4.9.8 Analytical methods 
Concentrations of glucose and (D/L)-DHB were determined on a Dionex Ultimate 3,000 
HPLC system (Thermo Scientific, France) equipped with a RI detector (RID-10A, 
Shimadzu, Japan) and UV/Vis detector (SPD-20A, Shimadzu). The sample injection volume 
was 20 μL, and the compounds were separated on a Rezex RoA-organic acid H+ (8%) resin-
based column preceded by a SecurityGuard guard cartridge (Phenomenex, USA). The 
separation was performed at 80 ºC with 0.5 mM H2SO4 at 0.5 mL min
-1 as mobile phase.  
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All samples were centrifuged (2 min at 13,000 rpm) and syringe-filtered (0.2 µm), and the 
resulting supernatant stored at -20 ºC before analysis. A standard calibration curve was 
obtained by injecting standards and used for all compound analysis. 
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4.10 Supplementary information 
  
Table S4.1. Gibbs free energy of formation of PDO pathway intermediates. 
Compound  Contributing groups  ΔfG0’ [kJ mol-1] 
malate2-  2x –COO1-  
1x -OH  
1x -CH2-  
1x –CH<  
-840.98 
malyl-P2-  1x –COO1-  
1x -OH  
1x -CH2-  
1x –CH<  
1x -CO-OPO3H-  
-1740.1 
malate-SA-  1x -COO1-  
1x –OH  
1x -COH  
1x -CH2-  
1x –CH<  
-620.5 
DHB-  1x -COO1-  
2x –OH  
2x -CH2-  
1x –CH<  
-660.2 
OHB- 1x -COO1-  
1x –OH  
2x -CH2-  
1x >CO 
-626.6 
3-HPA 1x –OH  
2x -CH2-  
1x >CO 
-287.3 
PDO 2x –OH  
3x -CH2-  
-326.9 
ATP3- 
ADP2- 
NADPH 
NADP+ 
HPO42- 
H+ 
NADH 
NAD+ 
FMN 
FMNH2 
CO2 
 
 
-2819.4 
-1949.1 
-3082.9 
-3104.9 
-1096.1 
-39.9 
-2193.8 
-2215.8 
-1352.4 
-1449.0 
-386.0 
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Note S4.1. Standard Gibbs free energy of the DHB pathway 
The stoichiometry of the reactions malate kinase (MK), malate semialdehyde 
dehydrogenase (MSD) and malate semialdehyde reductase (MSR), 2,4-dihydroxybutyrate 
dehydrogenase (DD), OHB decarboxylase (OD) and aldehyde reductase (AR) is as follows 
(Equations S4.1-S4.6): 
MK:  malate2- + ATP3- + H+ = malyl-P2- + ADP2-  (S4.1) 
MSD:  malyl-P2- + NADPH = malate-SA- + NADP+ + HPO4
2-  (S4.2) 
MSR:  malate-SA- + NADPH + H+ = DHB- + NADP+  (S4.3) 
DD:  DHB- + FMN + H+= OHB- + FMNH2 (S4.4) 
OD:  OHB- + H+ = 3-HPA + CO2 (S4.5) 
AR:  3-HPA + NADPH + H+ = PDO + NADP+  (S4.6) 
 
The standard Gibbs free energy for the formation of the DHB pathway intermediates (ΔfG
0’) 
was calculated based on the group contribution theory35 using the dataset published by 
Jankowski36 (Supplementary Table 4). The standard Gibbs free energy of a reaction (ΔrG
0’) 
can be estimated according to Equation S8 from the standard Gibbs free energy of the 
formation of the participating compounds (ΔfG
0’), with νi being the stoichiometric 
coefficients. 
 
  (S4.8) 
 
Accordingly, the standard Gibbs free energy of the reactions S1 – S6 are MK: 11 kJ mol-1, 
MSD: 1.5 kJ mol-1, MSR: -21.8 kJ mol-1, DD: -23.1 kJ mol-1, OD: -6.8 kJ mol-1; AR: -21.7 
kJ mol-1. The upstream DHB pathway has a standard Gibbs free energy of -9.3 kJ mol-1, 
while downstream PDO pathway displays a standard Gibbs free energy of -51.6 kJ mol-1.  
The complete PDO pathway has a standard Gibbs free energy of -60.9 kJ mol-1. 
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Note S4.2. Calculation of the theoretical 2,4-dihydroxybutyric acid yield  
A previously published stoichiometric model of the central carbon metabolism in E. coli37 
was extended by 6 reactions steps enabling PDO production from malate. The theoretical 
yield was calculated based on elementary mode analysis using the CellNetAnalyzer 
software package38. The flux map showing one of the predicted carbon flux distributions 
that provide maximum yield was determined (data not shown). In the absence of cell growth, 
the maximum PDO yield is 1.5 mol per mol glucose. 
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Chapter 5. Development of a metabolite sensor for high-
throughput detection of aldehydes in Escherichia coli 1  
 
5.1 Introduction 
Aldehydes are a class of chemicals with a wide range of applications, namely in the 
synthesis of rubbers, plastics and formulation of flavors and fragrances. Formaldehyde, 
butanal and isobutyraldehyde are among the aldehydes produced in quantities greater than 
1 Mt per year, while the aromatic aldehydes vanillin and benzaldehyde are the two most 
widely used flavoring agents in food products1,2. Producing these compounds from 
inexpensive sugar feedstocks using microbial species is therefore an alternative to the 
currently established chemical synthesis and plant-extraction processes3. Beyond their use 
as end-products, many aldehydes are intermediates of metabolic pathways resulting in 
multiple and diversified products (e.g. fatty acids, alcohols, alkanes, carboxylic acids), 
including those developed by our group leading to the production of glycolic acid (via 
glycolaldehyde), 1,3-propanediol (via 3-hydroxypropanal) and 2,4-dihydroxybutyrate (via 
malate semialdehyde)4–7. Optimizing those enzymatic activities that produce aldehydes is 
an essential task during the improvement of the above mentioned synthetic metabolic 
pathways. However, the rational or evolutionary engineering of such new enzymatic 
activities can be subject to various bottlenecks.  
Recent advances in synthetic biology together with decreasing DNA synthesis costs allow 
today for rapid design and assembly of DNA sequences that may encode individual enzymes 
or even entire metabolic pathways8,9. While an increasingly large sequence space becomes 
accessible at lower costs and higher rates, the available analytical systems to screen this vast 
number of sequences for positive variants often do not provide the necessary throughput. 
Small molecules such as aldehydes can be detected and quantified through the use of 
conventional chromatography (GC-MS, HPLC-MS)10 and colorimetric techniques (Schiff’s 
test). However, the analytical throughput of these techniques is far from being exploitable 
for laboratory evolution campaigns that are based on random mutagenesis. The development 
                                                 
1 A modified version of the published manuscript Frazão CJR, Maton V, François JM, Walther T. (2018) 
Development of a metabolite sensor for high-throughput detection of aldehydes in Escherichia coli. Front. 
Bioeng. Biotechnol. 6, 118. 
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of high-throughput screening and selection methods is therefore of crucial importance for 
successful directed evolution of strains and enzymes aiming at aldehyde overproduction11. 
A variety of devices sensitive to the accumulation of intra- or extracellular small molecules, 
ions or changes in physical parameters have been evolved using microbial cells12. Among 
those, ligand-responsive transcription factors (TFs) play a major role in cell physiological 
adaptation. They are DNA-binding proteins that regulate gene expression by physically 
interacting with specific target molecules13,14. Therefore, they are interesting devices for a 
broad range of applications, including the construction of whole-cell biosensors or 
metabolite sensors for detection of, respectively, extracellular or intracellular target 
molecules15–17. Metabolite sensors are usually modular. While a sensing module contains a 
transcriptional regulator which is activated in the presence of a target ligand, a reporter 
module consisting of a corresponding cognate promoter which drives transcription of a 
reporter gene (e.g. lacZ, gfp and mutant variants) enables the output of measurable signals18. 
The utilization of metabolite sensors has recently gained particular interest for evolution of 
bacterial strains19–21 and enzymes22,23. 
When metabolite sensors that detect the intracellular production of target molecules are 
combined with FACS systems, ultra-high throughput analyses and sorting of individual cells 
become feasible at rates higher than 107 cells screened per hour24. While these numbers 
make metabolite sensors a highly attractive tool for strain and enzyme engineering, the use 
of these sensors and respective implementation in a screening protocol is still far from being 
an “off-the-shelf technology” thereby requiring significant research efforts for both, the 
optimization of the sensor and the screening protocols. In this work, a metabolite sensor for 
detection of various aldehydes in E. coli was developed which employs the aldehyde-
responsive transcription factor YqhC to drive the expression of the yellow fluorescent 
reporter protein SYFP2. Based on 5’-UTR engineering of the sensor and reporter modules, 
the gain of the fluorescence signal in response to the model compound glycolaldehyde was 
strongly increased. The best sensor variant detected various extracellularly added aldehydes 
at concentrations in the range of 1-10 mM. In addition, intracellular production of aldehydes 
via two in-house synthetic pathways was reliably detected. This result showed that the 
metabolite sensor can be applied in screening systems that rely on the detection of 
intracellular production of a target aldehyde in live cells.  
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5.2 YqhC can be employed as an aldehyde sensor 
In a previous study, YqhD was identified by our research group as the major glycolaldehyde 
reductase in E. coli4, while others demonstrated this enzyme to be active on a broad range 
of short-chain aldehydes (e.g. butyraldehyde, 3-hydroypropanal, acrolein)25. In a genomic 
context, YqhD is expressed from the yqhD-dkgA operon that is known to be induced by the 
divergently transcribed transcriptional regulator YqhC (Figure 5.1)26,27. Genome-wide 
transcriptome studies from our group, furthermore, revealed yqhD and dkgA genes to be 
strongly up-regulated (by 26- and 10-fold, respectively) when wild-type E. coli cells were 
exposed to 10 mM glycolaldehyde4. On the basis of these observations, the transcription 
factor YqhC may in principle be used to engineer an in vivo aldehyde-sensor system in E. 
coli.  
 
 
Figure 5.1. The yqhC/D-dkgA operon in E. coli MG165528. When cells are exposed to aldehydes, the constitutively 
expressed transcription factor YqhC binds to the promoter region of yqhD that contains a SoxS-like binding sequence as 
well as a 24-bp palindrome (red rectangles), enhancing/activating transcription of yqhD and dkgA genes, resulting in the 
increased expression of the NADPH-dependent aldehyde reductases YqhD and DkgA. Solid and dashed arrows represent 
the transcription start site of divergently transcribed genes. 
 
 
To investigate this possibility, a bi-modular system was constructed in which the sensing 
module (named pSENS-13) drove constitutive expression of the regulatory protein YqhC 
from a low-copy number vector. In the reporter module (named pREP-14), expression of 
the super yellow fluorescent protein SYFP229 was placed under transcriptional control of 
the yqhD promoter region, that included 150-nt of the yqhC coding sequence and the 
adjacent 108-nt yqhC/D intergenic region (until 28-nt downstream the transcription start site 
where the putative ribosome binding site pre-sequence upstream yqhD gene starts) (Figure 
5.2a). To maximize protein expression, a 35-nt strong ribosome binding site (RBS_01) was 
designed using the RBS calculator tool30 and placed in front of the syfp2 reporter gene 
(Table 5.1 shows DNA sequence). Reporter and sensing modules were then co-transformed 
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into the parent strain CF30 (MG1655 Δsad ΔyqhD), that was chosen as the host for 
evaluating biosensor-strains. Deletion of the yqhD and sad genes was expected to minimize 
intracellular degradation of short-chain aldehydes and semialdehydes, respectively. All 
resulting biosensor-strains were cultivated in M9 mineral medium and candidate aldehydes 
were added to the exponentially growing cells when OD600 reached ~0.6. It is of note that 
the utilization of a minimal medium resulted in a strong reduction of cell background 
fluorescence, as opposed to utilization of Luria Broth (LB) and 2x Yeast tryptone (YT) rich 
media (data not shown). Since glycolaldehyde was previously found as a potent inducer of 
the YqhC-dependent transcriptional response4, the behaviour of the constructed sensor  was 
evaluated in response to this compound at a non-lethal concentration of 5 mM. After a 4h 
incubation period, fluorescence intensity was measured at the single-cell level by flow 
cytometry and found to be increased by 6.8-fold when compared to cells which were 
cultivated in the absence of this aldehyde (Figure 5.2b). In a control experiment, the host 
strain CF30 was co-transformed with the pZS23 empty plasmid and the reporter module 
pREP-14. The resulting strain displayed no fluorescence increase upon aldehyde exposure, 
thereby confirming the feasibility of the developed metabolite sensor.  
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Figure 5.2. Design of the YqhC-based aldehyde sensor. (A) The sensing module pSENS-13 consists of a low-copy plasmid 
in which yqhC is under control of a medium-strength constitutive promoter (PBBa_J23106) and a weak ribosome binding site. 
The reporter module pREP-14 was built by fusing the syfp2 reporter gene (preceded by a strong RBS) to the YqhC cognate 
promoter in a high-copy vector. The 5’-UTR regions containing regulatory elements responsible by transcription of yqhC 
and reporter genes were named pX and pY, respectively. In each module, the antibiotic resistance marker and origin of 
replication is shown (grey and white boxes, respectively). (B) Fluorescence variation upon aldehyde exposure of 
engineered E. coli strain co-transformed with pSENS-13 and pREP-14. In a control experiment, the host strain was 
transformed with pZS23 and pREP-14. All strains are derived from the host strain CF30 (E. coli MG1655 Δsad ΔyqhD). 
Cells were cultivated in M9 mineral medium containing 20 g L-1 glucose and incubated for 4 h with 5 mM glycolaldehyde 
when OD600 reached ~0.6. SYFP2 fluorescence was calculated using cytometry data based on geometric mean. The 
reported values represent the mean ± S.D. (n ≥ 2). 
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Table 5.1. Constitutive promoters and RBS used for construction of sensing modules in the metabolite sensor. 
 
a  Nomenclature of promoters and relative promoter strengths as in Registry of Standard Biological Parts 
(http://partsregistry.org/Main_Page). 
b  Strength calculated based on information available at Registry of Standard Biological Parts 
(http://parts.igem.org/Part:BBa_J23114) and study from Davis and co-workers31. 
c  RBS with various strengths were designed using online RBS calculator tool (https://salislab.net/software/forward). 
 
5.3 Engineering biosensor modules for improved aldehyde detection 
The effect of varying yqhC expression levels on the strength of the fluorescence signal by 
engineering promoter and RBS sequences in the sensing module was next evaluated (Table 
5.2). The impact of three alternative constitutive promoters with different characteristics 
(strength, insulation) immediately upstream of the weak RBS that controlled protein 
expression from the yqhC coding sequence was first tested (see DNA sequences in Table 
5.1). Whilst keeping reporter module pREP-14 unaltered in the host strain, co-
transformation with the engineered pSENS-X plasmid variants (in which X = 16-18) 
resulted in distinct behaviors regarding fluorescence induction ratios upon glycolaldehyde 
exposure (Table 5.2). The expression of yqhC gene under control of a weak constitutive 
promoter (PBBa_J23114) resulted in the highest fluorescence induction ratios (18.9-fold, p < 
0.001), and the corresponding plasmid pSENS-16 was therefore used as the backbone for 
further modifications. The implementation of ribosome binding sites of variable strengths 
(pSENS-X, in which X = 19-21) resulted in further improved fluorescence induction ratios 
of up to 32.6-fold when the pSENS-20 plasmid (medium-strength RBS, p < 0.01) was used.
1
1
7
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Having optimized the sensing module, the aldehyde sensor was further improved by 
engineering the promoter region of the reporter module pREP-14 (Figure 5.3). To this end, 
the plasmid pREP-15 was first created by extending the promoter region to include the full 
yqhC/D intergenic region plus the adjacent 150-nt downstream coding region of yqhD 
followed by a stop codon (Figure 5.3a). The additional introduction of this nucleotidic 
region was made in an attempt of including possibly missing uncharacterized motifs present 
in the genome of E. coli. However, significantly lower fluorescence induction ratios (10.9-
fold) were observed upon aldehyde exposure when compared to pREP-14 (32.6-fold, p < 
0.001) (Figure 5.3c). For this reason, the optimization of the promoter region in the pREP-
14 module was rather attempted to further enhance SYFP2 expression. In the genome of E. 
coli,  the yqhD gene is preceded by the -35 and -10 elements TTGAGA and CACAAT, 
respectively, to which RNA polymerase and the sigma factor σ70 bind to initiate 
transcription (with C as the initiation element)26. This configuration was maintained in 
pREP-14 to control expression of SYFP2. But since the sequence of the -10 promoter core 
element deviates from the consensus sequence for σ70-dependent promoters (-35: TTGACA; 
-10: TATAAT; initiation element: A)32, the -10 core and downstream distal elements in 
pREP-14 were replaced by those found in the well-characterized synthetic IPTG-inducible 
and σ70-dependent promoter PLlacO-1 (Figure 5.3b). When the resulting plasmid pREP-22 
was used to detect glycolaldehyde, a 70-fold fluorescence induction ratio was observed 
(Figure 5.3c), which corresponded to a 2-fold improvement when compared to the 
utilization of plasmid pREP-14 as reporter module (p < 0.001). Therefore, the plasmids 
pSENS-20 and pREP-22 were used as sensing and reporter modules for subsequent 
experiments. 
 
 
 
 
 
 
1
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5.4 The YqhC-based aldehyde sensor detects various aldehydes 
The best metabolite sensor was next characterized in response to the presence of various 
aldehydes at a concentration of 5 mM (Figure 5.4). After incubating exponentially-growing 
cells with candidate aldehydes, a clear correlation between the fluorescence induction and 
the chain length or the chemical structure of the aldehyde could not be established, although 
the presence of a benzyl group in aldehyde molecules (vanillin and phenylacetaldehyde) 
resulted in comparatively high fluorescence. Additionally, the presence of the short-chain 
aldehydes acrolein and succinic semialdehyde led to inductions up to 20-fold when 
compared to non-induced cells, whereas the biosensor was almost insensitive to butanal, 
furfural and hexanal.  
 
Figure 5.4. Aldehyde detection spectrum (at a concentration of 5 mM) of E. coli host strain CF30 (MG1655 Δsad ΔyqhD) 
harboring pSENS-20 and pREP-22 as sensing and reporter modules, respectively. Cells were cultivated in M9 mineral 
medium containing 20 g L-1 glucose and incubated for 12 h with aldehyde inducer when OD600 reached ~0.6. SYFP2 
fluorescence was calculated using cytometry data based on geometric mean. The reported values represent the mean ± 
S.D. (n ≥ 2). 
 
The dose-response curves for the fluorescence-inducing compounds are depicted in Figure 
5.5. With the exception of vanillin, they show that extracellular aldehyde concentrations 
above 1 mM were necessary to trigger a significant increase of the fluorescence signal.  
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Figure 5.5. Dose-response curve of E. coli host strain CF30 (MG1655 Δsad ΔyqhD) harboring pSENS-20 and pREP-22 
as sensing and reporter modules, respectively, when exposed to various aldehydes in the concentration range of 0.1-10 
mM. Cells were cultivated in M9 mineral medium containing 20 g L-1 glucose and incubated for 12 h with aldehyde 
inducer when OD600 reached ~0.6. SYFP2 fluorescence was calculated using cytometry data based on geometric mean. 
The reported values represent the mean ± S.D. (n ≥ 2). 
 
 
 
5.5 The aldehyde sensor can detect in vivo aldehyde production 
To explore the applicability of the biosensor as a tool for strain and/or enzyme evolution, 
intracellular aldehyde production during induction of two in-house synthetic metabolic 
pathways was monitored.  
 
5.5.1 Xylulose-1-phosphate synthetic pathway 
In the xylulose-1-phosphate (X1P) pathway (Figure 5.6a), xylose is first converted into (D)-
xylulose by xylose isomerase (XylA, E. coli)4. Xylulose is then phosphorylated by an 
enzyme with xylulose-1-kinase activity (KhkC, Homo sapiens) before the resulting 
xylulose-1-phosphate is cleaved into glycolaldehyde and dihydroxyacetone phosphate 
(DHAP) by a xylulose-1-phosphate aldolase (AldoB, H. sapiens). While glycolaldehyde can 
be further metabolized into either ethylene glycol or glycolic acid, DHAP is metabolized 
through the Embden-Meyerhof-Parnas pathway thereby enabling cell growth. It was 
previously shown that deletion of the xylulose-5-kinase encoding gene xylB was necessary 
to deviate the xylose-derived carbon flux into the synthetic pathway4. Therefore, we 
evaluated whether the glycolaldehyde production via the synthetic pathway could be 
monitored by our metabolite sensor in an E. coli ΔxylB ΔyqhD mutant strain that expresses 
the aldehyde sensor modules (pSENS-20, pREP-22) and the synthetic pathway (pZA33-
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khkC-aldoB). Deletion of yqhD served to minimize reduction of glycolaldehyde to ethylene 
glycol and under these conditions, the production of glycolic acid is very low4. The resulting 
strain was cultivated in mineral medium containing either 20 g L-1 glucose or a mixture of 
1 g L-1 glucose and 10 g L-1 xylose as carbon sources. In both cases, expression of the 
synthetic pathway was induced by the addition of 1 mM IPTG at the start of the culture. 
Rapid growth was observed during the cultivation on glucose, resulting in a depletion of 
carbon source in the first 24 h of the cultivation (Figure 5.6b). Cells growing on glucose 
exhibited no increase in fluorescence or extracellular accumulation of glycolaldehyde. A 
different behavior was observed when cells were cultivated on the glucose/xylose mixture. 
As expected, glucose was first consumed resulting in a doubling of the cell density after the 
first 3h of the cultivation. During the diauxic shift which lasted approximately 3h, cell 
density increased only very marginally before the growth rate increased again concomitant 
with utilization of xylose as carbon source. The fluorescence signal further mirrors this 
behavior in that there was no observable increase of fluorescence during growth on glucose 
and during the diauxic shift. Only upon induction of the X1P pathway by xylose, an increase 
in single-cell fluorescence by more than 40-fold was measured, which nicely correlated with 
the accumulation of glycolaldehyde in the medium. 
 
 
1
2
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5.5.2 1,3-Propanediol synthetic pathway from 2,4-dihydroxybutyrate 
In Chapter 4, a de novo six-step pathway enabling biosynthesis of 1,3-propanediol (PDO) 
from malate was conceived and experimentally validated. During the study, metabolic 
inefficiencies linked, among other factors, to the low catalytic efficiency of 2-keto-4-
hydroxybutyrate (OHB) decarboxylases were observed, reason for which improving such 
enzymes by directed evolution campaigns may ultimately render the designed pathway more 
efficient. Therefore, this subsection aims at detecting the 3-hydroxypropanal (3-HPA) 
product released by the enzyme since previous incubation of the metabolite sensor with 
exogenously added 3-hydroxypropanal yielded no fluorescence increase (data not shown) 
presumably due to the high-instability of the commercial version of the aldehyde.  
In line with this information, an alternative strategy for demonstration of intracellular 
accumulation of the 3-HPA compound was employed and it is based on the expression of a 
fraction of the PDO pathway that links DHB to 3-HPA (Figure 5.7a). In this sub-pathway, 
DHB is first converted into OHB by a (L)-DHB dehydrogenase. OHB is then 
decarboxylated by an enzyme with OHB decarboxylase activity. Since expression of the 
aldehyde reductase Ec-YqhD was previously shown to catalyze the conversion of the 
released 3-HPA molecule to PDO, deletion of yqhD and sad genes was expected to avoid 
aldehyde degradation. The production of 3-HPA via the synthetic pathway was first 
monitored by the metabolite sensor in an E. coli Δsad ΔyqhD lldDproD glcAproD lacIQ::Sp 
host strain (named CF267) that harbored the aldehyde sensor modules (pSENS-20, pREP-
22) and a medium-copy pZA33 plasmid expressing various OHB decarboxylase variants. 
The overexpression of DHB dehydrogenase and DHB importer encoding genes lldD and 
glcA permitted increased flux towards OHB synthesis from DHB, while the constitutive 
expression of lacIQ ensured a strong repression of target genes expressed from the pZA33 
plasmid in the absence of IPTG inducer molecule.  
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Figure 5.7. The monitoring process of in vivo production of 3-hydropropanal (3-HPA) from a racemic mixture of (D/L)-
2,4-dihydroxybutyrate (L-DHB) (A) is hampered by the unstable levels of background fluorescence in the absence of DHB 
precursor molecule from the E. coli host strain CF267 (MG1655 Δsad ΔyqhD lldDproD glcAproD lacIQ::Sp) co-transformed 
with pYqhC-20, pREP-22 and pZA33-derived plasmids (B). Cells were cultivated in M9 mineral medium containing 20 
g L-1 glucose and IPTG (1 mM) was added when OD600 reached ~0.6 (t = 0 h), after which fluorescence was monitored. 
SYFP2 fluorescence was calculated using cytometry data based on geometric mean. The reported values represent the 
mean ± S.D. (n ≥ 2). 
 
The resulting strains were cultivated in mineral medium containing 20 g L-1 glucose, and 
IPTG was added at 1 mM at OD600 ~0.6 (t = 0 h) to express the OHB decarboxylase variants 
Ll-KdcA wt or V461I. In a control experiment in which the DHB precursor was not added 
to the cultivation medium (Figure 5.7b), the expression of both decarboxylases resulted 
however in a fluorescence increase over time thereby suggesting that both enzyme variants 
were able to convert other intracellularly available 2-ketoacids into corresponding 
aldehydes to which the metabolite sensor is sensitive. This was further confirmed by the 
expression of the empty plasmid pZA33, which resulted in nearly no fluorescence variation 
over time in the absence of DHB. Crucially, the Ll-KdcA wild-type enzyme has been 
previously shown to possess activity on a broad range of 2-ketoacids involved in the 
synthesis of branched chain amino acids (BCAA)33. The BCAA metabolic pathways leading 
to the synthesis of valine, leucine and isoleucine are represented in Figure 5.8. 
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Figure 5.8. Branched-chain amino acid pathway in E. coli involves the synthesis of intermediate 2-ketoacids. Adapted 
from Dietrich, 201334. 
 
 
In particular, the enzymes encoded from the ilvEDA operon are determinant for the 
anabolism/catabolism of valine, leucine and isoleucine. Whilst the addition of extracellular 
excess amounts of those amino acids has previously been reported to result in the 
transcriptional repression of ilvEDA operon and subsequent abolishment of BCAA 
synthesis35, no perceptible improvements in cell fluorescence background were observed 
when supplementing the cultivation medium with BCAAs at a concentration of 0.5 mM 
(data not shown). For this reason, step-wise gene deletion of ilvEDA operon from the host 
strain was envisaged. While ilvE gene deletion yielded no further improvements, the 
additional genetic deletion of ilvD and ilvA resulted in a low fluctuation in fluorescence 
levels up to 4 h post-induction in the absence of DHB (Figure 5.9). Therefore, the host 
strain CF267 ΔilvEDA was chosen to continue the studies aiming at demonstrating 3-HPA 
production from extracellularly added DHB. 
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Figure 5.9. Engineering the host strain CF267 harboring pYqhC-20, pREP-22 and pZA33-kdcA plasmids towards 
decreased levels of intracellular branched-chain 2-keto acids yielded a strong reduction in background fluorescence in the 
absence of DHB. Cells were cultivated in M9 mineral medium containing 20 g L-1 glucose and IPTG (1 mM) was added 
when OD600 reached ~0.6 (t = 0 h), after which fluorescence was measured. SYFP2 fluorescence was calculated using 
cytometry data based on geometric mean. The reported values represent the mean ± S.D. (n ≥ 2). 
 
 
Aiming at demonstrating intracellular production of 3-HPA, the strain CF267 ΔilvEDA 
harboring the metabolite sensor and pZA33-kdcA was cultivated in mineral medium and 
IPTG (1 mM) and a racemic mixture of (D/L)-DHB (20 mM) were added during cell 
exponential phase (OD ~0.6). Increased fluorescence levels were observed after 4h post-
induction reaching its maximum at 6h post-induction time (Figure 5.10). Crucially, 
expression of the catalytically more efficient OHB decarboxylase Ll-KdcA V461I as 
assessed by in vitro studies (see Chapter 4) yielded higher fluorescence values when 
compared to the utilization of its wild-type counterpart (Figure 5.10). On the other side, 
transformation of the host strain with the empty pZA33-plasmid resulted in a stable but low 
fluorescence background. These results suggest therefore that under optimal conditions the 
metabolite sensor is able to detect 3-HPA released from the synthetic pathway and that in 
principle E. coli does not possess any enzymes with sufficient OHB decarboxylase activity 
from its endogenous metabolism. The additional discrimination between enzyme variants 
possessing variable OHB decarboxylase activities further suggests the applicability of the 
metabolite sensor towards directed evolution campaigns. 
128 
 
 
Figure 5.10. Monitoring of in vivo production of 3-hydropropanal (3-HPA) by an artificial metabolic pathway using the 
aldehyde metabolite sensor. The E. coli host strain CF267 ΔilvEDA (MG1655 Δsad ΔyqhD lldDproD glcAproD lacIQ::Sp 
ΔilvEDA) was co-transformed with pYqhC-20, pREP-22 and various pZA33-derived plasmids. Cells were cultivated in 
M9 mineral medium containing 20 g L-1 glucose and IPTG (1 mM) and 20 mM (D/L)-DHB was added when OD600 reached 
~0.6, after which fluorescence was measured. SYFP2 fluorescence was calculated using cytometry data based on geometric 
mean. The reported values represent the mean ± S.D. (n ≥ 2). 
 
5.6 Discussion 
The success in improving individual enzymes and/or entire metabolic pathways by directed 
evolution is often hindered by the lack of high-throughput screening/selection methods 
enabling detection of target phenotypes11. Specific detection of small molecules is often 
required when large mutant libraries are screened for over-producing strains or improved 
enzyme activities. In the present study, the design and implementation of a metabolite sensor 
system for the detection of various aldehydes in E. coli was demonstrated. While other 
aldehyde-sensing systems have previously been developed on the basis of invasive and 
indirect sampling methods36, the herein developed system allows for direct aldehyde 
detection and may additionally enable FACS-based high-throughput screening and selection 
for aldehyde-producing enzymes or strains.  
In this work, YqhC served as the transcriptional regulator to detect the presence of an 
aldehyde and to induce expression of a fluorescent marker protein. Turner and colleagues  
previously constructed a YqhC-based metabolite sensor in E. coli, in which the firefly 
luciferase-encoding gene was put under transcriptional control of putative yqhD promoter 
region in a low-copy number plasmid27. Albeit the genomically expressed YqhC levels 
ensured a light response upon aldehyde exposure, the low measurable output signals 
observed from cell lysates were not compatible with high-throughput screening purposes, 
in which cell sorting is desired. In those cases, engineering poor ligand-transcription factor 
binding through protein or 5’-UTR engineering has previously been reported to dramatically 
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change the response profiles of metabolite sensors37,38. To this end, an alternative bi-
modular aldehyde sensor based on YqhC was constructed. A sensing module drives 
constitutive expression of yqhC gene, while a reporter module drives expression of syfp2 
reporter gene under transcriptional control of yqhD promoter region. One of the major 
challenges when developing metabolite sensors is to optimize their sensitivity and dynamic 
range. Therefore, SYFP2 was selected as a reporter protein since it allows for optimized 
folding, maturation and superior brightness when compared to sfGFP and eYFP 
autofluorescent protein variants29. Fine-tuning of the expression levels of YqhC by 
engineering the promoter and RBS region of the reporter module further resulted in a 10-
fold improvement over the initial sensor system. These results suggest the previously 
reported concept of two-module metabolite sensors16,39 to be particularly useful when it 
comes to optimization tasks, since it enables to independently fine-tune each of its parts.  
The specificity and dynamic range responses of the constructed biosensor were evaluated 
with respect to a spectrum of aldehydes, including short, medium carbon chain and aromatic 
compounds. At variance to Turner and colleagues27 who reported a YqhC-dependent 
transcriptional activation of the firefly-luciferase encoding reporter gene to ethanal, 
propanal, butanal, methylglyoxal and lignocellulose inhibitors (furfural, cinnamaldehyde), 
the biosensor was almost insensitive to some of these compounds, but responded to others 
such as glycolaldehyde, vanillin and phenylacetaldehyde. The discrepancy between the 
results herein achieved and those from Turner and colleagues can be explained in part by 
the difference in the genomic design of the constructed sensor. In this specific case, a bi-
modular sensor was employed in which the yqhC gene is used out of its natural genomic 
context and expressed constitutively from a low-copy plasmid, while the reporter module 
bears the syfp2 gene preceded by a strong RBS and flanked upstream by a promoter region 
that included 150-nt of yqhC coding sequence plus 108-nt of adjacent yqhC/D intergenic 
region. On the other side, a different reporter gene (leading to the expression of the firefly 
luciferase) immediately preceded by the yqhD promoter region was constructed by the 
Ingram group to investigate the response to aldehydes in a E. coli strain expressing YqhC 
from its genomic locus27. In addition, and whatsoever the difference between the two 
sensors, the structural diversity of the aldehydes that exhibit transcriptional induction raised 
questions about the mechanism by which YqhC may interact with these compounds. While 
the apparent lack of specificity can be regarded as a disadvantage, it can instead be 
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considered as an appropriate feature for the in vivo screening of synthetic pathways in which 
a single aldehyde is produced as an intermediate or end-product, and whose accumulation 
can be correlated to the catalytic efficiency of the upstream enzymatic reaction or can 
indicate a bottleneck in the downstream reaction in that pathway. This is nicely exemplified 
by the demonstration of glycolaldehyde detection produced by the synthetic X1P pathway 
and 3-HPA production via the artificial PDO pathway. 
Another key feature determining biosensor performance is its dynamic range of detection. 
We found that the sensitivity of our biosensor to aldehyde was in the range of 1-10 mM. 
However, in spite of this elevated minimum concentration, the application of the sensor 
should be possible when aiming at detecting aldehyde over-producing strains or enzymes. 
In addition, this relatively poor sensitivity could be an advantage as it may avoid 
perturbation resulting from potential endogenous aldehydes, whose concentrations are 
actually relatively low due to the presence of many aldehyde reductases in E. coli2. Also, 
fluorescence saturation from the metabolite sensor at higher concentrations may constitute 
an advantage in metabolic engineering projects, in which high product titers are desired. 
Indeed, as a first proof-of-principle application, the feasibility of the system to monitor 
intracellular aldehyde production from a strain harboring the xylulose-1-phosphate pathway 
that can generate glycolaldehyde from xylose at a theoretical yield of 1 mol mol-1. A 
remarkable increase of the fluorescence signal dependent on xylose consumption was 
observed. In a second proof-of-concept, the intracellular production of 3-HPA was 
monitored from a strain harboring a partial PDO synthetic pathway. The expression of OHB 
decarboxylases with distinct catalytic efficiencies matched well with the observed 
differences in fluorescence levels, thereby confirming the potential applicability of the 
developed high-throughput biosensor system towards metabolic and/or enzyme engineering 
projects upon minor optimization adjustments in each case scenario. 
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5.7 Materials and methods 
5.7.1 Chemicals and reagents 
All chemicals and solvents were purchased from Sigma-Aldrich unless otherwise stated. 
Restriction endonucleases and DNA-modifying enzymes were purchased from New 
England Biolabs and used according to instructions of the manufacturer. DNA plasmid 
isolation was performed using GeneJET Plasmid Miniprep Kit (Thermo Scientific). DNA 
extraction from agarose gel was carried out using the GeneJET Gel Extraction Kit (Thermo 
Scientific). DNA sequencing was carried out by Eurofins SAS (Ebersberg, Germany). 
 
5.7.1 Plasmid construction 
All plasmids and primers used in this study are listed in Tables 5.3 and 5.4, respectively. 
Construction of sensing modules: The upstream regions (including variable strength 
constitutive promoters and ribosome binding sites) were introduced into the forward primer 
that together with the reverse primer CF154 served to amplify the wild-type yqhC gene from 
genomic DNA of E. coli K-12 substr. MG1655 (ATCC 47076). Additionally, the primers 
used allowed the insertion of unique restriction sites upstream and downstream of the 
amplified fragments. Resulting PCR products and the low-copy vector backbone pZS23 
(Expressys, Germany) were digested with XhoI and BamHI restriction enzymes, gel purified 
and ligated with T4 DNA ligase. The resulting plasmids were transformed into DH5α 
competent E. coli cells (New England Biolabs) and inserts verified by DNA sequencing. 
Construction of reporter modules: The YqhD promoter region was PCR amplified from 
genomic DNA with primers pairs CF155/CF156, while the syfp2 gene (synthesized by 
Eurofins) was amplified with primers CF157/CF158. DNA fragments were gel purified and 
assembled by homologous recombination with the XhoI/BamHI-digested pZE13 vector 
using the NEBuilder® HiFi DNA Assembly kit (New England Biolabs). The resulting 
plasmid was named pREP-14. For construction of pREP-15 and pREP-22 vectors, promoter 
regions of yqhD gene were PCR-amplified from E. coli genomic DNA using respectively 
the primer pairs CF159/160 and CF155/324. The obtained PCR products and pREP-14 
plasmid were digested (XhoI, HindIII), gel-purified and complementary-ends ligated. After 
sequencing analysis, the resulting plasmids were named pREP-15 and pREP-22, 
respectively. 
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Construction of pZA33-khkC-aldoB: The khkC-aldoB operon was amplified by PCR from 
pEXT20-khkC-aldoB 4 using the primer pairs Pen268/Pen269, while the medium-copy 
vector pZA33 (Expressys, Germany) was PCR-linearized using primer pairs 
Pen321/Pen322. Resulting PCR products were gel purified and assembled by homologous 
recombination using the NEBuilder® HiFi DNA Assembly kit (New England Biolabs). The 
resulting plasmid was transformed into DH5α competent E. coli cells and the assembled 
operon verified by DNA sequencing. 
Construction of pZA33-kdcA variants: The kdcA gene variants were amplified from pET-28 
derived vectors using the primer pairs CF183/CF192. Resulting PCR products and the 
medium-copy vector pZA33 were digested with EcoRI and BamHI restriction enzymes, gel 
purified and ligated with T4 DNA ligase. The resulting plasmids were transformed into 
DH5α competent E. coli cells (New England Biolabs) and inserts verified by DNA 
sequencing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
3
3
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Table 5.4.  Primers used in this study for plasmid construction and strain validation. 
Primer Sequence (5' – 3') 
 
Construction of sensing modules (pSENS) 
CF149 
 
CF154 
CF161 
 
CF162 
 
CF163 
CF164 
 
CF257 
 
CF258 
 
CF259 
tatataGtcgagtttacggctagctcagtcctaggtatagtgctagcGGTCCACCGCTTACCCCCCCA
AGGGACGAATAAAatgCTACAAAATTGCGCACA 
tgcttaggatcCttaATTCCCCTGCATCG 
taagcactcgagtttatggctagctcagtcctaggtacaatgctagcGGTCCACCGCTTACCCCCCCA
AGGGACGAATAAAatgCTACAAAATTGCGCACA 
taagcactcgagctgatggctagctcagtcctagggattatgctagcGGTCCACCGCTTACCCCCCCA
AGGGACGAATAAAatgCTACAAAATTGCGCACA 
taagcactcgagCACAGCTAACACCACGTC 
TGTGCGCAATTTTGTAGcatTTTATTCGTCCCTTGGGGGGGTAAGCGGTGGACCAAA
GTTAAACAAAATTATTTGTAGAGG 
taagcactcgagtttatggctagctcagtcctaggtacaatgctagcGTCTTAACAAAGGAAAAAAT
TTACTatgCTACAAAATTGCGCACA 
taagcactcgagtttatggctagctcagtcctaggtacaatgctagcAAATTTACTTATAAAGGAGG
AGATAGatgCTACAAAATTGCGCACA 
taagcactcgagtttatggctagctcagtcctaggtacaatgctagcTCGGAAGAAGAATCGAGGA
GGAGGTATCAatgCTACAAAATTGCGCACA 
 
Construction of reporter modules (pREP) 
CF155 
CF156 
CF157 
 
CF158 
CF159 
CF160 
CF324 
gaggccctttcgtcttcacctcgagttaCACATCGGGCAACAGTCC 
gtatttaagttggaaagcttAGGGCAGAGAACGATCTG 
tctctgccctaagctttccaacttaaatacaaggaaaataaggaggtcaacATGGTTAGCAAGGGCGA
AG 
gtacgcgtaccatgggatccTTATTATTTATACAGCTCATCCATACCC 
TAAGCActcgagttaCACATCGGGCAACAGTC 
tgcttaAAGCTTTTAAACTTGATCGAGAACGCC 
tgcttaAAGCTTGGTCAGTGCGTCCTGCTGATGTGCTCAGTATCATCGCCAGCGCCCTG 
 
Construction of xylulose-1-phosphate pathway 
Pen268 
Pen269 
Pen321 
 
Pen322 
cggctgctaacaaagcccg 
gaattctgtgtgaaattgttatccgc 
tttcacacagaattcGTTTAACTTTAAGAAGGAGATATACCATGGAAGAGAAGCAGATC
CTGTGC 
ctttgttagcagccgggatcctcaTTAATACGTGTAACAGGCCGTAAACAGA 
 
Construction of pZA33-kdcA variants 
CF183 
 
CF192 
cggataacaatttcacacagaattcatcgacgctaaaacaaaaatataaggaggaacataATGTATACC
GTTGGGGATTATC 
cagtggtggtggtggtggtacgcgtaccatgggatccTTATTTGTTCTGTTCAGCAAAC 
 
Strain construction 
glcA-proD_fw (CF253) 
 
glcA-proD_rv (CF254) 
 
lldP-prod_fw (CF249) 
 
lldP-prod_rv (CF250) 
 
CCGAACCGTTATTACACGCCTGGCGTTTACGCGAAAAAGAAAGTCATTAAGTGTAG
GCTGGAGCTGCTTC 
GCCCCAGTCCTCCCATCGGCATATACATTTGGGTCCAGGTAACcatATAATACCTCCT
AAAGTTAAACAAAATTATTTGTAG 
CAATTCTCTGATGAGGATTGCCCTTTTCTTTACCAGACATCTCCCCCCACGTGTAGGC
TGGAGCTGCTTC 
CCAGATATTCCCGGCGGGATCGTAGTTTTGTTGCCAGAGATTcatATAATACCTCCTA
AAGTTAAACAAAATTATTTGTAG 
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Table 5.4.  (continued) 
Primer Sequence (5' – 3') 
 
Strain verification 
Δsad-ver-fw 
Δsad-ver-rv 
ΔyqhD-ver-fw (Pen15) 
ΔyqhD-ver-rv (CF346) 
glcA_ver_fw (CF255) 
glcA_ver_rv (CF256) 
lldP_ver_fw (CF251) 
lldP_ver_rv (CF252) 
LacIQ_fw (CL20)  
SpecR_rv (CL21)  
CTGCCAGCTTCGGCAA 
GGGTAAAGTCGCGGATTAT 
CAAGCGGCAAATCTCTTCAC 
TGGATTAGCCATACGTTCCT  
AATTTCGCTAACTCGTG  
ATGTCCTTTCAGACGTAATA 
ATTCTGCACATTCCTATAGG 
CATTTTATAGAACAGCAAAG 
CCAATCAGCAACGACTGTTT 
CGTACATTTGTACGGCTCC 
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5.7.2 Strain construction and growth conditions  
E. coli K-12 substr. MG1655 (ATCC 47076) was used as the parental strain for all 
constructions in this study. Single gene deletion (yqhD, sad, ilvE) and constitutive 
expression of lacIQ was achieved using the phage transduction method adapted from 
Miller41. Expression of glcA and lldD genes was rendered constitutive by replacing the 
native chromosomal 5’-UTR of each gene by the synthetic constitutive and insulated 
promoter proD. The proD sequence was preceded by a kan resistance cassette which was 
amplified by PCR adding 50-bp flanking sequences that were homologous to the target 
locus. The resulting DNA fragment was used to replace the natural gene promoter by 
homologous recombination31. Primers used are listed in Table 5.4. Positive clones were 
selected on LB agar plates containing either kanamycin (50 µg mL-1) or spectinomycin (50 
µg mL-1) and verified by PCR analysis. The kan cassette was removed from the genome by 
expressing FLP recombinase from the pCP20 plasmid40 and correct excision of the cassette 
was verified by PCR using locus specific primers (Table 5.4). Plasmids were transformed 
into the target E. coli strains using standard protocols42. 
The cultures of E. coli strains were carried out at 37 ºC on a rotary shaker running at 200 
rpm in a M9 mineral medium which, unless otherwise stated, contained per liter: 20 g 
glucose, 18 g Na2HPO4*12H2O, 3 g KH2PO4, 0.5 g NaCl, 2 g NH4Cl, 0.5 g MgSO4*7H2O, 
0.015 CaCl2*2H2O, 1 ml of 0.06 M FeCl3 stock solution prepared in 100 times diluted 
concentrated HCl, 2 ml of 10 mM thiamine HCl stock solution, 20 g MOPS, and 1 ml of 
trace element solution (containing per liter: 0.04 g Na2EDTA*2H2O, 0.18 g CoCl2*6H2O, 
ZnSO4*7H2O, 0.04 g Na2MoO4*2H2O, 0.01 g H3BO3, 0.12 g MnSO4*H2O, 0.12 g 
CuCl2*H2O). The pH was adjusted to 7 and the medium was filter-sterilized. The antibiotics 
ampicillin and kanamycin sulfate were added when required at concentrations of 100 mg L-
1 and 50 mg L-1, respectively.  
For assaying in vivo production of glycolaldehyde by the E. coli strain CF272 harboring the 
xylulose-1-phosphate pathway and metabolite sensor, the experiments were carried out as 
follows. Pre-cultures were grown in 10 mL M9 mineral medium in the presence of the 
antibiotics ampicillin, kanamycin sulphate and chloramphenicol at 100, 50 and 35 mg mL-
1. After an overnight incubation, cells were spun down by centrifugation (4000 rpm, 10 min 
at 4 ºC) and washed with sterile water. They were resuspended at an initial OD600 of 0.5 in 
25 mL of fresh M9 mineral medium containing 1 mM IPTG and appropriate antibiotics and 
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in the presence of glucose or a mixture of glucose / xylose. Cell growth was followed by 
monitoring OD600, and samples were regularly withdrawn for flow cytometry analyses and 
sugars consumption. 
For assaying in vivo production of 3-HPA by various E. coli host strains harboring the 
metabolite sensor and pZA33-derived plasmids, the experiments were carried out as 
follows. Pre-cultures were grown in 5 mL M9 mineral medium in the presence of the 
antibiotics ampicillin, kanamycin sulphate and chloramphenicol at 100, 50 and 35 mg mL-
1. After an overnight incubation, cells were added at an initial OD600 of 0.2 in 10 mL of fresh 
M9 mineral medium containing 20 g L-1 glucose and appropriate antibiotics. When OD600 
reached ~0.6, IPTG (1 mM) and a racemic mixture of (D/L)-DHB (20 mM) were added to 
the cultivation medium. Samples were regularly withdrawn for flow cytometry analyses. 
 
5.7.3 Microtiter plate screening system 
Screening of biosensor-strains: Pre-cultures were grown overnight in 5 mL of M9 mineral 
medium (37 ºC, 200 rpm). They were used to inoculate 10 mL of M9 mineral medium 
supplemented with the appropriate antibiotics starting at an initial OD600 of 0.2 in 50 mL 
falcon tube flasks placed on a rotary shaker set at 200 rpm and at 37°C. When OD600 reached 
~0.6, 200 µL of cell culture were transferred in a 96-well plate and supplemented with 
glycolaldehyde at a final concentration of 5 mM. During the induction phase, microplates 
were incubated at 37 ºC with an orbital frequency at 807 rpm (Epoch 2, BioTek). After 4 h 
of incubation, single-cell fluorescence was measured by flow cytometry.  
Aldehyde dose-response curves: Pre-cultures were grown overnight in 5 mL of M9 mineral 
medium (37 ºC, 200 rpm). The biomass needed to start main cultures with a starting OD600 
of 0.2 was transferred to 250 non-baffled shake flasks containing 25 mL of M9 mineral 
medium with appropriate antibiotics (37 ºC, 200 rpm). When OD600 reached ~0.6, 200 µL 
of cell culture were inoculated in a 96-well plate and supplemented with aldehydes at the 
desired concentrations. During the induction phase, microplates were incubated at 37 ºC 
with an orbital frequency at 807 rpm (Epoch 2, BioTek). After 12 h of incubation, single-
cell fluorescence was measured by flow cytometry. 
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5.7.4 Flow cytometry 
Flow cytometry measurements were performed with an Attune™ Acoustic Flow Cytometer 
(Life Technologies) with 488 nm excitation. Forward-scatter characteristics (FSC) and side-
scatter characteristics (SSC) were detected as small-angle and large-angle scatters of the 
488 nm laser, respectively. SYFP2 fluorescence was detected using a 530/30 nm (channel 
BL1) band-pass filter set. Data were analyzed using the Attune™ software (Life 
Technologies). A total of 100,000 events was recorded per sample, and electronic gating 
was applied on the densest subset of cells on the basis of forward- versus side-scatter height. 
The same gate was used to estimate geometric mean levels of SYFP2 fluorescence.  
 
5.7.5 Analytical methods 
The concentrations of glucose and xylose were determined on a Dionex Ultimate 3,000 
HPLC system (Thermo Scientific, France) equipped with a RI detector (RID-10A, 
Shimadzu, Japan). The sample injection volume was 20 μL, and the compounds were 
separated in an Aminex HPX-87H column protected by a Micro-Guard Cation H+ pre-
column (BioRad, USA). The separation was performed at 35 ºC with 1.25 mM H2SO4 at 0.5 
mL min-1 as mobile phase. All samples were centrifuged (2 min at 13,000 rpm) and syringe-
filtered (0.2 µm), and the resulting supernatant kept at -20 ºC until analysis.  
 
5.7.6 Statistical methods 
All statistical analyses were conducted in Microsoft Excel® using the Analysis ToolPak 
package. A two-tailed unpaired t test was to use to compare fluorescence induction levels, 
in which an alpha level of p < 0.05 was set for significance. 
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Chapter 6. Conclusions and future directions 
 
As discussed throughout this work, a central goal of this thesis has been the construction of 
synthetic metabolic pathways for the synthesis of two industrially relevant commodity 
chemicals: 1,3-propanediol and (L)-2,4-dihydroxybutyrate. In this context, rational enzyme 
engineering was applied towards the generation of enzyme activities necessary for pathway 
operation, while the construction of an aldehyde-metabolite sensor may contribute for 
further improvements of the established non-natural routes. This thesis is likely to mirror 
the challenges in creation of metabolic pathways for which required biocatalysts are not 
known to exist in nature. 
 
6.1 A set of pathways with DHB as key intermediate molecule 
While (L)-2,4-dihydroxybutyrate is a non-natural metabolite, recent efforts have proved 
synthetic pathway engineering to enable its biosynthesis in E. coli. In particular, this work 
outlined enzyme engineering as a mean towards optimization of a metabolic route yielding 
DHB as final product via homoserine (see Chapter 3). An alternative three-reaction step 
synthetic route aiming at DHB biosynthesis from the Krebs cycle intermediate malate was 
previously developed by our group. Extension of the malate DHB pathway with three 
additional steps further allowed conversion of DHB into PDO (see Chapter 4). This work 
contributed therefore to the optimization of metabolic pathways in which DHB can be seen 
as a key player molecule (Figure 6.1).  
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Figure 6.1. Synthetic metabolic pathways with 2,4-dihydroxybutyrate (DHB) as key (intermediate) molecule. Each 
rectangle represents an engineered enzyme. Legend: OHB, 2-keto-4-hydroxybutyrate. 
  
 
6.2 Engineering DHB pathway via homoserine 
Construction of a catalytically efficient functional OHB reductase which could be employed 
as part of the DHB pathway via homoserine proved to be a difficult and labor-intensive task. 
As detailed in Chapter 3, sequence comparative analysis and computationally-aided protein 
design permitted the identification of amino acid substitutions likely to introduce OHB 
reductase activity into the template enzyme. Characterized by possessing a very strong 
affinity towards the reduction of oxaloacetate, substitution of Arg81 by an alanine residue 
in Ec-Mdh yielded an enzyme variant with 287-fold improved activity on OHB substrate. 
This substitution in particular has previously been reported as essential towards a shift in 
Ec-Mdh activity in dicarboxylic acids. But no saturation was observed under the tested range 
of OHB concentrations. Only when amino acid substitutions were simultaneously 
introduced into three different regions of the protein, highly active variants with low Km 
values on OHB were observed. However, the increased OHB reductase activity as observed 
in most-promising variants was accompanied by an increase in activity on the natural 
oxaloacetate substrate, yielding variants with catalytic efficiencies comparable between 
both substrates.  
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To demonstrate the applicability of the best mutant enzymes for in vivo applications, each 
of those was individually expressed as part of the DHB pathway via homoserine in E. coli. 
Shake-flask experiments resulted in increased DHB titers and yields of up to two-fold when 
compared with the previously reported OHB reductase variant Ll-LdhA Q85C. The 
simultaneous expression of the best-performing OHB reductase Ec-Mdh-5Q variant 
(I12V:R81A:M85Q:G179D:D86S) and the Ec-AlaC A142P:Y275D homoserine 
transaminase variant in the homoserine-overproducing ECO4 parent strain, together with 
carbon flux redirection allowed further improvements in the designed synthetic pathway. 
Cell cultivation under well-controlled conditions in fed-batch mode further resulted in the 
production of up to 10.7 g L-1 DHB. Whilst it corresponds to the highest titer reported to 
date, the concomitant accumulation of high amounts of homoserine precursor and alanine 
anticipate HMS transaminase as a major rate-limiting step of the pathway. As a part of a 
competitive project with an industrial partner, several strategies are in current development 
by our team in an attempt to overcome this bottleneck, which could not be solved in this 
thesis.  
 
6.3 Construction of a PDO pathway via DHB 
Product derivatization (e.g. DHB) into other compounds of industrial interest (e.g. PDO, 
1,2,4-butanetriol) is notably important in the context of biorefinery, thereby allowing for a 
flexible commercialization of a range of related but diversified products according to market 
needs. 
In this scope, a synthetic metabolic pathway enabling direct biosynthesis of 1,3-propanediol 
(PDO) from glucose via the Krebs cycle intermediate malate was conceived. The proposed 
route extends the previously published pathway for the synthesis of DHB with three 
additional reaction steps catalyzed by DHB dehydrogenase, OHB decarboxylase and PDO 
oxidoreductase. Screening and structure-guided protein engineering provided a (L)-DHB 
dehydrogenase from the membrane-associated (L)-lactate dehydrogenase from E. coli and 
OHB decarboxylase variants derived from either the branched-chain ketoacid decarboxylase 
encoded by kdcA from L. lactis or pyruvate decarboxylase from Z. mobilis, whose 
simultaneous overexpression with the ydhD-encoded aldehyde reductase enabled PDO 
biosynthesis from DHB. Simultaneous expression of the six enzymatic activities in a single 
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E. coli strain resulted however in a low production of 0.1 mM PDO from 110 mM glucose. 
A metabolic burden and the occurrence of bottlenecks in the pathway may be behind the 
observed weak titers. However, a co-cultivation strategy in which an E. coli strain 
expressing the DHB-yielding pathway and another strain bearing the plasmid with the DHB-
to-PDO pathway resulted in increased PDO titers up to 3.4 mM. While co-cultivation of two 
E. coli strains proved effective in increasing product formation, this strategy is less desired 
for industrial applications.  
 
6.4 A metabolite sensor for high-throughput aldehyde detection 
In this work, a fluorescence-based metabolite sensor enabling in vivo detection of various 
aldehydes of biotechnological interest in E. coli was developed. By assuming that a native 
transcription factor promoter pair which is capable to detect any small molecules can be 
identified in Nature, the E. coli YqhC-PyqhD system was selected in an attempt to 
demonstrate its potential application as high-throughput screening and selection devices. 
YqhC is a transcriptional regulator that is known to be involved in the upregulation of the 
yqhD-dgkA operon in the presence of aldehydes. By taking advantage of this property, a bi-
modular biosensor was constructed, in which a sensing module constitutively expresses 
yqhC while a reporter module drives the expression of the syfp2 reporter gene that is put 
under control of the yqhD promoter.  
The sensitivity of the sensor has been optimized by engineering the 5’-untranslated region 
of both the sensing and reporter modules, resulting in a 70-fold gain of fluorescence in 
response to the model compound glycolaldehyde at 5 mM. The optimized sensor further 
responded to other aldehydes when supplemented to the cultivation medium at 
concentrations of 1-10 mM.  
Additional studies further demonstrated that this metabolite sensor was functional in vivo 
upon expression of two in house synthetic pathways. In particular, it responded to the 
presence of glycolaldehyde that is specifically produced upon induction of a synthetic 
xylulose-1-phosphate pathway expressed in E. coli, as well as to 3-HPA produced from a 
fraction of the PDO pathway via DHB. This bi-modular sensor has been shown to constitute 
a potential tool for FACS-based ultra-high throughput screening of aldehyde (over-) 
producing enzymes. 
 
147 
 
6.5 Future work 
As previously outlined, this thesis contributed to the establishment of a set of synthetic 
pathways in which DHB can be seen as a central metabolite. In particular, production of 
DHB was accomplished from homoserine or (L)-malate, while extension of the malate-to-
DHB pathway allowed for PDO biosynthesis. But this work further opens the possibility to 
produce PDO from homoserine if the herein identified HMS transaminase, OHB 
decarboxylase and PDO oxidoreductase enzymes are expressed in a homoserine-
overproducing strain (Figure 6.1). Interestingly, PDO synthesis from homoserine has the 
advantage of only requiring three additional reaction steps, as opposed to its formation from 
malate via DHB. But in both cases further enzyme engineering is likely critical so that 
proposed routes can operate at efficient rates. 
In particular, the designed pathways as assessed in Chapters 3 and 4 were shown to possess 
several botlenecks including rate-limiting steps (e.g. HMS transaminase, OHB 
decarboxylase), which resulted in the accumulation of intermediate molecules. In line with 
this information, the metabolite sensor as developed in Chapter 5 can be applied in 
combination with FACS technology in high-throughput screening studies aiming at the 
selection of randomly-mutated enzyme variants with higher catalytic efficiencies, as far as 
3-HPA can be generated as end-product from a single enzyme or combination of multiple 
enzymes (as shown in Figure 6.1) with minor adjustments of the metabolite sensor. The 
metabolite sensor has, additionaly, the advantage of being well-suited for alternative 
metabolic engineering projects, in which randomly mutated strains expressing pathways 
yielding 3-HPA can be detected and selected.  
While identification of highly-efficient enzymes is crucial in the construction of metabolic 
pathways, it only comprises one step in the long process of metabolic engineering.  A more 
comprehensive analysis of cell metabolism can identify further bottlenecks, which can be 
addressed by host strain engineering. Also, process engineering and optimization of 
conditions of cell cultivation in well-controlled bioreactors will allow to reach higher 
productivities and titers.    
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"Valeu a pena? Tudo vale a pena 
Se a alma não é pequena. 
Quem quer passar além do Bojador 
Tem que passar além da dor. 
Deus ao mar o perigo e o abismo deu, 
Mas nele é que espelhou o céu."  
―Fernando Pessoa 
 
 
 
The End 
 
 
 
 
 
